Polymeric micelles for solubilization and targeting of hydrophobic drugs by Miller, Tobias
Polymeric micelles for
solubilization and targeting of
hydrophobic drugs
Dissertation zur Erlangung des Doktorgrades
der Naturwissenschaften (Dr. rer. nat.)
der Fakultät für Chemie und Pharmazie
der Universität Regensburg
vorgelegt von
Tobias Miller aus Potsdam
Juni 2012
Diese Doktorarbeit entstand in der Zeit vom April 2009 bis Juni 2012
bei der Merck KGaA, Exploratory Pharmaceutical Developement, Darm-
stadt, in Zusammenarbeit mit dem Institut für Pharmazeutische Tech-
nologie der Universität Regensburg.
Die Arbeit wurde von Prof. Dr. Achim Göpferich betreut.
Promotionsgesuch eingereicht am: 04.06.2012
Datum der mündlichen Prüfung: 27.06.2012
Prüfungsausschuss: Prof. Dr. Sigurd Elz (Vorsitzender)
Prof. Dr. Achim Göpferich (Erstgutachter)
PD Dr. Rainer Müller (Zweitgutachter)
Prof. Dr. Frank-Michael Matysik (Drittprüfer)


To try and fail is at least to learn; to fail to try is to suffer the inestimable loss of what
might have been.
Chester Barnard

Contents
1 Introduction 1
1.1 Academic research vs industrial development . . . . . . . . . . . . . . . . . . 2
1.2 Stress factor analysis: implications on drug targeting . . . . . . . . . . . . . . 5
1.2.1 Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
1.2.2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
1.2.3 Analysis of stress mechanisms occurring immediately upon injection of
polymeric micelles . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
1.2.3.1 Physical events during injection - formulations entering the
body . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
1.2.3.2 Biophysical events upon injection . . . . . . . . . . . . . . . . 10
1.2.4 Implications for passive targeting . . . . . . . . . . . . . . . . . . . . . 20
1.2.4.1 Evidence of EPR effect for macromolecules . . . . . . . . . . 20
1.2.4.2 The EPR effect in case of nanoparticles . . . . . . . . . . . . 21
1.2.4.3 Additional factors shaping EPR effect . . . . . . . . . . . . . 23
1.2.5 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
1.2.6 Future perspective . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
1.3 Research objectives of the thesis . . . . . . . . . . . . . . . . . . . . . . . . . 27
2 Drug loading of polymeric micelles 29
2.1 Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
2.2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
2.3 Materials and methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
2.3.1 Materials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
2.3.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
2.3.2.1 Preparation of drug loaded micelles . . . . . . . . . . . . . . 32
2.3.2.2 Drug load determination . . . . . . . . . . . . . . . . . . . . 33
2.3.2.3 Particle size measurement . . . . . . . . . . . . . . . . . . . . 34
2.3.2.4 Lyoprotector screening via Differential Scanning Calorimetry
(DSC) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
2.3.2.5 Lyoprotector screening via lyophilization of placebo micelles . 34
2.3.2.6 Influence of lyoprotector concentration on micelle reconstitution 35
vii
Contents
2.3.2.7 Cryo-Transmission Electron Microscopy (cryo-EM) . . . . . . 35
2.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
2.4.1 Solvents for cosolvent evaporation . . . . . . . . . . . . . . . . . . . . 35
2.4.2 Preparation of drug loaded micelles . . . . . . . . . . . . . . . . . . . . 36
2.4.3 Lyoprotector screening via DSC and lyophilization of placebo micelles 36
2.4.4 Optimum concentration of lyoprotector . . . . . . . . . . . . . . . . . . 39
2.4.5 Morphological and size analysis by cryo-EM . . . . . . . . . . . . . . . 40
2.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
2.6 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
3 In vitro serum stability 51
3.1 Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
3.2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
3.3 Materials and methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
3.3.1 Materials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
3.3.2 Polymer characterization by differential scanning calorimetry (DSC) . 55
3.3.3 Micelle preparation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
3.3.3.1 Samples for determination of critical association concentration
(CAC) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
3.3.3.2 Samples for serum incubation studies, Asymmetrical Flow
Field Flow Fractionation (AF4) experiments, and Transmis-
sion Electron Microscopy (TEM) . . . . . . . . . . . . . . . . 56
3.3.4 Micelle characterization . . . . . . . . . . . . . . . . . . . . . . . . . . 56
3.3.4.1 Determination of critical association concentration (CAC) . . 56
3.3.4.2 Particle size measurements . . . . . . . . . . . . . . . . . . . 57
3.3.4.3 Transmission Electron Microscopy (TEM) . . . . . . . . . . . 57
3.3.5 Determination of micelles’ in vitro serum stability . . . . . . . . . . . 57
3.3.5.1 Sample incubation, FRET ratio determination, calculation of
stability parameters . . . . . . . . . . . . . . . . . . . . . . . 57
3.3.5.2 Asymmetrical Flow Field Flow Fractionation (AF4) . . . . . 58
3.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
3.4.1 Polymer and micelles characterization . . . . . . . . . . . . . . . . . . 59
3.4.2 FRET stability assay . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
3.4.3 Asymmetrical Flow Field Flow Fractionation (AF4) . . . . . . . . . . 65
3.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66
3.6 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
4 Cytotoxicity and immunogenicity 71
4.1 Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72
viii
Contents
4.2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73
4.3 Materials and methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
4.3.1 Materials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
4.3.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
4.3.2.1 Synthesis of PEG-PEI as reference material . . . . . . . . . . 74
4.3.2.2 Micelle preparation . . . . . . . . . . . . . . . . . . . . . . . 75
4.3.2.3 Particle size measurements . . . . . . . . . . . . . . . . . . . 77
4.3.2.4 Cell incubation experiments . . . . . . . . . . . . . . . . . . . 77
4.3.2.5 Determination of complement scission products upon serum
incubation . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78
4.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78
4.4.1 PEG-PEI synthesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78
4.4.2 Particle size of test materials . . . . . . . . . . . . . . . . . . . . . . . 78
4.4.3 Cytotoxicity assay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78
4.4.4 Complement activation assays . . . . . . . . . . . . . . . . . . . . . . . 81
4.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
4.6 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
5 Drug encapsulation and biodistribution 87
5.1 Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88
5.2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89
5.3 Materials and methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89
5.3.1 Materials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89
5.3.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90
5.3.2.1 Solvent screen prior to cosolvent evaporation . . . . . . . . . 90
5.3.2.2 Polymer screen to load compound A into micelles . . . . . . 90
5.3.2.3 Preparation of study materials . . . . . . . . . . . . . . . . . 91
5.3.3 Particle size measurements . . . . . . . . . . . . . . . . . . . . . . . . 91
5.3.4 Biodistribution experiments of micelles vs. solution . . . . . . . . . . . 92
5.3.5 Preparation of radiolabeled H2N-PEG-PLGA and bioimaging . . . . . 92
5.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93
5.4.1 Solvent screen for cosolvent evaporation . . . . . . . . . . . . . . . . . 93
5.4.2 Drug loading, particle sizes and size distributions for compound A
loaded micelles . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94
5.4.3 Injected formulations for biodistribution purposes . . . . . . . . . . . . 94
5.4.4 Biodistribution of compound A-loaded PEG-PLGA micelles . . . . . . 96
5.4.5 Synthesis of H2N-PEG-PLGA and bioimaging . . . . . . . . . . . . . . 97
5.4.5.1 Synthesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97
ix
Contents
5.4.5.2 Bioimaging . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98
5.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100
5.6 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
6 PEG-PVPy labeling and biodistribution 105
6.1 Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106
6.2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107
6.3 Materials and methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107
6.3.1 Materials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107
6.3.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108
6.3.2.1 PEG-PVPy quaternization and labeling with radioactive io-
dine isotopes . . . . . . . . . . . . . . . . . . . . . . . . . . . 108
6.3.2.2 Bioimaging of labeled PEG-PVPy micelles . . . . . . . . . . 109
6.3.2.3 Biodistribution of labeled PEG-PVPy micelles . . . . . . . . 109
6.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
6.4.1 Preparation of labeled PEG-PVPy . . . . . . . . . . . . . . . . . . . . 109
6.4.2 Bioimaging of labeled PEG-PVPy micelles . . . . . . . . . . . . . . . . 110
6.4.2.1 IFF in unlabeled PEG-PVPy micelles . . . . . . . . . . . . . 110
6.4.2.2 Labeled PEG-PVPy micelles . . . . . . . . . . . . . . . . . . 110
6.4.2.3 Elucidation of PEG-PVPy body clearance . . . . . . . . . . . 111
6.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112
6.6 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113
6.7 Outlook . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113
7 The fate of carrier and ecapsulated drugs 115
7.1 Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 116
7.2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 117
7.3 Materials and methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 118
7.3.1 Materials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 118
7.3.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 118
7.3.2.1 Synthesis of H2N-PEG-PDLLA . . . . . . . . . . . . . . . . . 118
7.3.2.2 Polymer analytics . . . . . . . . . . . . . . . . . . . . . . . . 119
7.3.2.3 Radioactive labeling of H2N-PEG-PLA . . . . . . . . . . . . 119
7.3.2.4 Radiolabeling of H2N-PEG . . . . . . . . . . . . . . . . . . . 120
7.3.2.5 Formulation preparation for biodistribution and bioimaging . 120
7.3.2.6 Animal preparation and in vivo studies . . . . . . . . . . . . 121
7.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 122
7.4.1 Polymer synthesis, analytics and micelle characterization . . . . . . . . 122
x
Contents
7.4.2 Bioimaging . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123
7.4.2.1 Drug-loaded polymeric micelles . . . . . . . . . . . . . . . . . 123
7.4.2.2 111In-DOTA-NH-PEG-PLA solution . . . . . . . . . . . . . . 124
7.4.2.3 111In-DOTA-NH-PEG solution . . . . . . . . . . . . . . . . . 125
7.4.3 Biodistribution of dual-labeled polymeric micelles with 131IFF payload
in several animal groups of tumor-bearing mice . . . . . . . . . . . . . 126
7.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128
7.6 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 131
8 Summary and conclusion 133
Bibliography 138
List of abbreviations 164
List of figures 167
List of tables 169
Appendix 171
Curriculum vitae . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 172
List of publications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 173
Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 175
xi

Chapter 1
Introduction
1
CHAPTER 1. INTRODUCTION
1.1 Drug delivery at the interface of academic research and
industrial development
Pharmaceutical companies underwent massive economic pressure in the last decades. The
major reasons for this were and still are varying challenges which comprise of 1) increasing
regulatory hurdles to enhance drug safety, 2) decreasing effectiveness of industrial research
and development processes in receiving drug approvals and 3) decreasing financial resources
of the society which is less able to fund drug innovations.
The less effective efficacy of development processes was impressively shown by Mullard
[1]. From 1996 to 2010 the number of the yearly drug approvals by the Food and Drug
Administration (FDA) declined from 53 (in 1996) to 15 (in 2010) in a time period of only
14 years. Simultaneously the development costs and the market entry time for each new
drug candidate were continuously rising resulting in less profitability of the newly approved
medicines [2]. In this connection the questions becomes relevant: Why do so many novel
drugs fail? Kola and Landis [3] reviewed this issue in 2004 and presented the most prominent
reasons for drug attrition upon approval. These comprised of factors such as 1) insufficient
clinical efficacy, 2) undesirable pharmacokinetics and low bioavailability, 3) unexpected toxic
side effects, 4) insufficient formulation stability as well as economical reasons like 5) low
marketing success or 6) unjustifiable cost of goods. It can be suggested that these issues
were not limited to drug attrition but also were important factors for the failure of discovery
compounds in early phases.
Looking again at the facts 1) to 6) that Kola and Landis reported, the question arises
which impact novel drug delivery technologies might have to reduce drug failure rates.
Based on the idea of targeted, organ specific delivery, nanoparticles have the potential to
change drug disposition in the body compared to freely administered small molecules [4].
The controllable size, charge and material properties of nanoparticles allowed for potential
changes in biodistribution of the encapsulated drugs. Consequently by controlling the
pharmacokinetic properties of the drug by the carrier system, the drugs’ efficacy, bioavailability
and toxicology profile can be altered (factors 1, 2 and 3 reported by Kola and Landis [3]).
Summarizing all these factors, by increasing the efficacy of development processes, all
participants, pharmaceutical companies and society, will benefit.
Polymeric micelles present a promising tool to increase bioavailability and alter the toxi-
cological profile of the encapsulated drug. Based on above suggestions, the topics of this
thesis comprised of solubilization of hydrophobic drugs combined with in vitro and in vivo
approaches to investigate the micelles’ targeted delivery potential. As many discovery com-
pounds in pharmaceutical industry are hydrophobic [5, 6], polymeric micelles are a highly
interesting drug delivery system which requires intensive fundamental research prior to their
2
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implementation in industrial development processes. Specific knowledge gaps to date are
in the fields of drug-polymer, micelle-blood and body-polymer interactions. The thesis will
focus on some aspects of these interactions such as 1) drug loading, 2) stability in biofluids, 3)
potential cytotoxic and immunogenic reactions and finally 4) in vivo performance regarding
pharmacokinetics.
Despite the specific gaps in fundamental understanding of micellar systems, a few products
already entered the market: the anticancer drugs Paclitaxel/Docetaxel containing micellar
drugs Genexol-PM® and Nanoxel-PM®. Both drugs reduce the toxicity of the original
formulation Taxol® containing a mixture of CremophorEL® and ethanol as solubilizers.
Finally these novel formulations led to increased tolerated doses and therefore higher efficacy
compared to the original one [7].
To pick up the thoughts outlined above, the multiple interactions of colloidal carriers with the
biological systems to which they are applied, determine efficacy and safety of nanomedicine.
The fate of nanoparticles upon injection is still quite unknown but definitely will have a strong
influence on both, the particles and the biological system. Enlightenment regarding this topic
will be delivered by analyzing the stress mechanism which colloidal carriers encounter upon
injection. For this purpose, literature was revisited and analyzed in section 1.2 which finally
led to the question what factors can be made responsible for successful accumulating colloidal
carriers in tumor tissue.
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1.2.1 Abstract
Polymeric micelles are ideal carriers for solubilization and targeting applications using
hydrophobic drugs. Stability of colloidal aggregates upon injection into the blood stream is
mandatory to maintain the drugs’ targeting potential and to influence pharmacokinetics. In
this review the most relevant stress mechanisms that polymeric micelles and related colloidal
carriers encounter upon injection are analyzed and discussed (Fig. 1.1), including: 1) dilution,
2) interactions with blood components and 3) immunological responses of the body. In
detail the opsonin-dysopsonin hypothesis was analyzed that points at a connection between
a particles’ protein-corona and its tissue accumulation by the enhanced permeability and
retention (EPR) effect. In the established theory size is seen as a necessary condition to
reach nanoparticle accumulation in disease modified tissue. There is, however, mounting
evidence of other sufficient conditions (e.g. particle charge, receptor recognition of proteins
adsorbed onto particle surfaces) triggering nanoparticle extravasation by active mechanisms.
In conclusion, the analyzed stress mechanisms are directly responsible for in vivo success or
failure of the site-specific delivery with colloidal carrier systems.
Figure 1.1: Summary of stress factors which colloidal carriers encounter upon injection.
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1.2.2 Introduction
Polymeric micelles currently receive the widespread attention of the scientific community as a
drug carrier system for parenteral delivery. This technology is seen to be as equally promising
compared to the well-investigated liposomes in terms of the two major driving forces for their
development: solubilization and site-specific delivery. Compared to other nanoparticulate drug
delivery systems, polymeric micelles exhibit many unique properties that make them an ideal
approach in the treatment of unmet medical needs. These properties generally comprise of 1)
particle sizes below 150 nm (preferentially 100 nm), which allows for escape of the mononuclear
phagocyte system (MPS) [8], 2) multiple possible core properties and morphologies due to
a variety of applicable chemistries which can increase drug loading and circulation half-life
of the systems [9], and 3) stimulus responsive release of the drug payload in dependence of
particle environment [10]. However, the first micellar products on the market (Genexol-PM®,
Nanoxel-PM®) and ongoing clinical investigations (e.g., NK-105, NK-911, DACH-Platin,
Lipotecan) seem to justify this view on the superiority of polymeric micelles. But only few of
these products alter drugs’ pharmacokinetics significantly and successfully target their site
of action. Reaching both goals by formulation approaches still remains highly challenging.
The main reason for this is that some of the most urgent questions in the application of
nanoparticulate delivery systems have not yet been sufficiently addressed: 1) the idea of
drug targeting is based on the questionable stability of cargo incorporation and consequently
protection from premature release and from circulation elimination, 2) the mechanisms that
accelerate particle accumulation into target tissue are still not fully understood and 3) the
body’s responses to nanoparticle therapies seem unpredictable and exhibit high inter- and
intrapatient variability. Moreover, the interactions between colloidal carriers and living
organisms are very complex and many of them will change the integrity and structure of
such systems in the bloodstream. Dominant stress factors among these interactions comprise
of the following: 1) immediate high dilution of the formulation, 2) interaction with blood
components, as well as 3) rapid responses by the immune system. All of these factors play a
key role in nanomedicines’ safety and efficacy. A powerful protective tool against the influences
of stress factors is a nanoparticle design that reduces the rapid remodeling of the drug delivery
system. In the special case of polymeric micelles, cargo protection is achieved by encapsulation
of the active pharmaceutical ingredient in the hydrophobic particle core which is surrounded
by a hydrophilic shell that prevents rapid clearance by the MPS from the bloodstream [11].
Consequently, the drug-loaded particles exhibit a prolonged circulation time. This necessary
condition is seen to be responsible for site-specific delivery into tumors [12, 13, 14] or arthritic
tissue [15] based on the enhanced permeability and retention effect (EPR) [16, 17, 18]. In the
EPR concept, particle sizes are assumed to be the decisive factor for this passive type of drug
targeting. Maintaining colloidal stability to allow for passive guiding of drugs by the carrier
7
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system led to a number of micellar products. However, many of these products have not
been approved yet by the health regulatory authorities, although some of them are subject
to clinical trials. A micelle-related colloidal drug delivery system that successfully targets
the drug to tumors received FDA approval in 1995: this liposomal product is marketed as
Doxil® or Caelyx®. It contains the anticancer agent doxorubicine encapsulated in liposomes
made from a mixture of PEGylated and non-PEGylated lipids of 1,2- distearoyl-sn-glycero-3-
phosphoethanolamin (mPEG-DSPE/DSPE) that exhibits excellent in vitro stability [19]. A
number of pharmacokinetic studies with this product have been conducted in animals and
humans. The resulting data contribute significantly to the understanding of nanoparticle
biodistribution and its underlying mechanisms. It was found that a rapid primary blood
clearance of nanoparticles occurred within the first 2 h and was followed by a terminal
clearance after 26 h [20]. In the discussion of these biphasic pharmacokinetics, opsonization
and dysopsonization came into play. Both terms rely on the fact that plasma proteins
adsorb onto nanoparticle surfaces. Opsonins ultimately lead to enhanced phagocytosis of
the tagged particle, whereas dysopsonins prevent particle uptake [21, 22]. Depending on the
nanoparticle properties, one of these species was preferentially attracted onto the surfaces
[23]. This balanced composition is known to be time-dependent [24]. In the case of Doxil®,
one explanation for its pharmacokinetics was thought to be rapid complement activation
[25, 26] combined with opsonization within the first 2 h leading to increased liver uptake
of the liposomes. However, it was found that the adsorption of opsonins was saturable and
incomplete so dysopsonins could attach onto the particle surfaces [20]. Finally the dysopsonins
were seen to be responsible for the increased circulation time. Apart from nonspecific serum
protein interactions another important aspect was revealed for PEGylated nanoparticles:
upon multiple dosing of placebo liposomes, anti-PEG-antibodies were produced as a bodily
response, this phenomenon is also known to arise from the multiple-dosing of PEGylated
drugs [27]. This example makes it quite clear, that a colloidal system undergoes significant
changes once it is exposed to biological systems that lead to alterations in its surface chemistry
completely. This will have a strong impact on the in vivo disposition of such systems. It is,
therefore, the intention of this review to analyze these rapidly occurring mechanisms upon
injection of colloidal systems with special emphasis on polymeric micelles. Furthermore, it
is aimed to revisit the impact of such stress mechanisms on current hypotheses regarding
passive particle targeting in the last section of this article. Such a detailed analysis can
contribute to a better understanding of nanoparticle biodistribution, premature clearance
mechanisms and in vivo failure of targeting. It is intended to renew the views on the design
of in vitro and in vivo experiments when working with colloidal drug delivery systems.
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1.2.3 Analysis of stress mechanisms occurring immediately upon injection of
polymeric micelles
1.2.3.1 Physical events during injection - formulations entering the body
The most relevant physical stress factor appearing upon injection is immediate dilution of the
formulation. Dilution effects of colloid dispersions are highly crucial to the integrity of micellar
formulations. In regards to this, the most important ones are the thermodynamic and kinetic
stabilities of colloidal associates. Thermodynamic stability is related to the critical association
concentration (CAC) of the micelle forming block copolymers. Upon immediate dilution
which obviously takes place during injection, low molar mass surfactant micelles disintegrate
very quickly [28]. It is well-known that block copolymer micelles exhibit much lower CACs
compared to these low molar mass surfactant micelles [29, 30]. Another advantage of block
copolymers is the possibility to modify the hydrophobic core: an increase in the length of the
hydrophobic block generally leads to a decrease in CAC [31]. Consequently, block copolymer
micelles with long hydrophobic blocks typically exhibit an enhanced thermodynamic stability
and therefore dilution has less of an impact on their stability. These are results from
experiments conducted by Kang et al. who synthesized varying PEGylated polylactic acid
(PEG-PLA) block copolymers and studied their micellar association and kinetic stability [32].
Specific interactions between hydrophobic blocks increased association tendency as studied
with mixed micelles composed of PEGylated poly-D-lactic acid (PEG-PDLA) and PEGylated
poly-L-lactic acid (PEG-PLLA) [33]. Other groups made similar observations and based the
increased stability on an increased number of hydrogen bonds in the core forming blocks
[34, 35], pi−pi-stacking [36], hydrophobic interactions [37], ionic interactions in the core [38],
and core cross-linking [39, 40]. Typically CAC values of block copolymers are between 1 and
5 mg/L [41]. Consequently, maintenance of polymer blood concentrations above the CAC
level requires a minimum polymer dose between 6 and 30 mg for an average adult (6 L blood
volume assuming immediate complete distribution). These numbers clearly demonstrate
the importance of association properties especially at low concentrations. Another point is
the kinetic stability of micelles upon dilution in the bloodstream. If micelles are kinetically
stable, dilution below CAC does not necessarily lead to an immediate dissociation of the
polymeric associates. This has been proven by Hans et al. who investigated the in vitro drug
release from micelles upon dilution below CAC in PBS buffer [42]. In this study, mPEG-
PLA micelles with varying hydrophilic/ hydrophobic ratios were loaded with haloperidol
physically or by combining covalent coupling with physical incorporation. Depending on
the core−shell ratio, the physically incorporated drug haloperidol was released immediately
upon dilution (55% w/w PEG) or released in a sustained fashion over days (68% w/w PEG).
These observations were confirmed by fluorescence probe studies that measured the integrity
of micellar associates and found that 55% w/w PEG ratio micelles disassembled into unimers
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whereas 68% w/w PEG ratio micelles remained intact. Interestingly the group concluded
from the combination of drug physical and chemical coupling that an initial burst release even
from the 68% w/w PEG ratio micelles occurred from intact micelles. In their experiments
an enhancement of the hydrophobic block lengths of the polymer did not lead to a decrease
in the burst release as expected. Apart from dilution, kinetic stability also implies stability
against detergents like surfactants [43] or proteins [44, 45]. In this field, the physicochemical
status of the micellar core plays a key role besides the properties of the micellar shell. Micelles
with cores that exhibit high glass transition temperatures, a high degree of crystallinity, or
low interfacial tension of the hydrophobic block with water (“frozen micelles”) [46] reduce the
tendency of disassembly into single polymer chains upon dilution. Another micelle-like carrier
system is dendritic “unimolecular micelles” [47], which exhibit a hydrophobic core as well
as a hydrophobic shell. Due to their unimolecular nature, they do not show disassembling
properties upon dilution but are similarly effective in drug loading of hydrophobic compounds
[48, 49]. Furthermore, they are stable against shear forces and show drug release in a
sustained fashion [50]. To summarize, the existing strategies to increase micellar stability
and reduce premature disassembly upon dilution are based on the following: 1) increasing
hydrophobic block lengths, 2) altering hydrophobic/hydrophilic ratios, 3) selection of the
type of hydrophobic block in terms of physical status and 4) core cross-linking. Another
strategy to overcome the disadvantages of stability upon dilution of such self-assembling
systems could be the preparation of the above mentioned unimolecular micelles. For all of
the above mentioned strategies when fine-tuning the micellar properties, one has to consider
an altered drug release and drug loading capacity [42]. Existing products in clinical testing
that have shown to be successfully at targeting, currently rely on ionic interactions in the
micellar core for stabilization (NK-105, NK-911) by using PEG-polyamino acids [51, 52].
Biodegradability and biocompatibility are excellent for these systems. Evaluations of the
other stabilization strategies such as particle crosslinking seem to strongly increase particle
stability and require further investigations in vitro (drug load, release) as well as in vivo
(degradability and compatibility).
1.2.3.2 Biophysical events upon injection
Apart from immediate dilution of the applied formulation during its injection, polymeric
micelles come in contact with corpuscular blood ingredients as well as humoral components
such as serum proteins, enzymes, electrolytes, lipid particles, and cells. Indeed, these factors
represent a strong stress for micelles and challenge the maintenance of stability. Consequently,
a detailed understanding of the processes appearing at the interface between nanoparticle
surfaces and surrounding biological media is of high relevance. While dealing with this
question the major blood components with strong interaction potential have been identified:
10
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Figure 1.2: Scenario analysis of micelle-protein interactions. PEG-coating of the particles was
made to avoid protein adsorption. Nevertheless, this seems to happen not entirely.
However, proteins can 1) destabilize the colloidal aggregates, 2) extract the drug
from the micellar core due to small diffusion length or 3) completely cover the
nanoparticle. The latter mechanism might lead to a prolonged circulation and
decreased MPS uptake or extended phagocytosis.
certain fractions of serum proteins seem to have a very deep impact on micellar stability and
carrier properties whereas several studies revealed the low influence of corpuscular blood
ingredients [45, 53]. As summarized in Figure 1.2, multiple interaction scenarios of serum
proteins with micelles are possible: 1) destabilization followed by disintegration, 2) drug
distribution from particle core toward proteins by maintaining particle stability, and 3)
opsonization/dysopsonization of particles leading to phagocytosis by the MPS or to extended
circulation.
Stability against serum proteins
Theories of nanoparticle-protein interactions as explanation for disassembly of micelles
The prevention of premature disassembly of the nanoparticles is extremely important for
their in vivo success. A number of studies in the past years have focused on this analytically
11
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challenging issue. Recently, some progress has been made due to the development of easy to
access in vitro experiments for screening the colloidal carrier systems’ serum stability. These
techniques focus on 2D-PAGE analysis [54, 55, 56], Foerster Resonance Energy Transfer
[53, 57], dialysis against serum proteins [58], and separation-based approaches such as size
exclusion chromatography [59], asymmetrical field flow fractionation [57], or fast protein liquid
chromatography [45]. One of the first investigations of interactions between hydrophobic
surfaces and proteins was carried out by Leo Vroman [60]. The Vroman effect describes
protein adsorption onto a limited number of hydrophobic surfaces and a competition was
found between various protein types depending on their affinity to this surface. Directly
upon exposing the surface to serum or plasma, proteins with low affinity adsorb rapidly and
are replaced later by proteins with higher affinity to this surface. This phenomenon had
been studied with fibrinogen [61] that exhibited high initial adsorption onto surfaces, which
decreased over contact time. The adsorptive properties depended on serum concentration
(dilution) [62, 63]. High serum concentrations led to low fibrinogen adsorption, whereas low
concentrations exhibited the opposite effect. Destabilization of colloidal aggregates by proteins
can only take place when proteins are allowed to adsorb onto the surfaces of the nanoparticles.
The suppression of serum protein adsorption from the particle surface is typically thought to
be achieved by a PEG shielding. Complete particle surface coverage and a minimal thickness
in a “brush”-like conformation of PEG chains is seen as the ideal condition to obtain long
circulating particles [64]. If the surface is perfectly protected, thermodynamically triggered
repulsion [64] forces and entropically mediated interfacial water layers [65] prevent proteins
from adsorption. Additionally, Lasic et al. [66] developed an extension of the DLVO theory
for liposomes which helps to explain the repulsive effects of non-ionic surfaces. This theory
already considers colloidal particle surfaces of micelles or liposomes that exhibit a dynamic
equilibrium of associated macromolecules with rather fluidic surfaces. Another theory to
explain extended circulation properties denies the stealthiness of particles themselves and
speaks of a saturable protein opsonization phenomenon. This opsonin−dysopsonin theory was
formulated first by Moghimi and Patel [67] in 1989 based on experimental observations from
1983 with liposomes [68]. It was found that cholesterol-rich liposomes exhibited longer blood
circulation times due to lower protein opsonization compared to liposomes with lower or no
cholesterol content. Furthermore, once the particles were opsonized they showed preferred
accumulation in the liver or spleen [69]. Interestingly, opsonization experiments with serum
from healthy and tumor-bearing rats showed remarkable differences in terms of their blood
clearance by liver and spleen macrophages [70], indicating altered pharmacokinetics in diseased
animals. However, the nature of proteins that act in a similar way to opsonins/dysopsonins
remains partly unknown. Studies have reported calcium-dependent proteins as opsonins [71],
whereas other investigations limited the knowledge of dysopsonins to their molar masses
above 100 kDa [22]. Fibrinogen was found to be an opsonin [72] and albumin was believed to
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be a dysopsonin [23]. In theory, after clearing the pool of protein-opsonins in the bloodstream,
the remaining particles showed prolonged circulation. This hypothesis was used to explain the
biphasic pharmacokinetic of the liposomal drug Doxil® [20]. Other studies with liposomes
supported this hypothesis [73]. Doubts on the perfect stealth properties of PEG surfaces have
arisen from several groups in the past: Vert et al. [74] showed the high compatibility of serum
albumin to PEG of certain molar masses. For specific PEG molar masses (<8 kDa), the group
postulated perfectly albumin covered surfaces. Consequently, the resulting particle mimicked
“native” albumin particles. This hypothesis is supported by the recent studies of Tenzer
et al. [75]. The group investigated the protein-corona of modified silica nanoparticles and
identified albumin as the most abundantly absorbed protein on the surface. Furthermore, they
impressively showed the major influence of particle size and the minor role of particle surface
charge on protein adsorption. In total, more than 125 different proteins could be identified
on the surfaces. Emmenegger et al. investigated anti-fouling properties of PEG-coated gold
chips in the presence of serum proteins. They found that a certain serum fraction (>350
kDa) was adsorbed onto the surface of PEG with varying molar masses [76]. Also, a similar
yet unusual behavior of fibrinogen on hydrophilic surfaces was found to be modulated by high
molecular weight kininogens [24, 77]. Fibrinogen, albumin, and complement adsorption were
also found on PEG surfaces in dependence of PEG density, as studied by Unsworth et al. with
PEGylated gold nanoparticles [78]. This effect was also observed on other particle species,
such as solid lipid nanoparticles [79, 80]. Summarizing these studies on the stealthiness of
PEG surfaces, legitimate doubts could arise if this material is able to completely prevent
protein adsorption and consequently allows for selective opsonization/dysopsonization. In
this connection, the observations of Vroman can be used to explain time-dependent changes
of opsonin and dysopsonin adsorption. Moreover, many different proteins participate in the
formation of this effect and it is not completely clear which role each species plays with regard
to opsonization-dysopsonization. In this context, the questions arise how stealthy PEGylated
micelles are and what impact the repulsive properties have on micellar stability. However,
once proteins are allowed to adsorb to the surface, cohesive forces of the micellar core decide
about the particle stability. Again, similar issues are responsible for nanoparticle stability as
previously discussed for thermodynamic and kinetic stability. Furthermore, it is remarkable
that this physicochemical status can be altered by residual solvents [81] from preparation
and water, as well as drug incorporation. These moieties can act as plasticizers and increase
or decrease carrier stability. For example, Chen et al. identified α- and β-globulines that led
to fast disassembly of PEG-PDLLA micelles [53]. Similar observations and impacts of these
serum fractions were found by Diezi et al. who investigated PEG-DSPE micelles that showed
rapid disintegration [82]. In the same study, PEG-block-poly-(N-hexylstearate-aspartamide)
(PEG-b-PHSA) micelles exhibited high stability against serum proteins. As indicated by
these studies, micellar architectures are very heterogeneous, and there seems to be no direct
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correlation between a particular physicochemical parameter and serum stability [57]. Apart
from this, the mechanism of micellar disassembly upon contact with serum proteins has
not been fully understood yet. However, the examples above make it clear that the results
concerning influence of the PEG shell on micellar stability are quite heterogeneously shown
and discussed in literature. Prediction seems to be challenging if the protein coating acts as
stabilizer or increases the tendency of the system to disassemble.
Stability of drug incorporation against extraction As previously analyzed, protein binding
to nanoparticle surfaces is an important event upon injection. The most abundant protein in
serum is albumin. Generally the diffusion pathways of small molecules between micellar core
and proteins adsorbed on nanoparticle surfaces are short because PEG shieldings exhibit
typical thicknesses of about 1−5 nm [83]. Consequently, the question arises if additional
distribution phenomena from nanoparticle cores toward adsorbed serum proteins play a role.
In the following section it is intended to point out drug properties that are associated with
nanoparticle design to finally clarify the role of such distribution phenomena. Originally,
the motivation for developing polymeric micelles was solubilization and bioavailability en-
hancement for poorly soluble drugs. However, most drugs in pharmaceutical development
with solubility issues are hydrophobic as well and therefore eligible for encapsulation into
nanocarriers. But, in line with hydrophobicity, the drug’s protein binding affinity is increasing:
Ritchie and Macdonald [84] have shown by analyzing ∼8000 drugs in the GlaxoSmithKline
library that the probability of low aqueous solubility increases with the number of aromatic
rings in the drug molecule and simultaneously goes along with stronger albumin binding.
On average, albumin binding of these compounds is heavily increased, up by 75% when 1−3
aromatic rings are present and even up to 95% or more when 4 aromatic rings appear in
the drug molecule structure. Consequently, drug disposition within colloidal carriers toward
extraparticulate acceptors like proteins pose a dynamic equilibrium. Especially in the case of
polymeric micelles, this equilibrium can shift upon injection from the hydrophobic particle
core toward surrounding proteins depending on the affinity of the drug. Generally, in the
circulating bloodstream the number of proteins that could serve as a drug acceptor exceeds the
reservoir of nanoparticles. Concluding from this it would be an appropriate scenario that long
circulating particles can lose their drug payload due to simple distribution toward serum pro-
teins and continue circulating as “empty carriers”. First observations of this issue were made
by Burt et al. [85]. The group loaded 3H-labeled Paclitaxel into 14C-labeled mPEG-PDLLA
micelles and followed biodistribution in rats. As a result of their studies the authors found a
discrepancy between drug and micelle biodistribution even after a couple of minutes upon
injection. The group concluded that Paclitaxel was rapidly released from the micelles, while
the carrier system was circulating for a longer time (∼15 h). Later Burt’s group investigated
the Paclitaxel plasma distribution in vitro in dependence of drug formulation. Drug solution
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was compared to 2 PEG-poly-(-caprolactone) (PEG-PCL) formulations [86]. After 1 h
of incubation with human plasma, the drug encapsulated in mPEG114-b-PCL19 micelles
showed a similar protein distribution compared to drug solution. Prolonging the hydrophobic
block to mPEG114-b-PCL104 led to the majority of drug remaining in the micelles. A highly
interesting finding came from the inverse designed experiment in which Paclitaxel solution was
incubated with plasma and blank mPEG114-b- PCL104 micelles were added. Unexpectedly,
the results showed that drug distribution from plasma proteins toward micelles appeared in
the other direction as well. The group suggested from their findings that the redistribution
and accumulation of Paclitaxel from proteins took place at the interface between PCL core
and PEG shell. The recent investigation of Letchford and Burt [87] proved this hypothesis of
drug extraction in vivo. The authors included the previously described block copolymers in
their study and investigated mPEG114-b-PCL104 and mPEG114-b-PCL19 on in vitro serum
stability and in vitro drug release, as well as in vivo biodistribution. As expected, the polymer
with the longest hydrophobic block exhibited higher in vitro serum stability assessed by the
FRET technique [53], which had been previously used to study micelles on their stability in
biofluids. Moreover, the particles from this polymer species released the drug Paclitaxel in a
more sustained fashion compared to the polymer with shorter hydrophobic block length. By
employing radiolabeling of polymer and analyzing the distribution combined with the drug,
the in vivo biodistribution revealed rapid dissociation of the micellar adducts: independently
of their in vitro properties, 99% of the drug was eliminated from plasma within 15 min upon
injection, whereas the polymeric carrier systems remained circulating for several hours. These
results were very awakening and questioned the overall concept of drug targeting with drugs
encapsulated in self-assembling systems. However, as shown in the studies of Burt et al.,
drug distribution from micelles to protein fractions in blood is a dynamic equilibrium. The
investigated drug Paclitaxel is highly lipophilic with ∼95% protein binding affinity, primarily
to albumin and α-1-acid glycoprotein [88]. Liu et al. [89] observed similar distribution
phenomena with PEG-poly-(5-benzoyloxytrimethylene carbonate) (PEG-PBTMC) micelles
loaded with ellipticine. In this study, drug release was found to be strongly dependent on
protein concentration. A similar observation of drug extraction from carriers was made by
Chen et al. who investigated PEG-PDLLA micelles loaded with two dyes exhibiting a FRET
pair (DiI and DiO) [53]. After a short period of time (15 min) upon injection into mice, the
FRET effect decreased strongly, indicating loss of dye payload. The group also investigated
the in vitro serum stability of these micelles with the same dyes and found them to be quite
stable. A possible explanation for this observation could be the high lipophilicity of the dyes
and, consequently, a high affinity to lipid bilayers. Furthermore, in systemic circulation, the
amount of proteins is certainly higher than in in vitro experiments. Summarizing the cited
studies above it is clear that the relevance of drug distribution between nanoparticles and
serum proteins is highly important. According to the contemporary literature, it seems as if
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this problem is underestimated. A strong drug−polymer interaction is essential for stable
drug incorporation into nanoparticles. In the case of low interaction forces between the drug
and the nanoparticle core, premature drug release combined with continued “empty” particle
circulation could occur. As previously shown in published literature, this effect takes place and
has two major consequences on the results of in vivo experiments: 1) the highly hydrophobic
drug is released and can be distributed toward serum proteins that are able to carry it to the
target site and 2) if biodistribution of the carrier is followed, an accumulation of the carrier at
the target site does not necessarily lead to an accumulation of its cargo. Consequently, carrier
and payload follow completely different biodistribution patterns. As indicated by the studies
of Burt et al., the distribution effect is very fast. This generally questions the application
of self-assembling systems with physically incorporated drugs that rely on weak interaction
forces such as hydrophobic interactions for altering drugs’ pharmacokinetics. A strategy to
avoid this release was shown by the product NC-6004, which incorporated Cisplatin in a
coordinative complex with a polyglutamine micellar core. Pharmacokinetic studies showed
an incredible extension of circulation time compared to drug solution [90].
Immunological responses Strong immunological responses of the body upon nanoparticle
injection is a major mechanism that triggers rapid particle clearance from circulation. In
Figure 1.3 the most relevant interactions are portrayed. In the following sections of the
article, the most relevant effects will be highlighted.
Complement activation Introduction of foreign macromolecular materials into a living
body leads to an activation of the humoral immune system [91, 92, 93]. As a part of this
system, complement activation is an efficient mean for the immune system to recognize and
initiate clearance of particle-like organisms such as viruses or bacteria from the bloodstream
[94]. It is worth mentioning the fact that typical sizes of viruses are equal to that of colloidal
systems [95]. As discussed above, PEG is a widely used material to achieve stealthiness
that aims at avoiding opsonization and, consequently, rapid uptake by the MPS. The mode
of binding of complement factors onto the particle surface was nicely reviewed by Karmali
and Simberg [93]. Furthermore, the investigations of Szebeni and Moghimi contributed to
the knowledge and understanding of complement activation by PEGylated surfaces. The
authors revealed that, as a special type of hypersensitivity reaction, CARPA (C-activation
related pseudoallergy) is associated with nanoparticles [96]. This reaction is known to be
non-IgE based but initiated by the classical, alternative, or lectin pathway of complement
activation (C3a-, C5a-activation). Upon injection of nanoparticles, complement activation
appears rapidly which finally activates immune competent cells such as mast cells or other
granulocytes. In sensitive patients this could lead to anaphylactic reactions [97]. Several
in vitro tests were proposed for screening the tendency of nanoparticulate formulations on
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Figure 1.3: Immunological effects that are responsible for premature nanoparticle clearance.
The most impacting mechanisms are shown: 1) complement activation, 2) unspe-
cific antibody attraction and 3) anti-PEG antibody attraction.
complement activation [98, 99], as well as a porcine in vivo test [25]. The high relevance of
complement activation in humans was already investigated with the liposomal drug delivery
system Doxil® [100]. Apart from severe hypersensitivity reactions complement activation
plays an important role in particle opsonization followed by phagocytosis in the MPS and
is therefore an important mechanism that can alter particle biodistribution and circulation
kinetics. Once “detected” by the complement system, rapid clearance can occur.94 Considering
this idea, Yang et al. performed an in vitro study to answer the question of complement
activation and phagocytotic uptake in relation to PEG block lengths on the particle surfaces
[101]. The group prepared PLGA nanoparticles with and without varying PEG chains and
incubated them with different sera types. The incubated and opsonized particles were studied
on phagocytosis by murine peritoneal macrophages. To distinguish between effects caused
by 1) antibodies or 2) the complement system, the authors applied murine anti-IgG (model
protein for inhibiting antibody response), EGTA (inhibits classical complement pathway),
and EDTA (inhibits both pathways). As a result of their study, decreasing phagocytotic
uptake of nanoparticles was found less dependent on anti-IgG but more on complement
system. Furthermore, widely accepted “stealth” PEG block lengths (2 and 5 kDa) and
hydrophilic/hydrophobic ratios (from 2.5% to 10%) played a significant role in reducing
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adsorption of opsonins due to complement activation onto particle surfaces. The influence of
the PEG chain on nanoparticle distribution compared to bare PCL nanoparticles dependent
on complement activation was also studied by Shan et al. [102]. Although PEG is known as
a complement activator, lower opsonization and phagocytotic rates by macrophages (bare
NP, 90% phagocytosed 5 min upon injection; PEGylated NP, 45% phagocytosed 5 min
upon injection) were found for the PEGylated species that reduced complement activation
significantly and finally increased circulation time of PEG-PCL particles. Polymeric micelles
also present PEG at their surfaces and therefore could be able to activate the complement
system. As indicated by the cited studies, complement activation upon nanoparticle injection
plays an important role in their safety and biodistribution. Although the liposomal product
Doxil® showed strong complement activation in vitro [98] and most likely in vivo by causing
anaphylactic reactions in certain patient groups [26], these liposomes showed a prolonged
circulation time in the second part of their biphasic pharmacokinetics [20]. Consequently,
the influence on circulation times of nanoparticles seems to be more or less unpredictable.
Opsonization by complement can lead to rapid particle phagocytosis and the underlying
mechanisms have not been fully understood yet.
Unspecific antibody attraction and opsonization Apart from antibody opsonization upon
complement activation, very little is known about the direct interaction between circulating,
unspecific antibodies and nanoparticle surfaces. Some studies reported in the past an influence
of Immunoglobulin G [103, 104, 105] and M [106] on particle opsonization. From the cited
studies it is very speculative to make a conclusion on the relevance of this phenomenon.
Finally, it is hard to distinguish in experiments between complement activation followed by
immunoglobulin attraction or immediate immunoglobulin attraction without any complement
activation. Nevertheless, it has been shown in these studies that PEGylated surfaces can
inhibit very strong immunoglobulin attraction and, consequently, maintain the stealth effect
of the particles.
Anti-PEG-antibodies When PEGylation arose as a strategy to prolong circulation and
decrease degradation of therapeutic proteins, in 1983 Richter and Akerblom found an anti-PEG
antibody formation in rabbits and mice by coupling different PEG chain lengths with varying
adjuvant proteins [107]. As a result of their study, they could harvest anti-PEG antibodies and
concluded that a sequence of 6−7 ethylenoxide units was the “antigen determinant”. One year
later, in 1984, the same authors investigated the natural occurrence of anti-PEG antibodies in
allergic and healthy patients and identified them mainly as IgM isotype [108]. The prevalence
in allergic patients was significantly higher than that in healthy ones. Nevertheless, upon
PEG-hyposensitization nearly 50% of the patients showed an anti-PEG antibody response.
This number declined over 2 years of treatment to ∼28%. Overall, titer of these anti-PEG
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antibodies in patients’ serum was very low. Therefore, the authors concluded that their
findings were of no clinical significance. By increased usage of PEGylated drugs, knowledge
on clinical relevance increased simultaneously. Ganson et al. described the formation of IgM
and IgG anti-PEG antibodies in a phase I clinical study with PEG-uricase upon a single
s.c. injection [109]. The authors identified two patient collectives: the first with high drug
titers after 3 weeks of injection and the second with no detectable drug titers after 10 days of
treatment. Consequently, the second specific patient group was more susceptible to antibody
formation that led to rapid clearance of the drug. Interestingly, the analyzed anti-antibodies
were of two species: one against the drug uricase and the other against PEG. Armstrong
et al. analyzed serum samples from patients treated with PEG-asparaginase [110]. It was
previously reported that therapy with this drug could fail due to antibody formation in
25% of the patients. Armstrong et al. found a strong positive correlation between antibody
formation and rapid drug clearance and finally advised an anti-PEG antibody screening
prior to the therapy for every patient. Nowadays the formation and appearance of anti-PEG
antibodies upon multiple dosing of nanoparticles is still intensely discussed in literature; it
has been found that such antibodies have a huge impact on nanoparticle distribution: The
effect is called “accelerated blood clearance (ABC) phenomenon”, and is caused by anti-PEG
IgM formation and was first observed for nanoparticles in rodents and rhesus monkeys
[27, 111]. This antibody formation takes place in the spleen where a certain amount of all
nanoparticles, depending on their size, accumulate [112]. Recent studies in B- and T-cell
deficient mice make splenic B-cells responsible for this IgM secretion, whereas the detailed
mechanisms of this phenomenon yet remain unclear [113]. The studies of Ishida et al. with
liposomes revealed a dose dependency of the lipid inducing antibody formation. Predosing
low lipid amounts (1 mmol per kg) without drug (blank liposomes) induced increased antibody
concentrations, whereas higher doses (5 mmol per kg) of lipids showed lower IgM response.
When doxorubicine-loaded liposomes were applied, even in low lipid doses, the IgM formation
was decreased compared to empty liposomes. Upon injection of the liposomal drug Doxil®
for several times into animals, blood concentrations of doxorubicine, as expected, did not
decrease with every injection [113]. It was suggested in this study that the encapsulated
anticancer drug led to an inhibition of antibody induction by reducing the number of B-cells
as a result of cytotoxic effects. Similar observations of this ABC phenomenon were also made
by the group of Romberg et al. [114] with liposomes and by Ishida et al. for PEG-PLA
nanoparticles [115], as well as for siRNA-loaded cationic liposomes [116]. The relevance for
polymeric micelles was investigated and a strong size dependency was found. For micelles
<∼30 nm in diameter it was believed that the ABC phenomenon has no relevance [117].
The question remains as to what extent these results are unexpected and what impact
they have on multiple dosing in humans. From the current point of view, the probability
and clinical significance of anti-PEG antibody formation seems to be underestimated. A
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detailed understanding of the formation mechanisms is the basis for the avoidance of therapy
failures. The results from further studies could give an answer to the question if PEG was
the only highly suitable material to achieve stealth properties. Development of ELISA test
kits to screen anti-PEG antibodies state the upcoming clinical relevance of this issue [118].
Furthermore, Koide et al. [113] argued that this phenomenon is not seen for the liposomal
Doxil® due to cytotoxic effects of the anticancer agents on antibody producing splenic cells.
If this hypothesis is true, then the question is, if nanomedicine is only applicable for cancer
treatment or for other indications too?
1.2.4 Implications for passive targeting
Generally, there are two strategies available that allow for drug targeting to disease-modified
tissue. Active targeting focuses on the coupling of targeting moieties onto nanoparticulate
surfaces. The moieties represent ligands to cell-specific antigens that mediate coupling and
uptake of colloidal associates into the target cells [119, 120]. Contrary to this concept is the
passive targeting that utilizes the unique size properties of colloidal carriers. In the following
sections it will be focused on the passive targeting concept because the above stress factor
analysis contributed most to this concept.
1.2.4.1 Evidence of EPR effect for macromolecules
Accumulation of macromolecules in disease-modified tissue like tumors or arthritic tissue
is believed to be based on the Enhanced Permeability and Retention (EPR) effect. The
concept of EPR was formulated in 1986 by Maeda and Matsumura based on the observations
that macromolecules (e.g., albumin, dyes attached to albumin, IgG) show an enhanced
tumor accumulation and could sustain in tumor tissue for long periods of time [16]. The
group of Maeda et al. [18, 121, 122, 123, 124] named the following anomalies that could
be found in various disease-modified tissues “EPR”: 1) high vascularization density, 2)
leaky vasculature, 3) decreased lymphatic drainage, and 4) participation of certain tissue
inflammation mediators (e.g., NO, Bradykinin, VEGF, Prostaglandins) that support the
formation of 1) and 2). Further studies showed that a minimum molar mass for this tumor
accumulation is mandatory: macromolecules above 40 kDa cannot be excreted via free
filtration from the kidneys and represent the molar mass minimum [16]. The EPR effect
with macromolecules has been shown numerous times in diverse disease models and has
been reviewed extensively [12, 17, 125, 122, 126]. Apart from molar mass considerations,
the group of Dellian et al. [127] reported differences in tumor accumulation of BSA and
IgG that were chemically modified. The modifications changed the electrical charges of the
proteins by keeping their molar mass nearly constant. The results of their study showed,
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that the cationic particles of BSA and IgG exhibited the shortest serum half-life yet and
the highest tumor accumulation compared to the anionic species. Simultaneous uptake in
healthy tissue increased as well. This observation corresponded to the anionic surface charge
of endothelium cells in healthy and tumor tissue, which consequently increased the retention
of cationic particles. An often cited experiment in this context to prove the accumulation of
macromolecules in tumor tissue is based on experiments with the SMANCS adduct consisting
of poly-(styrene-co-maleic acid) (SMA) copolymer coupled to neocarzinostin (NCS) [18].
Maeda et al. compared tumor accumulation of the polymer adduct with the unbound NCS.
It was shown that the SMANCS adduct (16 kDa) was retained more effectively in the
tumor tissue compared to NCS (12 kDa) due to the SMANCS’ high affinity to albumin
[128, 129]. Consequently, the efficacy of SMANCS was based on the utilization of albumin
as a “ferry” (final molar mass: ∼92 kDa). This hypothesis was supported by Pimm and
Hudecz [130] who compared the tumor accumulation of varying serum proteins with that
of synthetic macromolecules. The results were acquired from radiolabeling natural proteins
(albumin, IgG, transferrin) and synthetic macromolecules (polypeptides with poly-L-lysin
backbone). The protein and macromolecular species were injected into tumor bearing mice
(subcutaneously implanted tumors) and tumor/blood concentration ratios were utilized to
evaluate the accumulation efficiency. As expected, the results showed a strong accumulations
of transferrin and albumin in the tumor tissue. Compared to the accumulation values of
these natural macromolecules, the synthetic macromolecules accumulated to a lesser extent
in the tumor tissue, even when exhibiting long blood circulation times (∼26 h and more).
The authors were aware of the fact that their polymers might not be suitable for such
distribution experiments, but according to the EPR theory, long circulating macromolecules
should invade the tumor extensively. Charge effects were included in the study by utilizing
two different labels (Iodine-125 and Indium-111). The authors raised the question how
permeability “enhancement” can be defined and what factor one could use to evaluate this
(organ/blood concentration ratios, control groups with serum proteins). The group concluded
that enhancing tumor uptake of macromolecules could simultaneously enhance uptake in
the liver, spleen, or kidneys as well. The authors stress the need for consideration of this
matter when deliberating passive tumor delivery of macromolecules. So far, there has been
no evidence of nanoparticle formation in the studies mentioned above yet.
1.2.4.2 The EPR effect in case of nanoparticles
It is generally believed that similarly to macromolecule accumulation in tumors one can
conclude that nanoparticle accumulation is based on similar effects, especially that long
circulation necessarily leads to superior tumor accumulation [131]. However, this remains
questionable due to the high molar mass differences between macromolecules in the several
21
CHAPTER 1. INTRODUCTION
hundred kDa range and nanoparticulate associates with masses of possibly several millions
of kDa. In this context, the investigations of Dreher et al. [132] revealed that, for dextran
macromolecules, the optimal tumor accumulation molar masses range between 40 and 70 kDa.
Although the plasma half-life of dextrans with higher molar masses up to 2 MDa resulted in
an extended blood circulation time, it still led to a less-effective extravasation and penetration
into tumor tissue. In detail, 2 MDa dextran exhibited the longest circulation time but did not
reach the extravasal tumor accumulation of 70 kDa dextran. Consequently, the often described
paradigm [12, 18, 122] that long blood circulation relates to high tumor accumulation of
macromolecules does not necessarily work. When high molar mass macromolecules show a
decreased extravasation compared to low molar mass species, then what does this mean for
nanoparticles? Many studies have revealed without any doubts that increased accumulation
of nanoparticular formulated drugs is related to the EPR effect [133, 134]. Other authors
that investigated particulate tumor accumulation were much more reserved in concluding
and supporting the existence of an EPR effect [135, 136] based on their observations. So far,
the proposed mechanisms leading to nanoparticle extravasation from bloodstream comprise
of leakage from blood vessels through fenestrations, transendothelial channels, and anomalies
in the endothelial basement membrane [137, 138]. When talking about nanoparticle tumor
accumulation, the question of size ranges for the tumor blood vessel fenestrae comes up.
Due to the varying expression of tissue anomalies in different tumor models, the information
reported in the literature is strongly scattered. The proposed size ranges for particles utilizing
the EPR effect range from several nanometers for macromolecules over 200−300 nm [134] to
2 mm [139]. Yuan et al. [140] proposed pore cutoff sizes between 400 and 600 nm. Hobbs
et al. [138] investigated the leaky vasculature extensively and revealed intercellular gaps
between 200 nm and 1.2 mm. The group also found an impact of hormones on the vascular
leakiness of hormone-dependent tumors. As an example, in a testosterone-dependent tumor
hormone withdrawal led to a decrease in the pore size from 200 to 7 nm within 48 h. Another
discrepancy was found between the same tumors in different locations within the animal.
Tumors grown in the cranial environment had smaller pore sizes compared to subcutaneously
implanted ones. Interestingly leakiness for albumin was found to be equal in all investigated
tumor models [138]. Xiao et al. [141] showed dependence of tumor size on the extent
of accumulation of polymeric micelles. Larger tumors showed a higher extent of particle
accumulation compared to smaller tumors which were related to “underdeveloped vasculature”
[141] in small tumors. Apart from this Feng et al. [142] found that tumor vessel fenestration
was highly dependent on the tumor model. It was previously shown by Maeda et al. [122]
that a vascular endothelial growth factor (VEGF) was of high relevance for the EPR effect.
The group of Feng et al. [142] investigated two well-known VEGF-secreting tumor models
and revealed fenestrations in only one of these models. By checking both tumor models
on vascular permeability with a plasma protein, extravasation was found in both models.
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The group especially argued for and proved the presence of endothelial cell vesiculo-vacuolar
organelles that allowed macromolecules to extravasate from vessels.
1.2.4.3 Additional factors shaping EPR effect
Upon discussing morphological and physiological issues of tumor tissue the question now
arises which additional mechanisms could play a role in accumulation of nanoparticles in
disease modified tissues? A point which has not been highlighted in this article yet is the role
of tumor nutrition: Rapidly proliferating cells obviously have an increased need of nutrients.
The review of Stehle et al. [143] nicely summarized tumor uptake of varying nutrients from
the bloodstream. The group concluded that glucose and albumin were the most relevant
molecules that maintain rapid cell growth in tumor tissue. The authors proposed that the
high albumin consumption of the tumor cells provided a negative nitrogen balance in a late
tumor state and that, therefore, tumors were often called “nitrogen traps”. In this case,
the effect could lead to cachexia. Additionally, the group described the accumulation of
albumin in the well oxygenated periphery of the tumor tissue due to the lack of lymphatic
drainage. Evidence for this phenomenon was provided by radiolabeled serum albumin,
which showed enhanced tumor accumulation [144], leading to increased osmotic pressure
in tumor tissue based on this natural macromolecule accumulation. Consequently, in the
tumor periphery, cell energy is generated from protein metabolism. It was presented by
Stehle et al. that uptake of albumin in tumor cells took place by pinocytosis, indicating
a nonspecific mechanism. Albumin accumulation in other disease modified tissue plays an
important role too, for example, in rheumatoid arthritis. Patients in their acute disease state
exhibited a hypoalbuminemia and an extremely high accumulation of albumin in inflamed
joints [145]. However, this physiology could favor the delivery of nanoparticles into disease
regions by utilizing proteins as “ferries”. The underlying physiology in arthritis and therefore
the retention of colloidal carriers were found to be based on a different mechanism compared
to the EPR effect: the reason for extravasation was seen in “leaky vasculature and subsequent
inflammatory cell-mediated sequestration (ELVIS)” [146]. Depending on the disease state
(acute vs chronic), lymphatic drainage is counterbalanced: in acute states the lymphatic
flow was increased, whereas in the chronic state the number of mainly leaky lymphatic
vessels increased [147, 148]. Consequently, the overall lymphatic flow is not decreased as
it was found in solid tumors. Therefore, enhanced retention in arthritic joints was found
to be increased by the uptake of colloidal systems into synovial cells [149]. Coming back
to the original discussion on tumor accumulation and retention, recent investigations with
Paclitaxel-coupled albumin nanoparticles (Abraxane®) suggest the involvement of active
mechanisms that guide albumin nanoparticles into the tumor region. According to Desai
et al. [150, 151], the following two mechanisms are involved: 1) transcellular uptake by
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gp-60 receptor on endothelial cell surfaces and 2) SPARC (secreted protein acidic and rich in
cysteine) overexpression in tumor cells with increased albumin retention. The group [150]
came to this conclusion on the gp-60 receptor mechanisms by performing in vitro uptake
experiments with Abraxane® compared to Taxol® (Cremophor EL®/ ethanol formulation).
Inhibition of gp-60/caveolar transport by addition of β-cyclodextrin decreased the transcytotic
transport of Abraxane®. SPARC was found to be secreted in many different tumor cell
lines [152] and to be a strong affinity albumin binding protein [153]. The group of Desai et
al. [151] investigated tissue samples from patients suffering from head and neck cancer that
were treated with Abraxane® on SPARC expression levels. They showed a correlation of
enhanced SPARC expression in head and neck cancer patients with increased response rate of
Abraxane® nanoparticles (83% responders in SPARC overexpression group vs 25% in SPARC
normal expression group). As indicated by this analysis of mechanisms upon injection, it is
highly unlikely that injected nanoparticles arrive at the tumor tissue in their original form.
Greish et al. [154] investigated styrene-maleic acid micelles for encapsulation of pirarubicin
and confirmed the high albumin binding capacities of the micelles. Upon albumin adsorption
the micelles reached a molar mass of around 94 kDa and were found to accumulate successfully
in tumors. So what role does the protein corona play in tumor accumulation? Walczyk
et al. published in 2009 their results on the “rigidity” of the protein corona adsorbed onto
nanoparticle surfaces. From studying several modified polystyrene (PS) and SiO2 particles
concerning their protein surface adsorption properties they revealed a “hard” corona (protein
double or single layer) protein species pattern that was highly dependent on the particle
type [155]. Due to the high stability of attached proteins they proposed that biodistribution
could be altered by protein adsorption and that this corona might change again once it has
reached the target cells. Most likely the target cells did not “see” the bare nanoparticles but
most likely these highly complex protein shells [156]. Ehrenberg et al. [157] investigated the
relation of nanoparticle surface properties (e.g., charge) and protein adsorption patterns on
the particle binding to a human endothelium cell line in vitro. The group found a direct
correlation between surface properties, protein content adsorbed onto the particles and
binding to endothelium cells. Upon depletion of the most abundant proteins from serum
and incubation with this depleted serum, the adsorption pattern on the surfaces changed as
expected. Unexpectedly, the binding properties to endothelium cells remained unchanged.
From their experiments the group concluded on the high relevance of unspecific uptake
mechanisms for particles with high protein coverage. For particles with low protein coverage
active receptor-mediated uptake could not be excluded. The dysopsonic [158] properties of
albumin were subject of further investigations by Furumoto et al. [159]. The group coupled
albumin onto the surfaces of PEG-liposomes and investigated biodistribution in rats. In
fact, albumin coupling prolonged circulation time of albumin-PEG-liposomes compared to
bare PEG-liposomes. Simultaneously, liver deposition of the albumin-bound PEG-liposomes
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decreased. The investigations of Crielaard et al. are in contrast to these, they utilized surface
plasmon resonance to elucidate PEG-liposome attachment on protein-coated chips [160].
They revealed high affinity of PEG-liposomes to apolipoprotein E and α2-macroglobulin
and a low affinity to human serum albumin. Both proteins are known to be opsonins. In
in vivo experiments, the interaction of several proteins with liposomes were successfully
correlated with plasma clearance. Considering these studies, there is strong evidence that
target accumulation of nanoparticles in tumor tissue is not only a matter of particle size, but
also depends on the protein corona adsorbed onto the particle surface. Albumin and other
proteins seems to play a highly important role as dysopsonins by prolonging the circulation
of nanoparticles and might present a nutrient for tumors or inflamed tissue, thus, being
preferentially phagocytosed by rapidly proliferating cells. The importance of other serum
proteins on tumor accumulation needs to be further elucidated. Furthermore, extended
circulation times of particles seem not to be a prerequisite to making use of the EPR effect;
it is rather a matter of surface attached dysopsonins that finally guides the particles to
the target organs. Apart from this, there are successfully targeting drugs on the market
or in research that are bound to albumin (Abraxane®) or bind to the protein in situ (e.g.,
Doxo-EMCH) [161]. Overall, the dysopsonin theory is not that new and was used to explain
the biphasic pharmacokinetics of Doxil® [20].
1.2.5 Conclusion
In this review it was analyzed relevant and important stress factors that colloidal drug delivery
systems encounter upon injection with special emphasis on polymeric micelles. High dilution,
multiple interactions with serum proteins, complement activation, and antibody attraction
can accelerate premature particle and drug clearance from the bloodstream. The mechanisms
involved are rather complex but should be considered when designing nanoparticles and
eventually in evaluating the failure of nanomedicines during in vivo experiments. In this
context it seems that protein adsorption has a strong impact on nanoparticle biodistribution
and their uptake into diseased tissue. Due to advances in analytical techniques, interactions
of nanoparticles with serum proteins can be monitored in vitro. The role of premature drug
redistribution from nanoparticles toward serum proteins remains unknown. In the case of
drugs with high protein binding affinities, successful transport to the target site of action
could be carried out by such drug−protein adducts. However, some studies indicate that
nanoparticle sizes and the selection of an appropriate tumor model state were necessary
conditions but not the only factors that affect the EPR effect. It is suggested to consider the
opsonin−dysopsonin model to explain the pharmacokinetics and tumor uptake of existing
successfully targeting systems as well.
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1.2.6 Future perspective
The performance of nanoparticles for intravenous drug delivery should be carefully evaluated
in terms of their 1) colloidal stability upon dilution and contact with serum proteins, 2)
drug incorporation stability, and 3) relevance of immunological responses of the human body.
Most of these questions can only be answered in vivo (preferentially human), but in vitro
approaches could give valuable hints (e.g., in vitro complement activation, serum incubation).
A subject of future investigations will be the appearance of nanoparticles (protein corona) at
their target site of action. A detailed understanding of all relevant uptake mechanisms into
tissue is extremely important. Additionally, future clinical trials must reveal the relevance
of the EPR effect in humans for colloidal nanoparticles to give evidence, if the promising
developments and theories from the past decades contribute significantly to the efficacy and
safety of drug therapies.
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1.3 Research objectives of the thesis
The research focus of this thesis was the preparation, characterization and investigation of
polymeric micelles for organ specific drug delivery purposes. This challenging issue was to be
clarified based on the following pillars:
1. Drug loading efficacy: Concerning therapeutic efficacy of colloidal carriers their
loading with the drug (drug/polymer ratio) is a crucial parameter [8]. Typically drug
loads in polymeric micelles are quite low and need enhancement by novel polymer
architectures or drug loading techniques. One example for this are griseofulvin loaded
PEG-PLA micelles with a load of 0.65% [162]. Other systems were more successful
and there are reports in literature which describe impressive loading rates e.g. of 10%
for taxane derivatives [163] or 19% for cyclosporin A [164]. Consequently one goal of
the thesis was the investigation of drug loading mechanisms into micelles which finally
could enhance the drug/polymer ratio (chapter 2).
2. Stability of polymeric micelles in biofluids: Stability of colloidal carriers is
essential to assure the long-circulating properties and to prevent premature drug release
upon injection. This issue can be addressed in vitro by incubation with relevant media.
One approach from literature is an analytical technique based on Foerster Resonance
Energy Transfer (FRET) [165, 53]. This method was selected as a starter. One aim
was to find a correlation between serum stability and physicochemical properties of
polymeric micelles and to select suitable candidates for in vivo applications (chapter
3).
3. Toxicological concerns and immunological responses against colloidal carri-
ers: Acute and chronic toxicity as well as reactions by the immune system prominently
by the complement system are severe drawbacks of micellar systems [166, 167, 168, 93].
For this purpose particle toxicity was to be elucidated in vitro on primary cells/cell lines
and in presence of serum. The goal was to discriminate between different polymeric
compositions in terms of cytotoxicity and complement activation. Both issues deliver
valuable information about drug safety of nanomedicines (chapter 4).
4. Drug targeting into tumor tissue: In case of high colloidal stability of drug-loaded
polymeric micelles upon injection it is believed that such PEGylated nanoparticles with
sizes below 200 nm were very effective in tumor targeting [131]. This passive targeting
concept was originally invented for macromolecules by Maeda and Matsumura [16] and
should allow for superior cancer treatment. Both assumptions, 1) colloidal stability
upon injection (chapter 6) and 2) passive targeting by size, were followed in vivo by
radiolabeling of carrier and payload. If both species, carrier and payload, reach their
target site of action in sufficient concentrations compared to other organs, this would
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indeed show rationale for improved cancer treatment (chapter 5 and 7). So far, only
a couple of studies were dealing with this extremely relevant question [53, 87].
Summarizing these research objectives, it is obvious that for addressing the open scientific
questions in vitro as well as in vivo experiments were necessary to conduct. Moreover, this
thesis could deliver the answer if the existing micellar technologies were sufficient for targeted
delivery or if further modifications of the systems have to be considered.
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2.1 Abstract
With this study it was intended to gain mechanistic insights into drug loading and lyophiliza-
tion of polymeric micelles. PEGylated poly-4-(vinylpyridine) micelles were loaded with the
model drug dexamethasone. Three different methods were applied and compared: 1) O/W
emulsion technique, 2) direct dialysis and 3) cosolvent evaporation (Fig. 2.1). Micellar disper-
sions with the highest drug load were lyophilized with varying lyoprotectors, including polyols
like sucrose, trehalose, maltose, a polyvinylpyrrolidine derivative as well as β-cyclodextrin
derivatives. For comparison other PEGylated block copolymers (PEGylated polylactic acid,
polylactic acid-co-glycolic acid, poly--caprolactone) were freeze-dried. Drug loading via direct
dialysis from acetone was a less effective loading method which led to dexamethasone loads
<2% (w/w). O/W emulsion technique from dichlormethane increased the drug load up to
∼13% w/w whereas the optimized cosolvent evaporation increased the load up to ∼19% w/w.
An important step for the cosolvent evaporation was the solubility screen of the drug prior to
preparation. The high drug load was maintained upon lyophilization with β-cyclodextrins
which proved to be excellent, versatile stabilizers for other block copolymer micelles as well.
In conclusion careful solvent selection prior to cosolvent evaporation was a beneficial approach
to load hydrophobic drugs into polymeric micelles. Moreover, β-cyclodextrins could be used
as versatile lyoprotectors for these micelles.
Figure 2.1: Summary of the most successful micellar preparation approach in the study:
cosolvent evaporation followed by lyophilization.
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2.2 Introduction
High Throughput Screening (HTS) of drug candidates increased the number of hydrophobic
new molecular entities in drug discovery [169, 170]. The amount of hydrophobic drugs
among development compounds was estimated by Lipinski in 2002 to be around 40% [5].
Recent investigations showed that the actual number of drug candidates which can be
categorized in class II or IV in the Biopharmaceutics Classification System (BCS) [171] was
75% and higher. However, low aqueous solubility resulting from HTS remains a challenge
in pharmaceutical industry leading to higher costs in development and drug attrition rates
upon approval [6]. Despite huge progress in advanced solubilization technologies, the options
for hydrophobic compounds aiming on intravenous injection are still limited [6] and often
bought dearly with toxic side effects of utilized excipients (e.g. Cremophor EL®/ethanol in
Taxol® [172]). Therefore nanosized approaches to overcome solubility issues became more
and more important over the last decades. However, encapsulation of therapeutically relevant
drug doses are a basic requirement for reasonable treatment and has been regarded as one
of the major drawbacks of nanoparticulate delivery systems [173]. Among nanoparticles a
very promising technology with high solubilization potential is based on polymeric micelles.
However, preparation of such micellar systems with high drug loads remains still challenging
[174, 8]. A number of different drug loading procedures were elaborated but often were
based on trial and error experiments and lack of a more systematic approach. The major
reason is the limited knowledge of the underlying mechanisms leading to sufficiently high
drug loadings. The organic solvent by which the drug loading process is initiated plays a
key role in all preparation methods: According to the solvent properties (water-miscibility)
an appropriate candidate is usually selected which finally defines the processing steps to
follow. In this context the following drug loading methods have commonly been used:
1) O/W emulsion techniques [175], 2) W/O/W emulsion techniques [176, 177], 3) direct
dialysis [178], 4) cosolvent evaporation techniques [179] and 5) loading via lyophilization [180].
Among those procedures especially 1), 3) and 4) are highly compatible with hydrophobic
drugs whereas 2) focuses on the encapsulation of more hydrophilic compounds and 5) has
limitations concerning polymer water solubility [180]. In this study the methods 1), 3) and
4) were selected as ideal loading methods for hydrophobic drugs and micelles were prepared
by encapsulating the model drug dexamethasone. With its aqueous solubility of 80 µg/mL
[181] it is a typical hydrophobic model compound which is in addition highly interesting for
parenteral application. For the encapsulation study the PEGylated poly-(4-vinylpyridine) was
selected that was known to form stable micelles in water [57]. As micelles are fragile dynamic
systems it is highly desirable to stabilize the particles after freeze-drying. It is known from
literature that besides classic lyoprotectors like sucrose or trehalose especially β-cyclodextrins
are suitable lyoprotection excipients [182, 183]. Consequently the question became relevant
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which kind of stabilizing mechanisms cyclodextrins might have compared to classical polyols
and if they might be helpful as versatile protectors for PEGylated block copolymer micelles.
The purpose of this study was to gain mechanistic insight into the micellar encapsulation
process of hydrophobic drugs by applying different preparation techniques using various
organic solvents. In addition, β-cyclodextrins were compared to standard lyoprotection agents
for their stabilizing properties. Such mechanistic insights in both the loading procedure and
lyoprotector stabilization are of immediate relevance for the development of novel preparation
techniques for polymeric micelles.
2.3 Materials and methods
2.3.1 Materials
PEGylated poly-(4-vinylpyridine) (PEG-PVPy) [5-b-20], PEGylated poly-(lactic acid) (PEG-
PLA) [5-b-23] and PEGylated poly-(-caprolacton) (PEG-PCL) [5-b-32.5] were purchased
from Polymer Source, Inc., Montreal, Canada. PEGylated poly-(lactic-co-glycolic acid)
(PEG-PLGA) [5-b-28] (Resomer RGP d 50155) was delivered from Boehringer Ingelheim,
Ingelheim, Germany. Dichlormethane (DCM), tetrahydrofurane (THF), acetonitrile (ACN),
methanol, ethanol, dimethylsulfoxide (DMSO) were obtained from VWR, Darmstadt, Ger-
many. Dexamethasone (Ph.Eur.) was delivered by Euro OTC Pharma from a local pharmacy
store. Dulbeccos Saline PBS buffer concentrate was obtained from Sigma Aldrich, Rossdorf,
Germany. Float-A-Lyzer G2 dialysis tubes (MWCO 8-10 kDa) and standard dialysis tubes
(MWCO 6-8 kDa) were obtained from Spectrumlabs Inc., Breda, The Netherlands. For
filtration of the micellar dispersions 0.2 µm Pall Acrodisc syringe filters with GHP membrane
were used (Pall Life Sciences, Ann Arbor, MI, USA). Sucrose, trehalose, glucose, lactose,
maltose and D-(-)-mannitol were obtained from VWR, Darmstadt, Germany. Kollidon 17PF
was delivered from BASF, Ludwigshafen, Germany. Kleptose® (HPβCD) was obtained from
Roquette, Frankfurt, Germany. Captisol® (SBEβCD) was delivered from Cydex, Lenexa,
KS, USA. Water was of MilliQ grade.
2.3.2 Methods
2.3.2.1 Preparation of drug loaded micelles
Direct dialysis from acetone 10 and 20 mg of block copolymer and 1 and 4 mg DXM,
respectively, were dissolved in 1 mL acetone. This solution was filled into a dialysis bag and
sealed. Dialysis was carried out over 24 h against 5 L water which was changed once after 4 h.
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The dispersion was filtered through a 0.2 µm membrane to remove drug precipitates. Finally
the mass of the resulting micellar dispersion was adjusted to 2 g by dilution with water.
O/W emulsion technique Micelles without DXM were prepared as described above in
the section “direct dialysis from acetone” without drug. For drug loading, 2 mg DXM was
dissolved in 1 mL DCM. This solution was injected under constant stirring to 2 mL aqueous
micellar dispersion containing the “empty” micelles. After stirring over night the resulting
dispersion was filtered through a 0.2 µm filter membrane to remove drug precipitates and the
mass was adjusted to 2 g by dilution with water.
Selection of appropriate solvent for cosolvent evaporation The following water miscible
organic solvents were included in a solvent screen for DXM: THF, ACN, acetone, DMSO,
DMF, methanol, ethanol. The screen was carried out by using the following procedure at
25°C: 1) Dissolving 1mg of drug in 100 µL organic solvent, 2) stepwise addition of 10 µL
water to this solution, 3) determination of drug precipitation by optical visibility of particles.
Precipitation was investigated against a black background with sample illumination by cold
light. The solvent in which the drugs exhibited the highest optical solubility was selected for
preparation in the solvent evaporation step.
Cosolvent evaporation Drug loaded micelles were prepared by the combination of solvent
evaporation followed by dialysis. 10 mg block copolymer and 2 mg drug were dissolved in
6 mL THF or 8 mL acetone; this solution was mixed with 2 mL water. The mixture was
transferred into a round bottom flask and evaporated by applying vacuum of 30 mbar at 25°C.
To remove the maximum amount of solvent this vacuum was kept constant for 10 min. The
remaining aqueous formulation was then transferred into a Float-A-Lyzer G2 tube for dialysis
to remove residual solvents. The formulation was dialyzed against 5 L DXM saturated water
for 24 h. Finally the formulation was filtered through a 0.2 µm membrane and mass adjusted
to 2 g.
2.3.2.2 Drug load determination
100 µL of the final micellar formulation was dissolved in 900 µL acetonitrile. This solution
was injected in a HPLC system (Merck Hitachi La Chrom Elite) equipped with a UV detector
(detection wavelength: 282 nm) and a Agilent Eclipse Plus C18 column (3.5 µm coarse, 5
cm length) at 35°C. A gradient method was used for separation where the mobile phase A
consisted of 90% (v/v) ACN/ 10% (v/v) ammonium acetate buffer (pH 4.5, 10 mM) pH 4.5;
mobile phase B had the opposite composition. DXM concentration was determined by drug
33
CHAPTER 2. DRUG LOADING OF POLYMERIC MICELLES
substance calibration curve. The polymer concentration was calculated from the initially
used polymer feed prior to the preparation of micelles. Drug load was calculated according
to equation 2.1:
Drug load [%] =
Drug concentration [mgmL ]
Polymer concentration [mgmL ]
· 100% (2.1)
2.3.2.3 Particle size measurement
Dynamic light scattering (DLS) was used to determine hydrodynamic diameter of the
nanoparticles. Therefore, a Zetasizer-ZS from Malvern Instruments, UK, was selected and
used in the backscattering mode. Measurements were performed in triplicate.
2.3.2.4 Lyoprotector screening via Differential Scanning Calorimetry (DSC)
10% w/v aqueous solutions of the selected lyoprotectors served as reference and were filled into
100 µL aluminum pans. Micellar formulations of DXM-loaded PEG-PVPy (0.5% w/v) were
mixed with the lyoprotector solutions (10% w/v) 1:1 to reach a final lyoprotector concentration
of 5 % (w/v). Each aluminium pan was filled with 80 µL and sealed. Thermoanalysis was
performed on a Mettler Toledo DSC 821e (Mettler Toledo GmbH, Giessen, Germany). The
samples were frozen from 25°C to -50°C with a cooling rate of 10 K/min followed by an
isothermal step of 5 min. The samples were heated to 25°C with a heating rate of 10 K/min.
After an isothermal step at 25°C of 5 min the whole procedure was repeated. Onset of glass
transitions were evaluated in the thermograms of the heating step. For stabilizer screening
each experiment was carried out in triplicate.
2.3.2.5 Lyoprotector screening via lyophilization of placebo micelles
Polymeric micelle formulations (0.5% w/v polymer) were prepared employing the cosolvent
evaporation method from THF, including either the DXM-loaded PEG-PVPy micelles or
unloaded PEG-PDLLA, PEG-PLGA and PEG-PCL micelles. The dispersions were premixed
with adequate amounts of β-cyclodextrin derivative solutions to reach final lyoprotector
concentrations of 5% w/v. The prepared solutions were transferred into 2R-glas vials; filling
height was adjusted to 1.0 mL for all samples. Lyophilization was carried out on a Christ
Epsilon 2-6 D freeze-dryer (Martin Christ GmbH, Osterode am Harz, Germany). The samples
were frozen over 2 h to -40°C, primary drying was achieved at -38°C (according to previous Tg’
determination) and 0.05 mbar over 48 h and followed by secondary drying step at 30°C and
0.005 mbar for 24 h. After drying was finished, all sample vials were sealed under nitrogen
atmosphere at 500 mbar. The lyophilized samples were reconstituted with 500 µL water
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and analyzed by DLS measurements. Data evaluation was carried out by the calculation
of a particle size increase factors as proposed by Abdelwahed et al. [184]. Following their
proposal the size increase factors were calculated as the ratio between initial particle sizes
prior to lyophilization and particles sizes upon reconstitution of the samples.
2.3.2.6 Influence of lyoprotector concentration on micelle reconstitution
Investigation of the influence of lyoprotector concentrations on the drug-loaded micelles was
carried out by preparation of lyophilizates with varying β-cyclodextrin concentrations. For
this purpose the dexamethasone-loaded PEG-PVPy micelles were freeze-dried with 0.5%, 1%,
2.5% and 5% of HPβCD and SBEβCD. Reconstitution properties were investigated by DLS.
2.3.2.7 Cryo-Transmission Electron Microscopy (cryo-EM)
Drug-free and DXM-loaded PEG-PVPy nanoparticles as well as nanoparticles upon reconsti-
tution of the lyophilizates with SBEβCD as cryoprotector were subjected to cryo-EM analysis.
To this end, 4 µl of sample were pipetted onto a glow-discharged holey-carbon copper grid,
blotted with filter paper and plunge-frozen in liquid ethane. EM grids were stored in liquid
nitrogen until imaging. Images were taken under cryo conditions in a Tecnai T12 (FEI,
Eindhoven, The Netherlands) electron cryomicroscope equipped with a MultiScan 794 CCD
camera (Gatan, Pleasanton, CA, USA) using a side-entry cryoholder (Gatan). Individual
nanoparticles were selected from the raw images, and the dimensions of the nanoparticles
were determined by comparing with reference binary discs of different diameters using a
multi-reference alignment [185]. The determined particle sizes were used to calculate cumulant
frequency curves for each sample. From these cumulant curves, the d10, d50, d90 values as the
size distribution paramters of the samples were calculated as the size distribution parameters
of the samples.
2.4 Results
2.4.1 Solvents for cosolvent evaporation
Based on previous reports that the preparation of drug loaded-micelles [179] requires a high
solubilization capacity of the selected organic solvents, the drug solubility was screened in
common fully water-miscible organic solvents. Fig. 2.2 shows the maximum volume of water
which could be added to 7 solvents without drug precipitation. From this screening it was
obvious that THF had the best solubilization properties in connection with water. Conse-
quently this solvent as the most appropriate one was selected for the cosolvent evaporation.
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However, for comparison purposes the preparation was additionally carried out using acetone
which has a still reasonable solubilization capacity and low toxicity [186].
THF ACN Acetone Ethanol Methanol DMSO DMF
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Figure 2.2: Solubility screening of 1 mg DXM in 100 µL of varying organic solvents upon
addition of water. Drug precipitation was detected visually against a black
background and illumination of the sample with cold light. The experiments were
carried out in triplicate (mode ± range).
2.4.2 Preparation of drug loaded micelles
The micelles were prepared and drug loaded according to the 3 selected methods. Table 2.1
reports the analytical results for the drug load determined by HPLC-UV, particle sizes and
size distributions obtained from DLS technique.
2.4.3 Lyoprotector screening via DSC and lyophilization of placebo micelles
DXM-loaded PEG-PVPy micelles prepared by cosolvent evaporation technique from THF
were selected for freeze-drying due to their high drug content compared to micelles made by
other methods. Prior to lyophilization the lyoprotector solutions were prepared, mixed with
micelles and analyzed by DSC measurements for their thermal properties. The thermograms
revealed the glass transition temperatures of the maximally freeze concentrated solutions Tg’
[187] (Fig. 2.3).
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Figure 2.3: Tg’ determination for the lyoprotectors included in the study (results: mean ±
SD, n=3) determined by DSC.
The Tg’ values of the pure excipient solutions and of the excipient micelle mixtures are
reported. Sucrose had the lowest Tg’ with ∼-32°C; the highest was reached with HPβCD at
∼-9°C. When the influence of nanoparticle presence was investigated by mixing DXM-loaded
PEG-PVPy micelles with lyoprotector solutions, the maximum deviation in Tg’ comparing
with and without micelles was found for SBEβCD, where the micelles led to 2 K lower
glass transition temperatures. Based on these results the primary drying temperature for a
generic lyophilization process was set to -38°C (-33°C for lowest Tg’ and 5 K safety margin).
This maintained the “glassy” state of the freeze-dried solution and prevented influence of
physical changes in the lyoprotector structure which could lead to micellar rupture and
non-redispersibility. The DXM-loaded PEG-PVPy micelles were dried in a lyophilization
process and screened with the selected lyoprotectors for reconstitution properties. The
screening results are shown in Fig. 2.4A. As a quality parameter the particle size increase
factor was calculated to compare the stabilizing properties of each lyoprotector with the
investigated micelles, a method that was proposed by Abdelwahed et al. [184]. As evaluation
criteria a change of hydrodynamic diameter of 10% compared to the micellar size before
lyophilization was considered to be acceptable. The PEG-PVPy micelles increased in size
by more than a factor of two when sucrose or Kollidon 17PF was used for stabilization.
Maltose led to non-redispersible lyophilizates whereas trehalose did not stabilize the micelles
sufficiently which can be seen by an increase in the size factor to 1.4. The investigation
revealed that HPβCD and SBEβCD stabilized micelles quite well, apart from HPβCD that
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decreased particle size by ∼30% after reconstitution. SBEβCD was able to stabilize the
micelles excellently. The question became relevant if the results of lyoprotector screening
were only valid for PEG-PVPy micelles and each polymeric micellar species requires a new
screening.
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Figure 2.4: A. Size increase factors of micelles upon reconstitution of the lyophilizates of
DXM-loaded PEG-PVPy [5-b-20] micelles prepared with varying lyoprotectors
(results: mean ± SD, n=3). B. Size increase factors of drug-free micelles upon
reconstitution of the lyophilizates of PEG-PDLLA [5-b-23], PEG-PLGA [5-b-28]
and PEG-PCL [5-b-32.5] micelles prepared with varying lyoprotectors (results:
mean ± SD, n=3).
To answer this question three different micelle forming block copolymers were selected and
screened accordingly on their reconstitution properties (Fig. 2.4B). The results showed
that HPβCD stabilized PEG-PLA, PEG-PLGA and PEG-PCL micelles excellently whereas
SBEβCD were only sufficient for PEG-PLGA micelles. Moreover, sucrose led to full reconsti-
tution of freeze-dried PEG-PLA and PEG-PLGA but could not stabilize PEG-PCL micelles.
Trehalose, maltose and the Kollidon derivative did not stabilize any of the investigated mi-
celles. Based on these results further mechanistic investigations of DXM loaded PEG-PVPy
micelles with both β-cyclodextrin derivatives HPβCD and SBEβCD in varying concentrations
were performed.
2.4.4 Optimum concentration of lyoprotector
Lyoprotector concentration played an important role for particle reconstitution. Consequently
varying concentrations of HPβCD and SBEβCD were screened to determine the optimal
ratio. As a result drug loaded PEG-PVPy micelles were reconstitutable in the selected
concentration range between 0.5% and 5.0% (w/v) of lyoprotectors concentrations (Fig. 2.5).
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The hydrodynamic diameter of the reconstituted micelles decreased for both stabilizers from
0.5% to 5.0%. It was remarkable that the micelles stabilized with 0.5% HPβCD exhibited
strongly scattering particle sizes (reported as size increase factors) upon reconstitution
whereas the micelles with 5.0% HPβCD were found to have strongly scattering particle
size distributions widths. Lyoprotector concentrations between 1.0% and 2.5% were ideal
to achieve reproducible hydrodynamic diameter and particle size distribution values. The
question remained which influence the presence of β-cyclodextrins have on the recovery of
dexamethasone before and after lyophilization. The results (data not shown) revealed the
robustness of the HPLC method against the presence of β-cyclodextrins in liquid formulation
(recovery: ∼102%). Moreover, upon reconstitution of lyophilizates the recovery decreased to
∼93%-95% from the initial liquid formulation.
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Figure 2.5: Size increase factors of micelles DXM-loaded PEG-PVPy micelles upon reconsti-
tution of lyophilizates with varying HPβCD and SBEβCD concentrations (results:
mean ± SD, n=3).
2.4.5 Morphological and size analysis by cryo-EM
Previous studies indicated that the PEG-PVPy material was able to form various particle
morphologies [188, 189]. For elucidation of the particle morphologies in the experiments
cryo-EM as the method of choice was selected. As shown in Fig. 2.6A-C (left and middle)
cryo-EM revealed spherical particles in the nanometer range for all analyzed samples.
Drug-free and DXM-loaded particles revealed a similar morphology, and the shape of the
micelles was independent of the particle processing steps, i.e drug-loading and lyophylization
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Figure 2.6: Cryo-EM analysis of PEG-PVPy micelles. The scale bar of the overview images
(left) corresponds to 40 nm, and the box length of the single-particles (middle)
corresponds to 53 nm. The size distribution of the respective sample is provided
on the right. A. Drug-free PEG-PVPy micelles. B. DXM-loaded PEG-PVPy
micelles. C. PEG-PVPy micelles loaded with DXM upon reconstitution of
lyophilizates stabilized with SBEβCD.
with lyoprotectors. Upon computational measurement of the particles, the distribution of
sizes was plotted. In line with the visual impression, this analysis confirmed that drug-free,
drug-loaded and reconstituted PEG-PVPy micelles exhibited comparable sizes (Fig. 2.6A-C,
right and Fig. 2.7). In particular, particles obtained by lyophilization and reconstitution of
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particles revealed similar particle sizes and size distributions. Size distributions obtained
from micrograph analysis are summarized in Table 2.2.
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Figure 2.7: Cumulant frequency curves of particle sizes obtained from cryo-EM image analysis.
Drug-free PEG-PVPy micelles (black), DXM-loaded micelles (red) and DXM-
loaded micelles upon reconstitution of lyophilizates stabilized with SBEβCD
(blue).
2.5 Discussion
The purpose of this study was to gain mechanistic insights into the drug-loading procedure
and the stabilizing mechanisms of β-cyclodextrins during lyophilization of polymeric micelles.
Three different preparation techniques for the DXM-loading of PEG-PVPy micelles were
studied. All these methods had in common that organic solvents were used to load the
micelles whereas the loading principles were completely different. The relevance of the organic
solvent during micellization process was subject of previous investigations in the literature:
Self-association of amphiphilic block copolymers in mixtures of organic solvents with water
was first described by Selb and Gallot in 1975 [190]. The authors investigated the influence
of the methanol/water ratio on the association properties of a polystyrene-poly-(vinyl-N-
alkylpyrididniumbromide) copolymer. From their results they concluded that decreasing the
methanol/water ratio led to the formation of star-shaped micelles due to the reduced solubility
of the hydrophobic part of the polymer in the more aqueous solvent mixture. A change in
intrinsic viscosity depending on the solvent composition (methanol/water) was additionally
highlighted. Intrinsic viscosity of the micellar core also played an important role during drug
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Table 2.2: Particle size distribution parameters obtained from cryo-EM micrograph analysis.
Sample d10[nm]
d50
[nm]
d90
[nm]
Number of
particles
evaluated from
micrograph
analysis
Drug-free
PEG-PVPy 19 22 27 216
DXM-loaded
PEG-PVPy 18 22 28 1881
DXM-loaded
PEG-PVPy
SBEβCD lyo
18 22 27 208
loading process. Organic solvents could act as plasticizers, making the core susceptive for
hosting drugs. This phenomenon was described by Cinelli et al. [191]. Furthermore, the
group of Zhao et al. [192] studied polystyrene-polyacrylate micelles with a fluorescent probe
concerning kinetic effects of molecule encapsulation. To this end, pyrene was selected as a
molecule which reported information about the micropolarity of its surrounding environment
by changes in fluorescence emission spectra based on the method of Wilhelm et al. [41]. In
Zhao’s study solvent mixtures of dimethylformamid/water with varying compositions were
used to reveal the partitioning of the probe into the micelles. By calculating the drug load of
pyrene as “number of molecules per micelle”, the authors concluded that a gradually change
in composition of organic/water solvent mixtures during preparation of the micelles led to
higher loading rates in polymeric micelles. Furthermore, the type of organic solvents was
known to have an influence on particle sizes of resulting micelles: Vangeyte et al. [193]
investigated PEG-poly-(-caprolactone) and PEG-poly-(γ-methyl--caprolactone) in terms of
particle sizes as a function of organic solvent type and mixture ratios. In their preparation
THF, DMF, dimethylacetate (DMAc) and dimethylsulfoxide (DMSO) was included. The
nanoparticles were prepared by 3 different methods: 1.) direct dialysis, 2.) addition of water
to organic solution and 3.) addition of organic solution to water. For the methods 2 and
3 the ratio organic solvent/water was fixed (1:4). The group showed, that direct dialysis
did not work reproducibly resulting in large particles in submicron range to micron range,
whereas the solvent evaporation techniques worked well (sizes < 100 nm). The resulting
particle sizes varied in this study depending on the used solvent. A size correlation was
found: THF (80-100 nm) > DMSO (70-80 nm) > DMF (30-60 nm) = DMAc. The group of
Aliabadi et al. picked up these thoughts about solvent influences and investigated the impact
of the solvent type on drug loading into polymeric micelles [179]. Cyclosporine A which was
encapsulated into PEG-poly-(-caprolactone) served as a model payload. Selected cosolvents
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were acetone, THF and acetonitrile. The group worked with fixed organic/water mixtures
1:6 and 1:2. For micellar preparation, either the organic/water mixture was injected into
water or it was prepared vice versa. In line with the studies of Vangeyte et al. [193], Aliabadi
et al. [179] found solvent dependent particle size of drug-free micelles in the order: THF >
acetone > acetonitrile. The authors selected acetone as the solvent of choice due to the nearly
unimodal size distribution of the formed micelles from this solvent. The system was then
investigated for drug loading and highest drug load as well as encapsulation efficiency was
found for the preparation method acetone injection in water (final acetone water ratio 1:6).
In their discussion the authors argued for a positive effect of gradually increasing the water
content in a micellar system during preparation that prevented the hydrophobic drug from
precipitation and consequently enabled encapsulation. Jette et al. [59] employed this cosolvent
evaporation technique from acetonitrile/water to load fenofibrate into PEG-PCL micelles
and drew similar conclusions on this method compared to Aliabadi et al. Summarizing these
studies it was obvious that the organic solvent selected for the preparation of a micelle had a
strong influence on drug load as well as particle sizes. Furthermore, the preparation technique
was decisive for the successful encapsulation even if the solvent was selected appropriately.
In this context the cosolvent evaporation technique employed e.g. by Aliabadi et al. [179]
seemed to be superior over the other techniques due to the wide spectrum of organic solvents
that can be used and its increased controllability by measurable physical factors during
preparation. However, while the findings afore mentioned are highly significant there are a
number of aspects they do not cover. This inspired us to further look into the drug loading
techniques for polymeric micelles. Most important is the influence of organic solvents and
preparation methods on the drug load of micelles. It was deemed necessary that it should be
clarified if the preparation technique, the organic solvent within the preparation technique or
the drug-polymer compatibility is most decisive for successful drug loading of micelles. To
address this point three different preparation methods were selected for this purpose: 1) O/W
emulsion technique, 2) direct dialysis and 3) cosolvent evaporation technique and assayed their
potential for loading polymeric micelles with drug. The O/W emulsion technique is based on
the use of water non-miscible solvents. By applying this method the organic phase (Fig. 2.8)
which dissolved the drug was injected into an aqueous phase under constant agitation (e.g.
stirring, ultrasound). Due to mechanical agitation the organic phase is distributed as small
emulsion droplets in the aqueous phase. Consequently this effect increased the surface area
of the organic phase. At those interfaces between organic and aqueous phase the distribution
of the drug from organic emulsion droplets towards micellar core was possible. Furthermore,
the slow evaporation of the organic solvent increased the time for this distribution process
compared to simple mixing of both phases with small interface areas.
This method resulted in quite high drug loads for DXM in PEG-PVPy micelles (up to ∼13%
w/w). Variation of the initial drug-polymer ratio from 1:10 to 4:10 increased the drug load
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from ∼10% (w/w) to ∼13% (w/w). This was concomitantly found to be the upper limit for
this method due to the occurring drug precipitation upon solvent evaporation. A completely
different loading mechanism exhibited the direct dialysis method (Fig. 2.9): Once the organic
drug/polymer solution was filled into the dialysis bag, the overall system immediately came
into contact with an aqueous phase during dialysis.
The exchange of organic solvent at the interface of the dialysis tube could be very fast and
less controllable. Finally the solution conditions of the drug decreased strongly which led
to immediate drug precipitation and resulted in a low drug load (∼2% w/w) independent
of the drug-polymer ratio. Once precipitated, the drug was not available for encapsulation
anymore. For the cosolvent evaporation mechanism there was a variety of water-miscible
organic solvents available in which the drug solubility was screened prior to micelle preparation
(Fig. 2.2). Compared to the direct dialysis premature drug precipitation was avoided during
the cosolvent evaporation by the selection of a “good” solvent for the drug DXM (Fig. 2.10).
The cosolvent evaporation was carried out from an initial solvent/water ratio which was able
to still solubilize both, drug and polymer. During evaporation the micelles were preformed
but simultaneously the drug was still dissolved at this point. This procedure enabled the
distribution from the outer aqueous/organic phase into the micellar core. By continuing the
evaporation the drug solubility decreased in the organic/water phase which finally shifted
the distribution equilibrium further towards the micellar core. At the end of this step the
formulations contained only low amounts of residual solvents which were further cleared
by dialysis. The dialysis step was implemented to overcome the disadvantage of cosolvent
formation: azeotropic mixtures [59]. These mixtures made it impossible to evaporate the
Figure 2.8: Schematic drawing of the O/W emulsion process.
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Figure 2.9: Schematic drawing of the direct dialysis process.
solvents completely. Overall the superior properties of cosolvent evaporation are reflected
by these results: the drug load of the system increased up to ∼19% w/w DXM for ∼1%
PEG-PVPy (w/v). As a next step, stabilization of this high drug load inside the micelles was
a focus of this study. Freeze-drying was selected as the method of choice to gain a storage
stable product. Maintaining full reconstitution properties of micelles with high drug load
is generally very challenging: during freezing of micellar dispersions varying stress factors
could appear which are of physical or chemical nature and which are well investigated for
therapeutic proteins [187]. For nanoparticles, they usually comprise: 1) particle aggregation
due to the loss of repulsive properties of steric stabilizers [194], 2) nanoparticle reassembly
and remodeling after reconstitution [195], 3) loss of encapsulated drug due to changes in the
physical status of the nanoparticle [196] as well as 4) chemical degradation of the carrier
polymer and the encapsulated drug [184]. Prevention of these stresses and full reconstitution
properties can be achieved by the addition of cryo- and lyoprotectors to the formulation [187].
There were two well established hypotheses for the explanation of the efficacy of protectors
which were nicely summarized by Abdelwahed et al. [184]: the water substitution model
explains protection during the drying step whereas the vitrification model highlights on the
stability during freezing [184]. The water substitution model suggests that water molecules
are substituted by OH-groups from molecules which are similarly hydrophilic e.g. polyols like
sugars which are widely used as lyoprotectors. This is known to assure chemical and physical
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Figure 2.10: Schematic drawing of the cosolvent evaporation process.
integrity of proteins [187] and consequently should be one approach to stabilize nanoparticles.
The vitrification model describes nanoparticle embedding into an amorphous stabilizer matrix
which finally prevents aggregation [184, 197]. Moreover, Allison et. al [198] brought the
“particle isolation hypothesis” [198] into play which argued for the isolation of particles in the
non-frozen fraction by polyols. It is worth mentioning that the above cited studies investigated
nanoparticles like liposomes or nanocapsules and did not highlight on the mechanisms of
freeze-drying of polymeric micelles. Since this is an important issue it will be discussed
below in more detail. Abdelwahed et al. [184] selected various sugars (maltose, sucrose,
trehalose) as cryo- (prevents from freezing stress) and lyoprotectants (prevents from drying
stress), a stabilizer and “collapse temperature modifier” [184] vinylpyrrolodin macromolecule
(PVP PF 17) and cyclic oligosaccharides (HPβCD, SBEβCD) (also “collapse temperature
modifier” [184]) for a lyoprotector screening. As a first step all considered lyoprotectors were
screened via DSC concerning their optimal freezing-properties. Tg’ was selected as a reporting
parameter for the optimization of the lyophilization process. Whereas HPβCD revealed a
Tg’ of ∼-10°C which could assure a short, effective and less costly lyophilization process all
the Tg’ values for the other investigated lyoprotectors scattered between ∼-22°C and ∼-33°C.
Consequently to run a generic lyophilization process for all stabilizers the primary drying
temperature was selected at -38°C. Interestingly the presence of micelles did not strongly
change the freezing properties of lyoprotectors. Obviously β-cyclodextrin derivates seemed to
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have excellent stabilization properties for various micellar species (Fig. 2.5B) and seemed to
be versatile lyoprotectors. Support of this hypothesis came from the investigations of the
other pegylated block copolymers PEG-PDLLA, PEG-PLGA and PEG-PCL (Fig. 2.5B).
HPβCD stabilized all investigated micelles very well and led to completely redispersable
formulations while SBEβCD excellently stabilized PEG-PLGA and PEG-PVPy micelles.
Especially the results acquired from HPβCD led to the assumption that for β-cyclodextrin
derivatives there might be an additional mode of action concerning stabilization besides
the water molecule substitution and vitrification model. All the investigated polymeric
micelles present PEG chains on their surfaces. It is known from the literature that PEG
and cyclodextrins are able to form inclusion complexes called pseudopolyrotaxanes [199, 200].
Less was known if this phenomenon appeared on micellar surfaces as well. Joseph et al.
described inclusion complexes of a cyclodextrin derivative with Pluronic® block copolymer
molecules which they proved by small angle neutron scattering (SANS) experiments [201].
The authors hypothesized that the β-cyclodextrin derivative preferentially covered the more
hydrophobic PPO block of the polymer. This observation was found for single polymer chains
and for micellar aggregates, but increasing β-cyclodextrin concentrations led to increased
complexation and finally to dissociation of the micelles. These phenomena were highly
temperature dependent; below room temperature pseudopolyrotaxane formation appeared
whereas above 50°C precipitation/gelation occured. Qin et al. investigated the interaction of β-
cyclodextrin with varying Pluronic® derivatives as well and confirmed the pseudopolyrotaxane
formation by two-dimensional NMR spectroscopy [201]. A strong dependency of cyclodextrin
concentration and temperature on the aggregate size was found. Moreover, such an inclusion
phenomenon was found to be very fast (< 3 min), preferentially below 25°C and could be
disturbed by changing the water cluster structure by chaotropic solutes (e.g. urea) [202].
The presence of pseudopolyrotaxanes on PEG brushes was at first described by He et al.
in 2005 [203]. The general question remains if pseudopolyrotaxane formation is beneficial
for the lyophilization of polymeric micelles and what makes them superior compared to the
other polyols? In this connection the influence of solutes on the water cluster structure
comes into play. Generally solutes can have “structure-making (kosmotropic)” [204] and
“structure-breaking (chaotropic)” [204] properties on the water cluster structure. Sugars
lead to kosmotropic structures as has been shown for trehalose, maltose and sucrose [205].
Trehalose is known to be a very effective cryoprotectant and superior to the other two sugars.
Investigation of the reasons for this observation was performed by Lerbret et al. [205]. These
three sugars were investigated and compared to each other on their changes in water cluster
structure by means of molecular dynamic simulations. As a result the group found trehalose
to form larger water cluster sizes compared to the other sugars. Consequently more water
atoms were associated by hydrogen bonding to trehalose molecules and the amount of bulk
water which induces nucleation during freezing was reduced. The group concluded on less
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drying stress and less risky ice formation to explain the superior cryoprotective properties of
trehalose. Coming back to the polypseudorotaxane formation of PEGylated block copolymer
micelles with β-cyclodextrins, the facts appear in a different light: Generally cyclodextrin
derivatives are known to be strong kosmotropic solutes [206]. In contrast, Sano et al. [206]
revealed by Raman spectroscopy that the formation of polypseudorotaxane recovered the
original cluster structure of pure water and denied a kosmotropic influence of cyclodextrin
derivatives. Consequently the water cluster model cannot be used for polypseudorotaxanes to
explain the results obtained from lyophilization. An alternate explanation is provided by Liu
et al. [207] who investigated the change of material properties of such inclusion complexes.
The group prepared guest-host complexes from an ABA triblock copolymer (poly-[(R,S)-
3-hydroxybutyrate]-poly(ethylene glycol)-poly[(R,S)-3-hydroxybutyrate] [PHB-PEG-PHB])
containing PEG as block B. They confirmed the selective formation of the inclusion complexes
with block B (central block) with an α-cyclodextrin derivative by differential scanning
calorimetry (DSC), 1H-NMR and X-ray diffraction (XRD) studies. As a result the partial
degree of crystallinity of PEG was strongly reduced and could not be detected after formation
of polypseudorotaxanes. Consequently the material properties were altered and the PEG part
was embedded into an amorphous matrix. Therefore it is postulated that the PEG shield
which covers the hydrophobic cores in the used systems is undergoing polypseudorotaxane
formation. Consequently freezing stress and crystallization of water that challenges the
core stability could be prevented by creating this kind of amorphous shield. Furthermore,
desiccation stress from the particles can be reduced by the amorphous matrix as well. Based
on these results and previous studies from literature there is mounting evidence for a direct
interaction between β-cyclodextrins and PEGylated block copolymers (Fig. 2.11) which could
explain the excellent results from lyophilization.
Figure 2.11: Schematic drawing of the β-cyclodextrin inclusion complexes with PEGylated
surfaces (pseudopolyrotaxane formation).
The formation of PEG-β-cyclodextrin inclusion complexes had a beneficial effect on the
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reconstitution properties of pegylated block copolymer micelles. Consequently these molecules
can be proposed as versatile lyoprotectors for such micellar systems.
2.6 Conclusions
In this study three different drug loading mechanisms for hydrophobic drugs into polymer
micelles were compared. Among those the cosolvent evaporation technique was superior
compared to O/W emulsion technique and direct dialysis technique. The reasons for these
observations were the possibility of appropriate solvent selection as well as a better control of
the evaporation step during preparation. This combination kept the drug as long as necessary
in solution during micelle formation and prevented premature precipitation. This high drug
load can be stabilized by final micelle freeze-drying. It was found that β-cyclodextrins are
versatile lyoprotectors for pegylated polymeric micelles due to a possible direct interaction
between PEG corona chains and the hydrophobic β-cyclodextrin cavity. The special stabi-
lization properties of β-cyclodextrins was seen to be based on 1) embedding of the PEG
parts into an amorphous matrix, 2) prevention from formation of crystalline PEG during
freezing and 3) stabilization of the hydrophobic core during freezing by prevention of water
crystallization in the hydrophilic shell.
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3.1 Abstract
Stability of polymeric micelles upon injection is essential for a drug delivery system but
is not fully understood. An analytical test was optimized allowing for quantification of
micellar stability in biofluids and applied to a variety of block copolymer micelles with
different hydrophobic block architechtures. Polymeric micelles were prepared from four
different polymers and investigated via encapsulation of two fluorescent dyes. Samples
were incubated in human serum; changes in Foerster Resonance Energy Transfer (FRET)
were recorded as a function of time. This fluorescence-based approach was supported semi-
quantitatively by results from Asymmetrical Flow Field-Flow-Fractionation (AF4). After
incubation experiments, micellar stability was determined by calculation of two stability-
indicating parameters: residual micellar fractions (RMFs) and in vitro serum half-lives. Both
parameters showed that PEG-PVPy micelles rapidly destabilized after 3 h (RMF<45%),
whereas PEG-PLA, PEG-PLGA and PEG-PCL micelles were far more stable (RMFs 65 to
98%). This FRET-based assay is a valuable tool in evaluating and screening serum stability
of polymeric micelles and revealed low serum stability of PEG-PVPy micelles compared to
polyester-based micelles.
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3.2 Introduction
During the past 20 years of drug research, the number of newly developed poorly soluble
compounds has steadily increased. Estimations suggest that 40% of new chemical entities
have an aqueous solubility problem that consequently leads to insufficient bioavailability and
undesired low therapeutic effects [5]. Varying approaches have been investigated to conquer
solubility problems by formulation processes. Several highly fascinating and yet challenging
options can be found in the field of nanosized carrier systems. For example, polymeric micelles
seem to be highly promising for overcoming the problem outlined above. This drug delivery
system can be formed from amphiphilic block copolymers leading to spherical nanosized
particles with a hydrophobic core surrounded by a hydrophilic shell. In the core, these particles
can host hydrophobic drugs, whereas the shell-forming corona confers the drug delivery system
stealth properties and, as a result, a less distinct recognition by the mononuclear phagocyte
system (MPS) [208, 8, 209, 210]. Such pegylated nanoparticles could achieve long blood
circulation times and, thus, can target tumors passively by the enhanced permeability and
retention (EPR) effect [12] or actively using appropriate ligands [211, 14, 212]. Currently, the
most advanced micellar formulations encapsulating the hydrophobic taxol-derivatives have
already entered the market in India (Nanoxel®) and Korea (Genexol-PM®) [7]. Generally,
when working with polymeric micelles, there are two methods to encapsulate drugs: physical
entrapment in the hydrophobic core or chemically linking the drug to the polymer chain by a
covalent bond. Both approaches have their advantages. The physical entrapment of the drug
is generally easier to prepare and leads to higher loading rates, while the chemical coupling
confers the polymer-drug adduct a higher stability upon injection [213]. Consequently, the
fate of micelles with physically incorporated drugs after intravenous application is a very
critical issue. Generally, micelles are in dynamic equilibrium and tend to disassemble upon
dilution below their critical association concentration. Contrary to the low molar mass
surfactants, polymeric micelles are known to be kinetically stable, taking hours to disassemble.
However, while circulating in the blood, the polymeric micelles can lose their drug payload
due to multiple reasons, including: 1) diffusion of the drug due to the small diffusion length; 2)
partitioning between the hydrophobic micellar core and the surrounding aqueous phase, as well
as binding to serum proteins or lipid membranes; and 3) eventual disassembly of the micelles
themselves due to the strong dilution below their critical association concentration (CAC) [174].
Such premature release can lead to undesired pharmacokinetics and/or severe side effects,
including the triggering of immunotoxicological cascades [214]. Considering these problems,
the aim of this study was to investigate the in vitro stability of polymeric micelles made
of different block copolymers, namely PEG-PVPy (PEG-poly-4-(vinylpyridine)), PEG-PLA
(PEG-poly-(lactic acid)), PEG-PLGA (PEG-poly-(lactic acid-co-glycolic acid)) and PEG-PCL
(PEG-poly-(-caprolactone)) based on an analytical test was adapted from the literature
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[53, 165] and then further improved. Additionally, the stability of these polymeric micelles
were benchmarked against those of Tween 80®, which was selected as an ideal reference non-
ionic surfactant due to the presence of already published studies in humans. For these in vitro
studies, the two fluorescent dyes 1, 1´-Dioctadecyl-3,3,3´,3´-tetramethylindocarbocyanine
perchlorate (DiI) and 3,3´-Dioctadecyloxacarbocyanine perchlorate (DiO) were incorporated
into micelles as a model for physically entrapped drugs. When both dyes are in close proximity,
Foerster Resonance Energy Transfer (FRET) can be measured and, hence, be used as a
marker for micellar integrity. To study the serum stability of PEG-PVPy micelles in vitro
and to compare the results with previously investigated block copolymers by other groups,
the FRET-based technique was refined in this study. In contrast to the existing studies of
Chen et al. [165] that calculate a FRET ratio from fluorescence maximum peak height, in
this study the recorded fluorescence spectra were integrated. This minimizes effects caused
by changes in Stokes shifts from fluorescence dyes due to hydrophobic interactions of dye
and polymer, as shown previously for poly-(4-vinylpyridine) by Kamat and Fox [215]. In
addition, it was possible to achieve complete dye release after incubation from the still intact
polymeric micelles by addition of 7.5% v/v TritonX-100 at 37°C. This non-ionic surfactant
leads to the dissolution of polymeric micelles, as indicated by Cerritelli et al. for PEG-PPS
micelles [43]. The resulting FRET ratio after complete dye release and the initial ratio enable
the calculation of two parameters reflecting the stability of micelles: the in vitro serum
half-life and residual micellar fraction (RMF). Some of the investigated materials (PEG-PLA,
PEG-PLGA and PEG-PCL) are well-known block copolymers, and their micelles have been
thoroughly investigated. Gref et al. studied the influence of PEG chain length, PEG surface
density, and different types of hydrophobic cores (PLA, PLGA and PCL) on plasma protein
absorption by two-dimensional electrophoresis. This group identified a pattern of different
proteins adsorbing onto the nanoparticulate surfaces [216]. The different micellar hydrophobic
cores showed qualitatively similar adsorption patterns with varying degrees in quantity of
each serum protein fraction. Additionally, PEG-PCL micelles were investigated by Aliabadi
et al. concerning their in vivo pharmacokinetic behavior [58]. This was correlated with an in
vitro serum stability experiment in which micelles were dialyzed against serum proteins to
determine the non-encapsulated drug fraction. The authors correlated high micellar in vivo
stability with the occurrence of low unbound drug fraction. As previously mentioned, Chen
et al. [53] have already shown by using a FRET-based method for PEG-PDLLA micelles
that the stability depends on the influence of varying serum proteins and red blood cells.
This group calculated FRET ratios from the emission maxima in the fluorescence spectra and
discussed the impact of varying serum proteins and red blood cells on stability qualitatively.
Furthermore, this technique has been applied to trace cellular uptake of intact micelles which
physically encapsulate the dyes by confocal laser microscopy [165]. Savic et al. conjugated a
fluoresceine derivative covalently to PEG-PCL micelles and performed cellular uptake studies.
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They were able to distinguish between intact micelles and single polymer chains [217]. These
existing methods, however, lack the possibility to quantify the micelles in human serum
and to directly compare between formulations composed of block copolymers with different
architectures.
3.3 Materials and methods
3.3.1 Materials
The following block copolymers were purchased from Polymer Source Inc., Montreal, Canada:
mPEG-PLLA [5-b-4.7], mPEG-PDLLA [5-b-23], mPEG-PCL [5-b-32.5], mPEG-Poly-(4-
vinylpyridine) [mPEG-PVPy] [2-b-5.5], mPEG-PVPy [2-b-10] and mPEG-PVPy [5-b-20].
mPEG-PLGA [5-b-28] (Resomer RGP d 50155) was obtained from Boehringer Ingelheim,
Ingelheim, Germany. Pyrene, tetrahydrofurane (THF) and acetone were delivered by VWR,
Darmstadt, Germany. Tween 80®, human serum from male (blood group AB), and fluorescent
dyes DiI and DiO were obtained from Sigma Aldrich, Rossdorf, Germany. SpectraPor dialysis
tubing with MWCO 3.5 kDa was delivered by Spectrum Laboratories Inc., Breda, The
Netherlands. Water was of MilliQ grade.
3.3.2 Polymer characterization by differential scanning calorimetry (DSC)
Thermoanalysis was performed on a Mettler Toledo DSC 821e scanning calorimeter to
investigate glass transition temperatures and melting points of the polymers. All dry block
copolymers were weighed into 100 mL aluminium pans. These samples were heated two times
from −50°C to 100°C (PEG-PVPy samples to 200°C) with a heating and cooling rate of
10 K/min. After each heating or cooling ramp, an isothermal step of 5 min was implemented.
The first heating and cooling cycle was used to clear thermal history of the polymers; the
second heating cycle was used to evaluate thermal events. All experiments were performed in
triplicate.
3.3.3 Micelle preparation
3.3.3.1 Samples for determination of critical association concentration (CAC)
For the determination of the CAC, the pyrene probing method described by Wilhelm et al.
was used and further adapted to the requirements of the tested polymer types [41]. This
method is based on the change of vibrational fine structure of the fluorescence light emission
spectra, which depends on the polarity of the probe environment [218]. Micelles were prepared
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by dissolving the polymers in acetone, reaching a final concentration of 0.5% w/v. This
organic solution was directly dialyzed against 5 L water for 7 h. The water was changed
twice. This preparation step forms dye-free micelles with very low residual solvent (data not
shown). In the second step, a pyrene stock solution was prepared and added to the dye-free
polymeric micelles in a third step. The pyrene solution was prepared by dissolving the dye in
tetrahydrofurane (THF, 6×10−2 mol/L). This solution was injected into water with a final
pyrene concentration of 6×10−6 mol/L (stock solution). THF was removed by evaporation
at 40°C and 50 mbar over 1 h. As a third step, the dye-free polymeric micelles were diluted
corresponding to a polymer concentration range from 1.0 mg/mL to 5×10−4 mg/mL. The
samples were incubated over 12 h with the pyrene stock solution, enabling the partitition of
pyrene into the micellar core. The pyrene concentration was kept constant in all samples at
1.2×10−7 mol/L.
3.3.3.2 Samples for serum incubation studies, Asymmetrical Flow Field Flow
Fractionation (AF4) experiments, and Transmission Electron Microscopy
(TEM)
DiI- and DiO-loaded polymeric micelles were prepared by solvent evaporation and finally a
dialysis technique. Both dyes and the polymer were dissolved in acetone and added to water
under stirring to reach a polymer target concentration of 2 mg/mL loaded with 0.0015% w/v
of each dye. PEG-PVPy-based micelles were loaded with 0.0045% w/v donor (DiO) and
0.0015% w/v acceptor (DiI). The latter donor/acceptor (d/a) ratio was selected due to the
light absorption properties of the vinylpyridine part in the block copolymer in contrast to
the nonabsorbing aliphatic polymers, such as PEG-PLLA, and is in line with investigations
of Berney and Danuser [219]. After evaporation overnight, the resulting micellar dispersion
was filled into a dialysis bag and dialyzed over 4 h against 5 L water. This step was carried
out to remove unentrapped fluorescence dye and residual solvent. Finally, the dispersion was
filtered through a 0.2 mm celluloseacetate filtermembrane.
3.3.4 Micelle characterization
3.3.4.1 Determination of critical association concentration (CAC)
Fluorescence excitation spectra of the pyrene-loaded micelles were recorded on an Aminco
Bowman luminescence spectrometer (Aminco Bowman, Urbana, Illinois) at 390 nm emission
wavelength and excitation wavelengths ranging from 300 nm to 360 nm using a spectral
bandwidth of 1 nm and 2 nm for fluorescence excitation and emission, respectively. The scan
rate was 0.5 nm/s. According to the method of Wilhelm et al., the I338 nm/I334 nm ratio was
evaluated for the determination of CAC [41]. Each experiment was performed in triplicate.
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3.3.4.2 Particle size measurements
The dynamic light scattering (DLS) technique was used to investigate the micellar average
diameter. For the measurements, a Zetasizer Nano ZS90 from Malvern, UK, was set to 173°
backscattering mode. The mean size and polydispersity index (PDI) were calculated by
cumulants analysis using ZetasizerNano® software.
3.3.4.3 Transmission Electron Microscopy (TEM)
Micellar size and morphology were investigated by transmission electron microscopy using
a negative staining technique. The samples were dried on the surface of carbon-coated
copper grids (400 mesh; Plano, Wetzlar, Germany) for electron microscopy. For staining of
PEG-PDLLA [5-b-23], a solution of 2% uranyl acetate solution in water (pH 4.5) was used,
while all the other samples were stained using an aqueous solution of 2% phosphor tungistic
acid (PTA; titrated to pH 7, using NaOH). The PEG-PLLA [5-b-4.7] sample was incubated
with TritonX-100 for 20 min to examine the micellar destruction process as used in the
FRET assay. All electron micrographs were digitally recorded using a CCD camera (TVIPS,
Gauting) on a CM12 transmission electron microscope (FEI Electron Optics, Eindhoven,
The Netherlands). For particle size determination, 100 particles in a predefined area of the
electron micrograph were measured. Statistical evaluation was performed by calculation of
arithmetic mean and standard deviation.
3.3.5 Determination of micelles’ in vitro serum stability
3.3.5.1 Sample incubation, FRET ratio determination, calculation of stability
parameters
Set-ups of fluorescence experiments were similar to the CAC determination. In contrast,
excitation wavelength was set to 484 nm, and emission was scanned from 495 nm to 600 nm
(for PEG-PVPy samples to 620 nm). All samples were incubated at 37°C over 3 h. Emission
spectra were recorded after 0, 15, 30, 45, 60, 90, 120, and 180 min of incubation. Additionally,
for PEG-PLGA [5-b-28] micelles, spectra at 4, 5, 6, 9, 12, 15, 18, and 26 h were recorded.
After the last recording time point, micelles were dissolved by adding 7.5% v/v TritonX-100.
The incubation was maintained for 20 min and a final spectrum was recorded. Each single
spectrum was integrated using Origin® software to determine the peak area of FRET-acceptor
maximum and donor maximum. Calculating the FRET was done according to Eq. 3.1:
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(3.1)
For each polymer, the interception point of the time-resolved fluorescence emission spectra
was determined. By overlaying the recorded spectra, this interception point is defined before
the emission peak of FRET acceptor dye (varying around 545 nm). “Spectrum start” was 495
nm emission wavelength for all DiO/DiI loaded micelles, whereas “spectrum end” was 600 nm
apart from the PEG-PVPy micelles. For the latter, the spectra were integrated to 620 nm
due to a wavelength shift caused by quenching effects of the dyes’ fluorescent emission from
pyridines’ aromatic rings. For quantitative evaluation of the data, the resulting FRET ratios
were normalized to the TritonX-100 FRET ratio and the initial ratio at t=0 min by Eq. 3.2:
Residualmicellar fractions [%] = 100 · FRET ratiot=xmin − FRET ratioTritonX−100
FRET ratiot=0min − FRET ratioTritonX−100
(3.2)
Residual micellar fractions (RMFs) were plotted and analyzed by Origin® software using
the first-order decay curve-fitting function. From the fitted curves at RMF50%, the serum
half-life was calculated if possible. Additionally, the RMF180 min was analyzed.
3.3.5.2 Asymmetrical Flow Field Flow Fractionation (AF4)
Due to the great versatility of AF4 concerning particle and protein separation [220], this
method was selected to confirm the hypothesis of micellar disassembly in the presence of
human serum. Therefore, dye-loaded PEG-PVPy [5-b-20] micelles, which showed intermediate
stability in the described FRET assay, were incubated with human serum at 37°C. The
incubation sample was prepared with a polymer concentration of 2 mg/mL and diluted with
human serum (1:2). The samples were injected into a Wyatt Eclipse F module (Wyatt Inc.,
Santa Barbara, USA) with a 26.5 cm separation channel using a 350 mm polycarbonate spacer
and polyethersulfone membrane with 5 kDa molecular weight cut-off (MWCO). The pump
system consisted of an Agilent 1100 HPLC pump and degasser; detection was performed on a
Wyatt DAWN EOS MALS detector and a Shodex RI-101 detector. A 50 mmol NaCl solution
with 0.05% NaN3 served as a mobile phase. The detector flow rate was 1.0 mL/min using
a cross flow gradient from 3.0 mL/min to 0 mL/min, and the injection volume was 100 mL.
The original incubated sample was separated using AF4 0, 90, 180, 270, and 1,440 min
after the beginning of incubation. During each separation run, the micellar fractions were
collected (from 28 min to 33 min) and concentrated using Vivaspin 6 tubes. The resulting
58
3.4. RESULTS
5 mL sample volume from the first AF4 experiment was concentrated to 0.5 mL. Finally,
this fraction was injected and separated again. The presented size and size distribution
equations were performed with Astra® 4 software. The particle diameters were calculated
from RMS radii (d50) in the particles mode, evaluating the angular dependence of scattered
light assuming spherical particles. Based on the Zimm equation [221], the “90° MALS detector
signal height” of the second separation step was used for semi-quantitative data evaluation of
the concentrated samples.
3.4 Results
3.4.1 Polymer and micelles characterization
The CAC of the tested block copolymers was studied due to its association with micellar
thermodynamic stability. The CAC values of the polymeric micelles ranged from 0.41 to
5.71 mg/L (Fig. 3.1), which is considerably low compared to Tween 80® micelles (11.16 mg/L)
and indicates a high stability upon dilution of block copolymer micelles.
Tween 80
PEG-PLLA [5-b-4.7]
PEG-PVPy [2-b-5.5]
PEG-PLGA [5-b-28]
PEG-PVPy [2-b-10]
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Figure 3.1: CAC values of the investigated polymers determined by the pyrene method.
Results are presented as mean ± SD (n=3).
To validate the accuracy of the method used in this study, the CAC value for Tween 80®
was compared with literature data which determined the CAC value by other methods.
A good correlation was observed (e.g., surface tension measurement: 15.7 mg/L [222]).
Furthermore, from the CAC data of the different PEG-PVPy micelles, it was obvious that an
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increasing hydrophobic block length leads to a lower CAC, in agreement with published data
[223]. Comparing CAC values of micelles based on copolymers with similar hydrophobic to
hydrophilic ratios, a decrease of CAC from PEG-PLGA to PEG-PVPy and PEG-PDLLA was
observed. The architecture of the micellar core, which can be either crystalline or amorphous,
plays an important role in the stability of polymeric micelles [223]. Therefore, the thermal
properties of the dry polymers were investigated as received (Table 3.1).
Table 3.1: Physical state of used block copolymers (mean ± SD (n=3)).
Polymer type Amorphous Crystalline Tg [°C] Tm [°C]
PEG-PLLA [5-b-4.7] - X - 46.23 ± 0.24
PEG-PDLLA [5-b-23] X - 5.07 ± 0.13 -
PEG-PLGA [5-b-28] X - 6.19 ± 0.57 -
PEG-PCL [5-b-32.5] - X - 55.84 ± 1.05
PEG-PVPy [2-b-5.5] X - 101.83 ± 4.58 -
PEG-PVPy [2-b-10] X - 109.19 ± 2.54 -
PEG-PVPy [5-b-20] X - 136.36 ± 1.36 -
Differential scanning calorimetry revealed that PEG-PLLA [5-b-4.7] and PEG-PCL [5-b- 32.5]
showed crystalline characteristics with melting points above room temperature, whereas for
the other investigated polymers glass transition temperatures that are typical for amorphous
materials were detected in their thermograms. The glass transition temperatures of PEG-
PDLLA [5-b-23] and PEG-PLGA [5-b-28] were below room temperature. In contrast, the
investigated PEG-PVPy showed glass transition temperatures above 100°C. It is worth
mentioning that the presence of water, encapsulated compounds, or residual solvents can act
as plasticizers and greatly affect the nature of the hydrophobic core, changing it from crystalline
to amorphous and/or reducing its glass transition temperature. Micellar morphology and
diameter were investigated by transmission electron microscopy (TEM) and dynamic light
scattering (DLS). Results are summarized in Table 3.2.
DLS revealed that Tween 80® forms the smallest micelles with a hydrodynamic diameter of
about 10 nm followed by the PEG-PVPy micelles ranging in size from ∼28 nm to ∼31 nm.
The micelles of PEG-PLA derivatives, PEG-PLLA and PEG-PDLLA were ∼49 nm and
∼45 nm in diameter, respectively. PEG-PCL and PEG-PLGA form larger micelles with a
diameter of around 80 nm. This trend in size can also be found in the TEM micrographs.
They revealed nanosized particles of spherical shape independent of the copolymers used
(Fig. 3.2).
The mean particle diameter observed by TEM is either smaller than or equal to the hydrody-
namic diameter measured by DLS. Both PEG-PDLLA [5-b-23] and all PEG-PVPy-based
micelles showed narrow and homogeneous particle size distribution in TEM micrographs,
although the PDI in DLS was relatively high. On the other hand, a wider size distribution
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Table 3.2: Particle Sizes and Size Distributions of Polymeric Micelles Resulting from TEM
and DLS (Mean ± SD).
Polymer TEM size [nm] DLS size [nm] DLS PdI
Tween 80® n.p.a 10 ± 0 0.09 ± 0.02
PEG-PLLA [5-b-4.7] 17 ± 6 49 ± 7 0.26 ± 0.01
PEG-PDLLA [5-b-23] 23 ± 4 45 ± 4 0.12 ± 0.03
PEG-PLGA [5-b-28] 32 ± 10 83 ± 4 0.14 ± 0.03
PEG-PCL [5-b-32.5] 38 ± 7 82 ± 5 0.06 ± 0.03
PEG-PVPy [2-b-5.5] 19 ± 4 30 ± 3 0.10 ± 0.05
PEG-PVPy [2-b-10] 24 ± 4 31 ± 2 0.18 ± 0.01
PEG-PVPy [5-b-20] 24 ± 5 28 ± 1 0.17 ± 0.01
a not possible with the used experimental setup: for a Cryo-TEM micrograph of Tween 80® micelles please
refer to Sagalowicz et al. [224]
was obvious for PEG-PLGA [5-b-28]- and PEG-PCL [5-b-32.5]-based micelles in the TEM
micrographs. Taking the negative staining sample preparation technique into consideration,
the single particles showed a bright grey micellar core surrounded by a shell-forming corona
visible as dark shadows. This observation confirms the well-established core-shell model for
polymeric micelles and had been shown also in TEM micrographs for drug-loaded micelles
by Wang et al. [225]. The TEM micrographs of TritonX-100 and PEG-PLLA [5-b-4.7] were
recorded to document the dissolution of the micelles by this detergent. The micrograph of
TritonX-100 alone did not show any visible particles. Particle diameter obtained from DLS
for TritonX-100 micelles are below 10 nm (data not shown). Incubation and preparation
of PEG-PLLA and TritonX-100 show large particles in the micrograph without the typical
core-shell structure. The contrasting agent was able to diffuse inside this larger particle and
indicated the principle of micellar disintegration.
3.4.2 FRET stability assay
In this study, FRET as a direct marker of micellar integrity was used. Energy transfer from
the fluorescence dyes DiO (emission maximum: 505 nm) to DiI (emission maximum: 575
nm) without light emission of DiO appears only when the distance between both molecules is
in the lower nanometer range. Due to overlapping DiO emission and DiI excitation spectra,
the DiI emission can be only observed after exciting DiO. This is the case in the micellar
core. Results and basic principle of this FRET assay are outlined in Fig. 3.3 for Tween 80®
micelles. The final data evaluation process is presented in Fig. 3.4. All investigated polymeric
micelles were analyzed accordingly, and the resulting data are summarized in Table 3.3 and
Fig. 3.5.
The calculation of a half-life after incubation in human serum was possible for Tween 80®,
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Figure 3.2: TEM micrographs of block copolymer micelles, negatively stained using uranyl
acetate (PEG-PDLLA) or phosphor tungstate (all other samples). Scale bar
represents 100 nm. (A) PEG-PLLA [5-b-4.7]; (B) PEG-PDLLA [5-b-23]; (C)
PEG-PLGA [5-b-28]; (D) PEG-PCL [5-b-32.5]; (E) PEG-PVPy [2-b-5.5]; (F)
PEG-PVPy [2-b-10]; (G) PEG-PVPy [5-b-20]; (H) PEG-PLLA [5-b-4.7] incubated
with TritonX-100 for 20 min at 37°C; (I) TritonX-100.
PEG-PLGA, and all PEG-PVPy micelles, whereas for the other investigated polymers the
calculated RMF values did not fall below 50%. All micellar disassemblies followed a first-
order kinetic profile, with a good correlation observed (R2>0.90). The PEG-PVPy micelles
showed an increase in halflife with increasing molar masses of the hydrophobic part. The
longest half-life which could be achieved with PEGPVPy [5-b-20] was similar to Tween 80®
micelles. In contrast PEG-PLGA formed more stable micelles and exhibited a half-life in
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Figure 3.3: Fluorescence spectra overlay for DiI/DiO-loaded Tween 80® micelles in human
serum. The maximum at 570 nm emission wavelength originally comes from the
acceptor DiI, the one at 505 nm from the donor DiO. The decreasing acceptor
and increasing donor maximum indicate the micellar disassembly during sample
incubation. After 3 h incubation time TritonX-100 was added. This destroys the
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Figure 3.4: RMF at different incubation times of Tween 80® micelles. Tween 80® micelles
show a first-order disassembly kinetic. To compare varying block copolymers from
the resulting graphs, the serum half-life (t0.5) and the RMF180 min were evaluated.
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Table 3.3: Stability of different block copolymers in human serum. All samples follow first-
order kinetics.
Polymer
Quality of
curve fitting
(R2)
t0.5[h]
RMF180 min [%]
(Mean ± SD)
Tween 80® 0.9924 1.48 38.73 ± 10.37
PEG-PLLA [5-b-4.7] 0.9886 >‌>26a 98.38 ± 1.00
PEG-PDLLA [5-b-23] 0.9901 >‌>26a 91.60 ± 1.28
PEG-PLGA [5-b-28] 0.9850 25.07 66.83 ± 1.23
PEG-PCL [5-b-32.5] 0.9946 >‌>26a 85.27 ± 1.24
PEG-PVPy [2-b-5.5] 0.9923 0.68 23.27 ± 10.37
PEG-PVPy [2-b-10] 0.9389 0.92 34.19 ± 2.57
PEG-PVPy [5-b-20] 0.9659 1.72 44.19 ± 4.26
a These micellar types exhibit very high serum stability in the assay; consequently, serum half-life was not
calculated due to necessary extrapolation of the existing data.
this assay larger than 24 h. The more stable micelles are characterized by the RMF values
above 50%. PEG-PCL, PEG-PDLLA, and PEG-PLLA micelles were the most stable ones
investigated in this study. Moreover, the best stability in human serum was detected using
PEG-PLLA-formed micelles showing nearly no influence of serum proteins on stability. Fig.
3.5 further illustrates that the investigated DiI/DiO-loaded polymeric micelles were stable
upon dilution in water above CAC over a time period of 180 min at 37°C.
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Figure 3.5: Residual micellar fraction [%] of the investigated polymers determined by the
FRET method in human serum compared to water. Results are presented as
mean ± SD (n=3).
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3.4.3 Asymmetrical Flow Field Flow Fractionation (AF4)
AF4 measurements were performed as a reference method to confirm micellar disassembly in
the presence of human serum. Fig. 3.6 illustrates the results of the AF4 experiments. First,
the behavior of the dye-loaded PEG-PVPy [5-b-20] micelles and human serum under the
selected separation conditions was analyzed (Fig. 3.6a). The chromatogram of PEG-PVPy
micelles showed a main peak ranging between 24 min to 31 min retention time. A sharp
signal observed from the polymeric micelles indicated their high stability upon dilution in
AF4 experiments. Although serum and micellar signals are overlapping, Fig. 3.6A shows
the detection of micelles in the presence of serum was possible due to slightly different
hydrodynamic radii of serum proteins and micelles. Therefore, micelles and serum were mixed
and investigated simultaneously in a second experiment (Fig. 3.6B). As shown in Fig. 6a by
single micelles and serum fractograms, the micelles are detectable in the mixture at retention
time between 28 min and 33 min. This fraction was collected and separated again to improve
resolution. Finally, polymeric micelles were incubated in human serum at 37°C, and samples
were analyzed at different time periods as described above (Fig. 3.6C). Table 3.4 summarizes
the changes in particle sizes of each process step.
Table 3.4: PEG-PVPy [5-b-20] micelles diameter determined by MALS detector signal after
incubation in human serum at different time points.
Sample Sample status Particle diameter [d50 nm]
Micelles (pure) Not processed 21.8
Micelles and serum t=0 min Untreated 50.5
Micelles and serum t=90 min Untreated 182.9
Micelles and serum t=180 min Untreated 183.8
Micelles and serum t=270 min Untreated 166.1
Micelles and serum t=1440 min Untreated 34.6
Pure micelles showed particle diameters of ∼22 nm, whereas immediately after addition of
human serum the particle size increased to ∼50 nm. During incubation, the particle diameters
of the untreated sample increased continuously after 180 min incubation time to ∼184 nm
and declined to ∼35 nm after 24 h. The particle size of the concentrated samples showed
a different trend. During the second separation, the d50-size parameter scatters around 22
nm ± 1.5 nm. This enabled the evaluation of the MALS detector peak height to correlate it
with the particle concentration. In Fig. 3.6D, 90° MALS detector signal height is shown for
the concentrated samples over time. Its decrease followed a first-order kinetics, which was
also observed in the FRET experiments.
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Figure 3.6: A. Overlay of light scattering detector trace of dye-loaded micelles and human
serum, B. dye-loaded micelles mixed with human serum, C. concentrated samples
of dye-loaded micelles in human serum over time, D. intensity decay of light
scattering detector signal height over sample incubation time, baseline corrected.
3.5 Discussion
In this study, different block copolymers were investigated for their applicability as a micellar
drug delivery system. For its clinical development, it is of high interest to understand the fate
of polymeric micelles after intravenous application [174]. This issue is also highlighted by the
regulatory authorities, as seen in the current guideline draft released by the EMA in the field
of micellar formulations [226]. Block copolymers were composed of different chain lengths
of polyethylene glycol as the hydrophilic part and varying hydrophobic parts with different
molar masses. Physicochemical characterization revealed that all polymers were able to form
nanosized micelles of spherical shape. The results show that particle size obtained from TEM
often is much smaller compared to the results from DLS. One explanation for this observation
could be the airdrying step involved in TEM sample preparation. The most probable reason
is the different measurement principle of DLS and TEM. DLS delivers an intensity weighed
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size distribution of hydrodynamic radii based on the Rayleigh approximation (scattering
intensity ∼d6), which finally overestimates the presence of larger micelles. Considering this
factor, the large discrepancy between the results of both techniques is not unexpected. The
recorded TEM micrograph indicated that the addition of TritonX-100 to copolymer micelles
led to a fusion of micelles. This goes along with FRET dye release obtained by fluorescence
spectroscopy. The lysis of the nanoparticles was responsible for the decrease of the FRET ratio
after TritonX-100 incubation. Similar disintegration effects of lipid membranes by detergent
interaction have been described previously by Ahyayauch et al. [227]. Consequently, this
enabled the investigation of the stability of different polymeric micelles in human serum. Dual
dye-loaded polymeric micelles were analyzed with a FRET-based technique. After fluorescence
spectra integration and FRET ratio calculation, the two serum stability parameters residual
micellar fractions (RMF) and serum half-lives were determined. Both parameters revealed
highly relevant properties concerning stability. In the FRET assay, PEG-PLLA [5-b-4.7],
PEG-PDLLA [5-b-23], PEG-PLGA [5-b-28], and PEG-PCL [5-b-32.5] micelles exhibited
an extended half-life longer than 24 h, whereas Tween 80® and PEG-PVPy micelles were
more labile, with half-lives below 2 h. Fast disassembly of Tween 80® micelles was expected
(FRET assay half-life ∼1.5 h). This non-ionic surfactant was chosen as an ideal reference
polymer to compare with the results from the block copolymers due to known very low in
vivo stability. For instance, Lasseter et al. performed a tolerability and bioequivalency study
of fosaprepitant compared to aprepitant, where the prodrug fosaprepitant was encapsulated
in Tween 80® micelles and applied to healthy subjects [228]. The pharmacokinetic data
revealed that after injection the prodrug was completely metabolized to the active drug by
ester hydrolysis in less than 45 min, indicating a full micellar destruction and drug release
from the Tween 80® micelles. Thus, a comparison between Tween 80® and the block
copolymer micelles in the developed in vitro assay was highly interesting and helps to better
interpret the obtained stability parameters. Comparing the stability based upon dilution
values of the polymers with the serum values, it is obvious that micellar disassembly did
not result from simple dilution phenomena as long as the final concentration is above the
CAC. A major change in FRET ratio was not detectable after dilution of the samples in
water still above CAC (Fig. 3.5). However, in this study it was furthermore investigated
which physicochemical properties of these micelle-forming block copolymers were strongly
linked with micellar stability: hydrophilic/hydrophobic ratio [229], particle sizes and particle
size distributions [229], critical association concentration (CAC) [223], and thermal status of
the block copolymers [230, 46]. Riley et al. reported for PEG-PLA micelles a dependence
of serum stability on particle size and hydrophilic/hydrophobic ratio [229]. While keeping
a constant block length of the PEG part (5 kDa), an increase of hydrophobic block length
led to larger micellar cores and finally larger particles. Consequently, the PEG shell had
only a minor influence on the properties of micelles and can lead to incomplete coverage
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and protection of the core from environmental milieu (as postulated for PLA blocks larger
than 30 kDa). According to Riley et al., this partially leads to the presence of PLA carboxyl
groups on the surface and confers the particles a surface charge, as indicated by zetapotential
measurements. Proteins could thus adsorb onto the less PEG-protected surface. Colloidal
stability was investigated by addition of the nanoparticles to different amounts of Na2SO4
solution and the determination of the critical flocculation points (CFPT). Interestingly,
copolymers with high molar mass PLA blocks (30 kDa and more) exhibited a lower CFPT
before protein incubation and similar CFPTs after protein incubation compared to lower
molar mass PLA blocks (<30 kDa). Riley et al.’s study revealed that incomplete PEG surface
coverage did not lead to lower colloidal stability when designing micelles with larger PLA
blocks [229]. This postulated mechanism could be one explanation for the high stability
of PEG-PDLLA [5-b-4.7] and PEG-PLLA [5-b-23] micelles, whereas thermodynamic and
kinetic approaches could not fully explain the high stability of PLA-based micelles. The
FRET assay showed that PEG-PLLA [5-b-4.7] with a molar mass of around 10 kDa and a
hydrophobic/hydrophilic ratio of nearly 1:1 exhibited much higher stability than PEG-PVPy
[5-b-20] with a molar mass of 25 kDa and a ratio 1:5. The same result was found with PEG-
PLGA [5-b-28] (lower stability) and PEG-PLLA [5-b- 23] (higher stability). Consequently,
the total molar masses and hydrophilic/hydrophobic ratios do not have a direct impact
on micelle serum stability when comparing different block copolymers. In contrast, it was
shown for the PEG-PVPy micelles with different PEG and vinylpyridine amounts in the
molecule that an increasing hydrophobic part also increased the serum stability. Although
PEG-PVPy [2-b-10] had a higher hydrophobic/hydrophilic ratio than PEG-PVPy [5-b-20],
the latter was more stable, indicating that the size of the hydrophobic part is more decisive
in determining the serum stability than the size of the PEG part. The same conclusion
was drawn by Toncheva et al. when investigating the stability of PEG-polyorthoester ABA
triblock polymers against bovine serum albumin [231]. Thermodynamic stability of polymeric
micelles is directly connected with the CAC. Data of CAC determination for the tested
polymers showed that PEG-PCL (CAC∼0.41 mg/L) micelles had the lowest aggregation
onset, whereas PEG-PLLA (CAC∼5.71 mg/L) micelles showed the highest CAC in this
study. In contrast to the block copolymers, Tween 80®, as a non-ionic surfactant, had an
aggregation onset at a much higher concentration (11.16 mg/L). Therefore, one would expect
PEG-PCL micelles to be most stable, and PEG-PLLA micelles would be associated with
lowest stability from a thermodynamic point of view. The crystalline and/or amorphous
nature of the dry polymer seems to have no connection with its in vitro serum stability. For
instance, the thermograms of PEG-PLLA [5-b-4.7] (Tm∼46°C) and PEG-PCL [5-b-32.5]
(Tm∼56°C) show melting events, while PEG-PLGA [5-b-28] (Tg∼6°C), PEG-PDLLA [5-b-23]
(Tg∼5°C), and PEG-PVPy (Tg∼102–136°C) are amorphous. If the hydrophobic core of the
micelles was crystalline or frozen due to a high Tg, analogous to the dry polymer, then one
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would expect PEG-PVPy to be more stable than the “softer” polylactide copolymers, which
was not the case in this study. The effect of micellar stabilities cannot be fully explained by
the thermal properties, as is also shown by Jacquin et al. [230]. This is because the presence
of water or encapsulated material can act as plasticizer or crystallization inhibitor, thus
changing the state of the hydrophobic micellar core compared to the dry polymer. Finally, it
was to clarify if the observed time-dependent changes in FRET effects are exclusively due to
micellar disassembly in the presence of serum. There is still a possibility that the fluorescent
dyes redistribute from the micellar core towards serum proteins. AF4 measurements were
used to substantiate the FRET results and exclude the latter possibility. For this experiment,
PEG-PVPy [5-b-20] micelles were selected due to their intermediate stability in serum as
determined by FRET measurements. The fact that during the elution of the pure micelles no
peaks for the polymer appeared in the fractogram (before the micellar peak) shows that the
micelles remained intact under the high dilution processes in the AF4 experiments. While
incubating the micelles with serum over time, a method for semiquantitative data analysis
was identified involving the evaluation of signal height of light scattering. This light scattering
intensity decreases over time in a first-order decay, showing similar kinetics to those found for
the FRET experiments (Fig. 3.6D). It is highly probable that the effects seen in the FRET
experiments were caused by micellar disassembly. Interestingly, the protein adsorption on
the micellar shell can be followed via the particle diameter, which increased from the initial
particle size of ∼51 nm to 184 nm after 180 min incubation time and subsequently decreased
down to ∼35 nm after 24 h. FRET experiments confirmed that only minor changes in
micellar concentrations can be expected after 120 min due to the observed first-order kinetics
(Fig. 3.4). Saturation of micelles with serum proteins is highly probable. AF4 experiments
further revealed that there are residual micelles with comparable size to freshly prepared
ones still present after 24 h incubation time. Based on this observation, high adsorption of
proteins on the micellar surface most likely occurred during the first few hours. However,
when the stability influencing protein fraction is saturated with polymer monomers, the
reaction rate slows down to a first-order kinetic. Additional data will be needed to confirm
this hypothesis. In summary, it was shown that all investigated block copolymer micelles
exhibited relatively high thermodynamical stability against dilution, whereas the serum
stability differed extremely between the different polymers.
3.6 Conclusion
By using an improved FRET-based assay, it was possible to discriminate between different
block copolymers quantitatively in terms of in vitro serum stability. PEG-PVPy showed very
low serum stability compared to the PEG-PLGA, PEG-PLA, and PEG-PCL. Within the
same homologous series, the length of the hydrophobic chain was more decisive regarding
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the serum stability than the hydrophobic/hydrophilic ratio or the length of the PEG chain.
Additionally, the crystalline/amorphous state of the hydrophobic chain in the dry polymer
could not predict the serum stability of the polymeric micelles. AF4 experiments are one
approach to confirm that a decrease in FRET ratio is due to micellar disassembly. Although
further relevance of these studies has to be carefully investigated in in vivo experiments, the
presented techniques and results offer the possibility to screen novel polymers in terms of in
vitro stability.
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In vitro cytotoxicity and interactions with
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4.1 Abstract
In vitro biocompatibility and potential immunological reactions upon application were
investigated prior to performing in vivo experiments for safety and ethic reasons. Different
test polymers of PEGylated poly-(lactic acid) (PEG-PLA), PEGlyated poly-(lactic acid-co
glycolic acid) (PEG-PLGA), PEGylated poly-(-caprolactone) (PEG-PCL) and PEGylated
poly-4-(vinylpyridine) (PEG-PVPy) were investigated on their potential biological effects.
Several benchmark materials which are approved for use in humans were compared to the test
materials aiming on the delivery of information concerning toxic effects. These benchmark
materials comprise of Tween 80® and Cremophor EL® for the cytotoxicity studies and Doxil®
for the complement activation studies. Furthermore, branched PEI [25 kDa] and PEG-PEI
0.1/0.1 which was synthesized from PEI [25 kDa] served as positive controls in the cytotoxicity
assays. PEI [25 kDa] and Zymosan were positive controls for complement activation assays.
Investigations were carried out in two different setups: 1) cytotoxicity experiments on HepG2
cells (staining and hand-counting) and on primary rat hepatocytes (ATP test readout) as
well as 2) elucidation of complement activation (ELISA based). As a result of these studies it
was found that the test materials PEG-PVPy was less cytotoxic compared to Tween 80®
and Cremophor EL®. Distinct toxic effects could be detected from metabolically active rat
hepatocytes. The other PEGylated block copolymer micelles exhibited no toxicity on these
assays. Moreover, Doxil® showed stronger complement activation compared to most of the
investigated test polymers. Consequently the selected polymeric micelles were not expected
to exhibit strong cytotoxic effects and immunological responses in vivo.
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4.2 Introduction
The biological responses upon injection of nanoparticles can be assessed with various in vitro
test assays prior to in vivo experiments. Such a strategy contributes, therefore, as a major
part to drug safety. Although assays for the investigation of drugs’ cytotoxicity were standard
industrial procedures [232, 233], the relevance for nanoparticles was not well investigated yet.
In this connection cytotoxicity can be either of acute [234] or metabolic type [235]: acute
toxicity leads to immediate cell death due to high specimen concentrations whereas metabolic
toxicity occurs after processing of the specimen by metabolizing cells also in subactutely
toxic concentrations. Consequently investigation of those cytotoxic effects is very important
to ensure safety for further in vivo experiments. For this purpose the HepG2 cell line and
primary rat hepatocytes were selected as suitable reporter cells for detecting cytotoxicity
of the nanoparticles. For the investigation of multiple dosing cytotoxicity, the HepG2 cell
line is an established reporter cell line [234]. Both liver cell species are expected to have a
comparably high exposure of the micelles in vivo due to the strong phagocytotic activity of
the reticulo-endothelial system in this organ. The HepG2 cells were derived from human
hepatoblastoma and possess only minor metabolic activity for xenobiotics [234]. In contrast
to this the primary rat hepatocytes exhibit full metabolic activity [235]. The non-ionic
surfactants Cremophor EL® and Tween 80® were selected for reference purposes. Both
excipients have FDA approval for intravenous injectable products and are highly interesting
for benchmarking. Interestingly, Cremophor EL® for example is approved for iv infusion
with an impressively high concentration of 52.75% w/v in Taxol®.
Apart from toxicity on cells, immunological reactions upon nanoparticle injection could be
severe and lead to death of the patient within minutes. Those rapid reactions are mainly
caused by responses of the complement system and are called CARPA (C-activation related
pseudoallergy) in literature [97, 99, 96, 25]. This allergic reaction is of non-IgE type and
therefore called a pseudoallergy. It was well described that liposomal (e.g. Doxil®) and
micellar encapsulated drugs (e.g. Taxol®) could lead to strong responses of the complement
system [236]. The in vitro complement activation can be monitored by detection of varying
complement scission products. For this purpose the readout was focused on: C3a, C5a
and SC5b-9. These three scission products are representative for the complement cascade
and can be detected by commercial ELISA test kits. Strong complement activation can be
a hint for potential immunological reactions which could lead to CARPA upon injection.
Therefore, it is essential to gather information about the test micelles in comparison to
other approved products. As a reference product Doxil® was selected due to the known
complement activation in vitro and in vivo [100, 99].
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4.3 Materials and methods
4.3.1 Materials
The following block copolymers were purchased from Polymer Source Inc, Montreal, Canada:
mPEG-PLLA [5-b-4.7], mPEG-PDLLA [5-b-23], mPEG-PCL [5-b-32.5], mPEG-Poly-(4-
vinylpyridine) [mPEG-PVPy] [2-b-5.5], mPEG-PVPy [2-b-10] and mPEG-PVPy [5-b-20].
PEG-PLGA [5-b-28] (Resomer RGP d 50155) was obtained from Boehringer Ingelheim,
Ingelheim, Germany. DMEM F12 buffer, DMEM F12 Glutamax® buffer, gentamicin solution
(50 mg/mL) and sodium pyruvate solution (100 mM) were delivered by Invitrogen Inc.,
Darmstadt, Germany. HepG2 cell line was ordered from ATCC, Manassas, VA, USA. Human
serum and branched PEI [25 kDa] were purchased from Sigma Aldrich, St. Louis, MO,
USA. Penicillin-Streptomycin solution and ITS insulin solution were delivered by Sigma
Aldrich, Rossdorf, Germany. mPEG succinimidylester [5 kDa] (mPEG-NHS) was purchased
from NANOCS Inc., New York City, NY, USA. ELISA test kits for complement scission
product detection were delivered by Quidel Corp., San Diego, CA, USA. Doxil® was delivered
by Pharmarama Inc., Boston, MA, USA. Tween 80® and D2O were obtained from VWR,
Darmstadt, Germany, and Cremophor EL® was delivered by BASF, Ludwigshafen, Germany.
Pall Acrodisc (GHP membrane) 0.2 µm filters were used for sterile filtration. Water was of
MilliQ grade.
4.3.2 Methods
4.3.2.1 Synthesis of PEG-PEI as reference material
PEG-PEI was selected as a reference material for the cytotoxicity studies. For material
synthesis the method of Hong et al. [237] was employed. In brief, branched PEI [25 kDa] was
PEGylated using a mPEG-NHS ester. The synthetic procedure was described in Fig. 4.1. For
this purpose different ratios of mPEG to PEI were selected: 1) 300 mmol PEI to 100 mmol
mPEG and (PEG-PEI 0.3/0.1) 2) 100 mmol PEI to 100 mmol mPEG (PEG-PEI 0.1/0.1).
Synthesis was carried out in PBS buffer pH 7.4. The appropriate reactants were dissolved
in 5 mL PBS buffer each, unified and stirred over 24 h. Finally the micellar dispersion was
dialyzed against 5 L water over 24 h for purification purposes. As last step the polymer
was lyophilized at -35°C over 48 h to remove water. Polymer analytics was performed via
1H-NMR spectroscopy in D2O on a Bruker 400 MHz spectrometer.
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Figure 4.1: Preparation steps for PEG-PEI derivatives.
4.3.2.2 Micelle preparation
For cytotoxicity assays All preparation procedures were carried out under aseptic conditions
using sterilized glass ware and equipment where possible. The micelles as well as each of the
reference materials for these test assays were prepared in the appropriate cell line buffers for
the final cell tests. For the HepG2 cell line DMEM F12® buffer was selected as dispersion
medium, for the primary rat hepatocytes DMEM F12® Glutamax buffer was selected.
However, for the micellar preparation a nanoprecipitation technique was employed. In brief,
50 mg polymer was dissolved in 2 mL acetone. This solution was injected into 5 mL of the
aqueous buffer phases under constant stirring. The organic solvent was evaporated under
normal atmosphere under continued stirring overnight. Finally all micellar dispersions were
filtered through a 0.2 µm filter. The exactly resulting polymer concentrations were determined
by gravimetry. Dilution with the appropriate buffers was carried out accordingly prior to cell
incubation.
For complement activation assays Micelle preparation was performed employing the
cosolvent evaporation method (section 2.3.2.1) which was previously developed. Differing
from this procedure acetone instead of THF was used for the cosolvent preparation. Dialysis
for further purification was performed against 2 L water over 24 h. The micellar dispersions
were prepared with polymer concentrations at 10 mg/mL.
Selection and purposes of the investigated materials Table 4.1 summarized the investi-
gated materials with the intended purposes in each study.
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4.3. MATERIALS AND METHODS
4.3.2.3 Particle size measurements
The dynamic light scattering (DLS) technique was used to investigate the micellar average
diameter. For the measurements, a Zetasizer Nano ZS90 from Malvern, Worcestershire, UK,
was set to 173° backscattering mode. The mean size and polydispersity index (PDI) were
calculated by cumulants analysis using ZetasizerNano® software. The samples were measured
in cell culture buffer for the cytotoxicity experiments and in water for the complement
activation studies.
4.3.2.4 Cell incubation experiments
Primary rat hepatocytes Rat hepatocytes were taken from male Wistar rats, Charles River
Corp., Wilmington, MA, USA. Upon resection of the liver, the cells were seeded into 96
well plates which were previously treated as follows: Type I collagen from rat tail fibers
(lyophilizate from Roche Diagnostics Inc., Mannheim, Germany) was dissolved in 0.2% acetic
acid to a final collagen concentration of 110 µL/mL. This solution was transferred into each
well resulting in a target concentration of 20 µg/mL. Finally the well plate was dried over 48
h prior to seeding the cells.
Approximately 3.5 x 104 cells/well were seeded into the plate and cultivated in a mixture
of DMEM/F12 Glutamax® buffer with streptomycin (100 µg/mL), penicillin (100 IU/mL),
sodium pyruvate (0.5 mM), dexamethasone (100 µg/mL), ITS Insulin (110 µg/mL) as
additives. Prior to incubation with the micelles the buffer supernatant was removed and the
previously diluted and in buffer formulated micelles were incubated with the cells over 24
h. After incubation the cells were washed three times with buffer and non-vital cells were
stained with trypanblue. A representative number of cells was counted in a Fuchs-Rosenthal
chamber.
HepG2 cell lines For this experiment the cells were cultivated in a DMEM/F12® buffer with
streptomycin (100 µg/mL), penicillin (100 IU/mL), sodium pyruvate (0.5 mM), gentamycin
(50 µg/mL) as additives. 2 x 104 cells/well were seeded into a 96 well plate 24 h prior to
addition of the micelles. The buffer supernatent was removed and the previously diluted
and in buffer formulated micelles were incubated with the cells over 24 h. After incubation
the cells were washed three times with buffer and detection of vital and non-vital cells was
carried out by using an ATP assay (CellTiter-Glo® Luminiscent, Promega, Madison, WI,
USA).
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4.3.2.5 Determination of complement scission products upon serum incubation
Incubation of the micellar dispersions was carried out in human serum. For this purpose,
250 µL micellar dispersion (10 mg/mL) or MilliQ water and 250 µL human serum were mixed
and incubated at 37°C over 2 h. Zymosan, PEI [25 kDa] and Doxil® served as reference
materials. A Zymosan solution was prepared at 5 mg/mL (according to Szebeni et al. [99]),
whereas PEI [25 kDa] and Doxil® concentrations were set to 10 mg/mL polymer and lipid
content, respectively. Upon serum incubation the mixtures were immediately centrifuged at
10.000 g for 10 min and the supernatent of these mixtures was taken for further analysis on
complement activation.
According to the ELISA test assay description provided by Quidel Corp. the samples were
diluted as follows: 1:5000 (C3a), 1:250 (C5a) and 1:100 (SC5b-9). The test was performed
according to the manufacturers protocol and finally detection of optical density was carried
out at 450 nm. The complement activation of the micellar/liposomal species was referred to
the baseline activation detected from water incubation with serum. Complement results are
reported as the ratio between baseline and sample activation in percent. According to the
ELISA specifications, a test result which scatteres below 10% from this baseline activation
was not considered to be significant. Each experiment was carried out with n=6.
4.4 Results
4.4.1 PEG-PEI synthesis
The resulting PEG-PEI polymers were investigated on composition and block lengths by 1H-
NMR spectroscopy. Figure 4.2 reports an example spectrum for PEG-PEI 0.1/0.1. Table 4.2
presents the polymer compositions obtained from 1H-NMR spectroscopy. The low Mn-values
(number average molar mass) for the PEG-PEI 0.3/0.1 species was not explainable from the
experiments. Therefore, PEG-PEI 0.1/0.1 was selected for further experiments.
4.4.2 Particle size of test materials
All materials were successfully prepared and analyzed for particle sizes and size distributions.
Table 4.3 summarized the results for the cell incubation and complement assays.
4.4.3 Cytotoxicity assay
The above described nanoparticles/polymers were assayed on HepG2 cells and primary rat
hepatocytes. Evaluation of the recorded data delivered sigmoidal curves from which the
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Table 4.2: PEG-PEI characteristics obtained from 1H-NMR spectroscopy.
Polymer
Feed ratio
n/n
[mol/mol]
PEG in
copolymer
[%] w/w
Block ratio
(PEG-chains
per PEI
chain)
Mn
[kDa]
PEG-PEI
0.1/0.1
0.1:0.1 16.9 0.20
26.1
(PEG: 4.4, PEI:
21.6)
PEG-PEI
0.3/0.1
0.3:0.1 36.0 0.55
12.2
(PEG: 4.4, PEI:
7.8)
EC50-values (effective concentration of analyte at which 50% of the cells were still viable)
were calculated. Fig. 4.3 shows a representative curve for this purpose.
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Figure 4.3: Cytotoxicity of Cremophor EL® micelles on HepG2 cells. Results were presented
in percent cell viability. The curve was representative in shape for the results of
the other investiagted micelles/polymers.
Table 4.4 summarizes the EC50-values on both cell types for all investigated micelles. Strong
differences in cytotoxicity was found for the investigated micellar samples. As expected fot
the negative control mPEG-PDLLA no toxic events were found up to a concentration of
10 mg/mL on both cell types. The positive controls PEI [25 kDa] and PEG-PEI 0.1/0.1
showed severe cytotoxic effects with effective concentration in the lower µg/mL ranges on
both cell types. The test polymers from the PEG-PVPy series showed very low cytotoxic
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effects on HepG2 cells whereas distinct toxicities were found on the primary rat hepatocytes.
Interestingly, the benchmark micelles composed of Tween 80® and Cremophor EL® showed
comparably toxic effects to the PEG-PVPy samples.
Table 4.4: Summary of the EC50-values for the investiagted micelles/polymers. Each EC50-
value was determined in triplicate. From the resulting sigmoidal curves the
EC50-values were calculated where possible.
Micelle type/polymer EC50 HepG2[mg/mL]
EC50 rat
hepatocytes
[mg/mL]
mPEG-PDLLA [5-b-23] >‌> 10 >‌> 10
PEI [25 kDa] 0.0099 ± 0.002 0.015 ± 0.002
PEG-PEI 0.1/0.1 0.0107 ± 0.003 0.028 ± 0.020
Tween 80® 0.49 ± 0.060 1.16 ± 0.182
Cremophor EL® 0.79 ± 0.030 1.56 ± 0.087
PEG-PVPy [2-b-5.5] > 10 1.15 ± 0.115
PEG-PVPy [2-b-10] >‌> 10 4.20 ± 0.216
PEG-PVPy [5-b-20] > 10 4.57 ± 0.404
4.4.4 Complement activation assays
The results delivered by the ELISA tests for the three investigated complement factors C3a,
C5a and SC5b-9 are presented in Fig. 4.4. As shown, the selected positive control Zymosan
(5 mg/mL) exhibited the strongest complement activation in all setups followed by PEI [25
kDa]. Doxil® resulted in comparable complement activation in the SC5b-9 assay and only a
slight increase in the C3a compared to water. The test polymers showed lower activation
of complement in all three assays compared to the reference materials. A negative value
compared to water could result from complement adsorption onto the surfaces of the micelles.
This effect was also considered in the graphs.
4.5 Discussion
Cytotoxiticty and complement activation assays generally are valuable tools for the elucidation
of drug/formulation risks prior to adiministration to living organisms. In this study cytoxicity
was investigated with two cell types: HepG2 cells and primary rat hepatocytes. Escpecially
the rat hepatocytes with their metabolic activity were taken as important reporter cells for
expected toxicity in later in vivo studies in rodents. However, the results reported in Table
4.4 revealed very differentiated properties of cytotoxicity for the test and reference polymers:
mPEG-PDLLA [5-b-23] did not show any cytotoxic effects on both cells types as expected
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for a negative control. The positive controls PEI [25 kDa] and PEG-PEI 0.1/0.1 showed
severe cytotoxic effects at very low concentrations [EC50 <20 µg/mL]. The expectation
that PEGylation of PEI reduced the toxicity [237] was not strongly detectable. PEG-PEI
exhibited only slightly lower EC50values compared to PEI. Interestingly the benchmark
polymers Tween 80® and Cremophor EL® showed distinct toxicity on both cell types as
certain toxic effects were expected from literature: for Tween 80® direct toxic interactions
with lipid bilayers were discussed [240] whereas for Cremophor EL® the formation of free
radicals is assumed to be one potential mechanism of cytotoxicity [241]. It is remarkable
that both polymers/surfactants received FDA approval although they are known to exhibit
cytotoxic effects. Taking this backgroud into consideration, the cytotoxicity of PEG-PVPy
derivatives are to be evaluated. The results showed that a strong toxicity on HepG2 cells could
not be detected (EC50 >10 mg/mL for all specimen) whereas differential picture was shown
on the metabolically active rat hepatocytes: All three polymer derivatives showed a distinct
toxicity with EC50values scattering between ∼1 mg/mL and ∼5 mg/mL. This could be due
to a potential metabolization of the polyvinylpyridine part of the PEG-PVPy: liver enzymes
were known to form N-oxides from pyridine [242, 243]. Those N-oxides are reactive species
and could induce cell death by forming of DNA adducts. These values were higher compared
to Tween 80® and Cremophor EL® indicating lower cytotoxicity. Consequently strong toxic
effects by the PEG-PVPy species were not expected in later animal experiments. However,
if extensive, multiple dosing of this polymer would be planned it needs to be evaluated if
mutagenic effects could occur from N-oxides formation [244]. The complement activation
assay which was employed to assess potential impacts of nanomedicine on severe body side
reactions was the complement activation assay. According to the suggestion of Szebeni et al.
[99] three readouts C3a, C5a and SC5b-9 for complement activation were selected. Zymosan
was suggested as a positive control by Szebeni et al. because this yeast enzyme was known
to be a very strong complement activator. In contrast to this, PEI [25 kDa] served as a
highly charged positive control. Both positive controls were expected to exhibit very strong
complement activation in all three assays. Increase of complement referred to water was
between ∼350% to ∼1500% for Zymosan and ∼150% to ∼400% for PEI [25 kDa], respectively.
However, the reference product Doxil® showed its strongest complement activation in the
SC5b-9 assay (∼150% referred to water). This was not unexpected because previous studies
in humans with Doxil® revealed a strong activation in the SC5b-9 readout [100].
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Figure 4.4: Results obtained from the complement activation assays: C3a readout (A), C5a
readout (B) and SC5b-9 readout (C). Bars represent increase of complement
factor level in percent compared to water baseline levels. Each experiment was
carried out n=6 (mean ± SD). The arterisk indicates which samples delivered
signifiantly different results compared to water (> 10% differences according to
manufacturer specifications).
Moreover, an activation > 10% referred to water was additionally found in the C3a assays,
whereas for C5a there was nearly no activation detectable. As liposomal Doxil® is a FDA
approved product, this complement activation should not be a problem for other low micellar
products. A complement activation chart which evaluates the obtained data and puts them
into connection was shown in Table 4.5.
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Table 4.5: Evaluation of the complement activation results.
Specimen C3a C5a SC5b-9 Evaluation/comment
mPEG-PLLA
[5-b-4.7]
- ↓ - Light C5a adsorption
mPEG-PDLLA
[5-b-23]
- ↓ - Light C5a adsorption
mPEG-PLGA
[5-b-28]
- ↑↑ - Stronger C5a activation
mPEG-PCL
[5-b-32.5]
- ↓ ↑↑
Stronger activation of
SC5b-9, adsorption C5a
mPEG-PVPy
[2-b-5.5]
↓ ↑ ↑↑
C5a and SC5b-9
activation, C3a adsorption
mPEG-PVPy
[5-b-20]
- ↑ ↑
C5a and SC5b-9
activation
mPEG-PDLLA
[5-b-23] mixture
with H2N-PEG-
PDLLA
[5-b-28]
- ↑ ↑
C5a and SC5b-9
activation
Doxil® ↑ - ↑↑
Light C3a activation,
strong SC5b-9 activation
PEI [25 kDa] ↑↑↑ ↑↑↑ ↑↑↑ Positive control
Zymosan ↑↑↑↑ ↑↑↑↑ ↑↑↑ Positive control
Legend: complement activation within range ± 10% (-), range 10% to 50% (↑ or ↓), range
50% to 200% (↑↑), range 200% to 400% (↑↑↑), range > 400% (↑↑↑↑)
4.6 Conclusion
In this study potential effects of micellar carriers on biological systems were investigated.
Prominent concerns which could limit the applicability of colloidal systems are 1) cytotoxicity
and 2) immunological responses. In vitro cytotoxicity and complement assays revealed
valuable information about possible interactions of micelles with components of the biological
system. The cytotoxicity studies were carried out on HepG2 cells and primary rat hepatocytes.
Compared to the bechmark systems such as micellar Cremophor EL® or Tween 80®, the
results indicated no enhanced toxicity of the test polymers compared to those already
approved systems. Interestingly cytotoxicity was increased for the PEG-PVPy polymers on
metabolically active cells whereas on metabolically inactive celles there was no strong toxicity
to be found.
For the complement activation studies in comparison to the liposomal market product Doxil®
it can be concluded that from all investigated test micelles none exhibited stronger complement
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activation. Consequently further in vivo studies with the materials should not cause any
issues in animal welfare or deliver results which are related to toxicity items.
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Figure 4.2: 1H-NMR spectrum of PEG-PEI dissolved in D2O. The signal at d 4.75 ppm
resulted from water residues in D2O.
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CHAPTER 5. DRUG ENCAPSULATION AND BIODISTRIBUTION
5.1 Abstract
The purpose of this study was the achievement of encapsulating compound A into polymeric
micelles. Therefore different polymers were screened for compatibility to the drug. These
polymers included PEGylated poly-(lactic acid) (PEG-PLA), PEGylated poly-(lacic acid-
co-glycolic acid) (PEG-PLGA), PEGylated poly-(-caprolactone) (PEG-PCL) as well as
PEGylated poly-(4-vinylpyridine) (PEG-PVPy). By preparing the micelles with all these
polymers, the highest drug solubilization capacity among the biocompatible polymers was
achieved by PEG-PLGA. By investigating the compound A loaded PEG-PLGA micelles
in an in vivo biodistribution experiment, the pharmacokinetic properties were compared
to the solution of compound B (salt form of compound A). The results revealed that
the drug independently of its formulation in micelles or solution showed nearly the same
pharmacokinetic profile. Radiolabeling of the carrier combined with a drug were applied to
clarify these observations. Animal experiments with such a system indicated that the model
drug IFF dissociated rapidly upon injection from its polymeric carrier.
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5.2 Introduction
Polymeric micelles are ideal systems for solubilization purposes and drug targeting of hydropho-
bic compounds. As many new drugs have severe solubility problems [5, 6], the applicability
of these systems was tested by encapsulation of compound A. Besides low aqueous solubility,
this drug exhibited a severe off-target toxicity: During animal experiments heart valve failures
were observed due to increased drug accumulation in the heart. This unlucky combination
between low solubility, organ-specific toxicity and the limitation in solubilizing excipients
presented a huge hurdle for this study. It was intended to guide the drug from heart tissue
toward other organs: Tumor, liver and spleen. This goal should be reached by applying
well-known, biocompatible polymers for encapsulation. Consequently encapsulation studies
were carried out with PEGylated poly-(lactic acid) (PEG-PLA), PEGylated poly-(lactic
acid-co-glycolic acid) (PEG-PLGA) and PEGylated poly-(-caprolactone) (PEG-PCL). How-
ever, for comparison purposes also the non-biodegradeble PEGylated poly-(vinylpyridine)
PEG-PVPy was investigated.
The biodistribution study of compound A loaded micelles was performed in tumor bearing
animals by recording drug distribution via an LC-MS method. Due to the study design, it
was not able to report information about the fate of the polymeric carrier. Consequently a
follow up study was started to clarify the fate of each, drug and carrier, within one animal.
For this purpose H2N-PEG-PLGA was synthesized for further labeling with 111In-DOTA. As
a radiotracable model compound the 125I labeled dechloro-4-iodo-fenofibrate (125IFF) was
selected [245].
In summary, the biodistribution assay with compound A loaded micelles investigated micellar
drug distribution vs solution. whereas the radiolabeling experiment revealed additional
information about the fate of drug and carrier.
5.3 Materials and methods
5.3.1 Materials
The following amphiphilic block copolymers in research grade were purchased from Poly-
mer Source, Inc., Montreal, Canada: PEGylated poly-(lactic acid) (PEG-PLA) [5-b-23],
PEGylated poly-(-caprolactone) (PEG-PCL) [5-b-32.5], PEGylated poly-(4-vinylpyridine)
(PEG-PVPy) [5-b-20]. PEGylated poly-(lactic acid-co-glycolic acid) (PEG-PLGA) [5-b-28]
(Resomer RGP 50155d) was delivered from Boehringer Ingelheim, Ingelheim, Germany. The
following solvents/chemicals in LC grade were deliverd by VWR, Darmstadt, Germany:
Tetrahydrofurane (THF), acetonitrile (ACN), actone, dimethylsulfoxide (DMSO), ethanol,
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methanol, dimethylformamide (DMF), trifluoracetic acid (TFA). Compound A (free drug
base, solubility: 1 µg/mL at pH 7.4, weak basic with pKa 3.2 for corresponding acid, logP 4.6
calculated with ChemDraw 8.0) and compound B (dimesylate salt of compound A) was
synthesized and provided from Merck Serono, department of medicinal chemistry, Darm-
stadt, Germany. Dechloro-4-iodo-fenofibrete (non-acidic, non-basic, logP 5.5 calculated with
ChemDraw 8.0, solubility <0.1 µg/mL) was synthesized and provided by Breyer et al. [245].
Dulbeccos Saline PBS buffer concentrate was obtained from Sigma Aldrich, Rossdorf, Ger-
many. Float-A-Lyzer G2 dialysis tubes (MWCO 8-10 kDa) were obtained from Spectrumlabs
Inc., Breda , The Netherlands. Water was of MilliQ grade. For sterile filtration the Pall
Acrodisc GHP membrane 0.2 µm syringe filters were used.
5.3.2 Methods
5.3.2.1 Solvent screen prior to cosolvent evaporation
According to the developed procedure in chapter 2 in section 2.3.2.1, the encapsulation of the
compound was carried out in this study by using the cosolvent evaporation technique. The
following water miscible organic solvents were included in the solvent screen for compound
A: THF, ACN, acetone, DMSO, DMF, methanol, ethanol. Compound A acts as a base
and, therefore, solvent screen was carried out by adjusting “apparent pH” with TFA for
determination of the solubility of compound A. The procedure was followed as described in
2.3.2.1. The solvent in which the drug exhibited the highest optical solubility was selected
for the cosolvent evaporation step. The screening experiments were carried out with n=1 due
to the very limited availability to the development compound.
5.3.2.2 Polymer screen to load compound A into micelles
Drug loaded micelles were prepared by a combination of solvent evaporation and dialysis
technique. 10 mg block copolymer and 1 mg drug were dissolved in 8 mL ACN/0.1% TFA by
ultrasonication and was mixed with 2 mL water. The mixture was transferred into a round
bottom flask and evaporated with decreasing pressure to 30 mbar at 25°C. To remove the
maximum amount of solvent, this pressure was kept constant for 10 min. The remaining
aqueous formulation was then transferred into a Float-A-Lyzer G2 tube for dialysis. The
formulation was dialyzed against compound A saturated PBS buffer pH 7.4 for 24 h. Finally
the formulation was filtered through a 0.2 µm membrane and volume adjusted to 2 mL with
PBS buffer.
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5.3.2.3 Preparation of study materials
Micelle preparation To prepare the micelles, a modified cosolvent evaporation method was
employed. Briefly, for preparation of 5 mL micellar dispersion, 5 mg compound A and 250 mg
PEG-PLGA was dissolved in a mixture of 20 mL acetonitrile/0.1% TFA (v/v). Finally,
5 mL water was added to this organic solution to preform the micelles. Evaporation of
acetonitrile was performed under reduced pressure (Buechi rotary evaporator) to load the
micelles. Removal of residual solvents was gained by a following dialysis step against drug
saturated PBS buffer. As a last step unentrapped drug was removed by filtration of the
formulation through a 0.2 µm filter membrane.
Drug solution According to the final drug concentration acquired from micellar loading
experiments, a solution of compound B was prepared to benchmark against the micelles. For
this purpose the drug was dissolved in citrate buffer pH 3 to avoid release of the free base
(aqueous solubility of compound A is highly pH dependent).
Drug load determination 100 µL of the final micellar dispersion was dissolved in 900 µL
acetonitrile. This solution was injected in a HPLC system (Merck Hitachi La Chrom Elite)
equipped with a UV detector (detection wavelength: 254 nm) and a Agilent Eclipse Plus C18
column (3.5 µm coarse, 5 cm length) at 30°C. A gradient method was used for separation
where the mobile phase A consisted of 90% ACN (v/v)/10% water with TFA (v/v); mobile
phase B had the opposite composition. Compound A concentration was determined by drug
substance calibration curve.
Drug load calculation The drug load was calculated according to Eq. 5.1:
Drug load [%] =
Drug concentration [mgmL ]
Polymer concentration [mgmL ]
· 100% (5.1)
5.3.3 Particle size measurements
Dynamic light scattering (DLS) technique was used to determine hydrodynamic diameter of
the nanoparticles. Samples were diluted 1:100 with water and analyzed with a Zetasizer Nano
ZS90 from Malvern, Worcestershire, UK, set to backscattering mode. Particle size calculations
were perfomed via cumulants analysis of the intensity weighed particle distributions.
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5.3.4 Biodistribution experiments of micelles vs. solution
Animal model All animal experiments were conducted according to regulations of the
German law.
5 weeks old BalbC mice (Charles River Inc., Wilmington, MA, USA) were inoculated with
5 · 104 4T1 cells (mouse mammary carcinoma) subcutaneously into the right flank of the
animal. Tumor growth was supervised over 14 days post injection. Animal selection for the
biodistribution study was based on tumor volume (minimum: 300 mm³). 100 µL of each
formulation (compound A in PEG-PLGA micelles, compound B as solution) was injected
into the tail vein of the mice and biodistribution was analyzed according to the following
time points: 0.5 h, 1 h, 3 h, 6 h, 24 h, 48 h, 72 h post injection. Three animals were sacrificed
per treatment group per time point and the organs were resected.
Drug analytics in resected organs The quantitative distribution data were acquired from
a HPLC-MS/MS assay. The resulting tissue/organ samples from the animal experiments
were treated with ethanol/water 80/20 (v/v) to precipitate proteins. Upon centrifugation,
the supernatent was then extracted with water/ACN 10/90 (v/v). 10 µL of this solution was
injected into a HPLC system (Agilent 1100). Separation was carried out on a Cromolith
FastGradient RP-18e (50 mm), Merck KGaA, Darmstadt, Germany column using a phase
gradient. The mobile phases consisted of water with 0.1% formic acid (phase A) and ACN
(phase B) 10/90 (v/v). Detection was performed on a API 4000 MS detector from AB Sciex
Instruments (quadrupole detector). Quantification was done by recording a drug substance
calibration curve.
5.3.5 Preparation of radiolabeled H2N-PEG-PLGA and bioimaging
Synthesis Generally the ring opening polymerization (ROP) procedure was employed which
is described in section 7.3.2.1. Deviating from this, instead of dilactide alone an equimolar
mixtures of dilactide and diglycolide prior to starting the synthesis was used.
Polymer analytics Molar masses and mass distributions of the resulting polymers were
determined on a Viscotek GPCmax system equipped with a TDA 302 triple detector system
(full system provided by Malvern Instruments Ltd., Worcestershire, UK). 0.1% TBABr in
DMF served as a solvent mixture on a Tosoh TSK Gel 3000 HHR column (Tosoh Biosciences
GmbH, Stuttgart, Germany). Calibration was carried out with a polystyrene standard. Prior
to NMR analysis the polymers were dissolved in CDCl3. Spectra were recorded on a Bruker
400 MHz NMR spectrometer (Bruker BioSpin GmbH, Rheinstetten, Germany).
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Radiolabelling of H2N-PEG-PLGA and micelle preparation for bioimaging The method
described in detail in section 7.3.2.3 was carried out to achieve a 111In-DOTA-HN-PEG-PLGA.
This polymer was used for bioimaging experiments. The labeled polymeric species was mixed
1:5 (w/w) with mPEG-PLGA [5-b-28]. The poylmeric mixtures were dissolved in THF and
mixed micelles were prepared by cosolvent evaporation following the protocol previously
described in section 2.3.2.1.
Animal experiment via bioimaging Clarification of carrier and drug payload fate in vivo
was carried out by employing bioimaging for the dual-labeled polymeric micelles. 100 µL of the
125IFF loaded 111In-mixed micelles were injected into the tail vein of a NMRI mouse (Charles
River, Wilmington, MA, USA). The mouse was kept under anesthesia with isoflurane prior
to injection. Bioimaging was carried out on a γ-imager SCT. After finishing the bioimaging
experiments, the animal was sacrificed and radioactivity of 111In and 125I was quantified in
different organs with a berthold LB951G γ-counter (Berthold Technologies, Bad Wildbad,
Germany).
5.4 Results
5.4.1 Solvent screen for cosolvent evaporation
The results from the solvent screen experiment to elucidate the highest optical solubility of
the drug was portrayed in Fig. 5.1.
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Figure 5.1: Results of the solvent screen for compound A. 1mg of drug was dissolved in
100 µL of the displayed organic solvents and water was added incrementally.
Precipitation was detected by optical turbidity. The screen was carried out with
n=1 due to the very limited availability of compound A.
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The critical precipitation ratio was ACN/water 2:1. Based on this solvent screen, fixed
mixtures of solvents were used for the preparation of drug-loaded micelles from cosolvent
evaporation. Due to practical considerations for the cosolvent evaporation the ACN/water
containing 0.1% TFA (v/v) was set to 5:1.
5.4.2 Drug loading, particle sizes and size distributions for compound A
loaded micelles
Compound A was encapsulated into polymeric micelles with the cosolvents evaporation
technique followed by dialysis against drug saturated solution. The preparation results are
presented in table 5.1. Due to the very limited availability of the development compound
(<100 mg in early stages) the polymer screen was carried out with n=1. The results showed
that PEG-PVPy exhibited the best polymer-drug compatibility leading to the highest drug
load among the investigated block copolymers. Despite these results, for further experiments
one of the polyester based block copolymers was selected due to their known biodegradability.
Comparison of PEG-PLA, PEG-PLGA and PEG-PCL revealed PEG-PLGA as the species
with the highest drug loads. Moreover, for the finally selected PEG-PLGA combination this
experiment was repeated in triplicate. The reasons for preferring PEG-PLGA compared to
PEG-PVPy polymers was the known biodegradability and biocompatibility of this polymer
[176]. Moreover, this formulation preparation was upscaled and then investigated in the
biodistribution experiment which was presented in section 5.4.3.
5.4.3 Injected formulations for biodistribution purposes
5mL of the compound A loaded PEG-PLGA micelles were prepared. Compound B was
dissolved according to the the final drug concentration of compound A. Table 5.2 summarized
the acquired formulations upon upscale which finally were used for the biodistribution
experiments. 100 µL of these preparations were injected into each animal.
Table 5.2: Physicochemical characterization of the injected formulations.
Parameter Compound A Compound B
Formulation type Micellar Solution
Particle size [nm] 112 ± 1 n.a.
Particle size distribution (PdI) 0.216 ± 0.03 n.a.
Drug concentration [µg/mL] 180 180
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5.4.4 Biodistribution of compound A-loaded PEG-PLGA micelles
The micellar formulation of compound A and drug solution of compound B were injected into
tumor bearing mice. After determined time points each group of three animals were sacrificed
and organs were resected for further LC-MS analysis on drug concentration. Fig. 5.2 reports
the time-dependent biodistribution values in varying organs for both formulations. Compared
to drug solution, the micellar formulation showed significantly increased accumulation in
lungs, liver and spleen. In tumor, heart and kidneys there was no significant difference
in drug concentration between micellar formulation to solution. This observation was
supported by plasma analysis as reported in Fig. 5.3. Over the investigated time period a
significant difference between both formulations has not been found. Tab. 5.3 summarizes
the pharmacokinetic data in plasma, tumor and heart. From these values it was clear that
overall exposure of drug either in micelles or solution in tumor and heart (AUC values) were
similar. Additionally, half life in plasma could be only extended from 0.6 h (solution) to 1.5 h
(micelles) but finally resulted in comparable AUC plasma values (Fig. 5.3).
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Figure 5.2: Biodistribution of compound A loaded PEG-PLGA micelles compared to com-
pound B solution. Drug concentrations at 48 h and 72 h post injection were not
reported in the figure because their values were below the limit of quantification
(<LOQ) in the used LC-MS method.
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Figure 5.3: Recorded drug plasma concentrations over time upon injection of micellar drug
or drug solution.
Table 5.3: Pharmacokinetic parameters of compound A and compound B in different tis-
sues/organs. Each value was taken from graph fitting of the pharmacokinetic
data.
Tissue/organ Half life t0.5 [h] AUC [h·%/g]Micelles Solution Micelles Solution
Plasma 1.5 0.6 12.5 12.7
Tumor 1.1 1.0 7.3 9.3
Heart 0.5 0.6 8.8 9.3
5.4.5 Synthesis of H2N-PEG-PLGA and bioimaging
5.4.5.1 Synthesis
Amino functionalized PEG-PLGA was successfully synthesized by ring opening polymerization
with the following characteristics obtained from GPC and NMR (Tab. 5.4). A representative
1H-NMR spectrum was shown in Fig. 5.4.
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Figure 5.4: 1H-NMR spectrum of H2N-PEG-PLGA.
Table 5.4: Molar mass characterizations of H2N-PEG-PLGA. Mn[calc] is the theoretical molar
mass of the polymers assuming full conversion of the educts.
Mn
[calc]
Mn
[1H-NMR]
Mn
[GPC]
Mw
[GPC]
Mw/Mn
[GPC]
H2N-PEG-
PLGA
g/mol
28.000 25.900 20.500 23.500 1.15
5.4.5.2 Bioimaging
Dual-labeled polymeric micelles were prepared by using 111In for carrier tracking (111In-
DOTA-HN-PEG-PLGA) and 125I for drug tracking (IFF). This micellar preparation was
injected into one NMRI mouse. To reduce the number of animal experiments, bioimaging was
carried out with only one animal. The results of this experiment were intended to support
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the previous biodistribution study of the compounds A and B.
For this experiment the injected activities for both isotopes were ∼3.3 MBq. Upon injection
into a healthy NMRI mouse, distribution of radioactivity was recorded as a function of
time. Fig. 5.5 reported the carrier distribution (111In) whereas Fig. 5.6 presented the drug
distribution (125I).
Figure 5.5: Scintigrams of 125IFF loaded 111In-DOTA-HN-PEG-PLGA. Presentation of the
111In traces. Bioimaging was performed by using one NMRI mouse to reduce the
number of animals in this study.
As reported by the scintigrams for the drug carrier (Fig. 5.5) the biodistribution of the
micelles was preferentially in the heart/lungs and liver region. Obviously shortly upon
injection the carrier accumulated in the lungs and liver whereas non-accumulated carrier
remained in circulation. This could be detected by the rather diffuse distribution pattern of
radioactivity signals in the scintigrams. 2 h upon injection the diffe pattern declined in the
scintigrams, whereas the staining of the lungs/liver remained constant. 24 h upon injection
the radioactivity signal could be further detected in the lungs/liver region. Interestingly
directly upon injection there was a strong signal of radioactivity in the bladder. After stopping
narcosis of the animal, the bladder was obviously emptied and the signal was not found in
later experimental imaging time points.
Simultaneously to recording the 111In radioactivity for the carrier system, the 125I activity
for the encpasulated IFF drug was detected (Fig. 5.6). For the drug directly upon injection
a strong signal in the liver was detectable. Besides the liver signal, a diffuse radioactivity
pattern was detected in the heart region indicating still circulating, drug-loaded carriers.
40 min post injection the excretion of the drug via the biliar route into the intestinal system
was visible. The excretion visibility continued until 6 h upon injection. 24 h post injection
there was nearly no radioactivity remaining in the animal. The scintigrams showed similar
99
CHAPTER 5. DRUG ENCAPSULATION AND BIODISTRIBUTION
Figure 5.6: Scintigrams of 125IFF loaded 111In-DOTA-HN-PEG-PLGA. Presentation of the
125I traces. Scintigrams were recorded simultaneously to the 111In traces of the
polymeric carrier. Consequently biodistribution could be followed qualitatively
within the same animal.
activity in the bladder upon injection and a signal loss after stopping narcosis of the animal.
So far, the incorporated radioactively labeled drug (Fig. 5.6) showed a similar biodistribution
pattern compared to the polymeric carrier. For comparison purposes the animal was sacrificed
after 24 h and the organs were resected and analyzed on radioactivity of 111In and 125I. Fig.
5.7 reports the actual quantitative distribution.
Whereas nearly no activity of 125I after 24 h post injection was detectable, there was a lot of
activity remaining from 111In. Unexpectedly the 111In activity resulting from carrier labeling
was remarkably high in liver, lungs, spleen, heart and kidneys compared to the 125I signals
from drug labeling. Interestingly 125I activity in the stomach was higher than that of 111In.
5.5 Discussion
The purpose of this study was to develop a suitable micellar formulation of compound A
to solubilize the drug and finally to change pharmacokinetics and biodistribution in terms
of decreasing heart accumulation and increasing tumor drug concentrations. To reach this
goal the development candidate was encapsulated into biodegradable PEG-PLGA micelles
as a commercially available block copolymer. The goal of encapsulation and consequently
solubilization was successfully gained. For this purpose varying amphiphilic block copolymers
were screened on drug-polymer compatibility. This screen revealed a reasonable compatibility
with PEG-PVPy and PEG-PLGA compared to PEG-PLA and PEG-PCL. At this point it
must be admitted that the resulting drug loads <0.6% were very low compared to other
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Figure 5.7: Biodistribution of 125IFF loaded 111In-DOTA-HN-PEG-PLGA species 24 h upon
injection. The data were recorded from the original animal of the bioimaging
study. As previously stated, to reduce the number of animal experiments the
micelles were followed on biodistribution in one NMRI mouse.
micellar systems (e.g. Genexol-PM® 16.6%). Due to the biodegradability of PEG-PLGA in
favour of PEG-PVPy, the encapsulation and animal studies were conducted with PEG-PLGA
micelles. Encapsulation in PEG-PLGA micelles increased drug solubility from 1 µg/mL (PBS
buffer pH 7.4) to ∼180 µg/mL (PEG-PLGA micelles in PBS buffer pH 7.4); consequently
drug solubility increased by factor 180. It is remarkable that although the drug-polymer
compatibility was quite low (drug loads <0.6%), the drug was solubilized with concentrations
up to ∼180 µg/mL. The previously developed method for loading DXM into PEG-PVPy
micelles (chapter 2) was sucessfully emloyed and derived for this development compound.
Moreover, the overall procedure consisting of 1) solvent screen prior to cosovlent evaporation,
2) cosolvent evaporation and 3) dialysis for purification delivered micelles with therapeutically
relevant drug concentrations.
As a next step the micelles were tested on their in vivo performance. In this experiment
the micellar formulation was compared to a drug solution of a soluble salt (dimesylate)
in terms of their biodistribution. According to the theory of the enhanced permeation
and retention (EPR) effect, long circulating nanoparticles are able to target tumors more
effectively than small molecule drugs [122, 131, 140]. A wide-spread approach to achieve
long circulation properties was the selection of PEGylated polymers for formulation that
present the PEG “stealth” shield to the surrounding biological media. Such micelle forming
block copolymers were utilized in the studies. Therefore it was expected that the micellar
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formulation would have enhanced circulation properties and consequently a significantly
increased tumor accumulation compared to the drug solution. As a result of this experiment
there were less distinct differences between both types of formulations in terms of their
biodistribution found. Completely unexpected was the high drug accumulation in the lungs,
liver and spleen compared to drug solution. This accumulation can be seen as responsible for
the low circulation times of the micelles. Simultaneously overall exposure of the formulated
and unformulated drug was nearly similar, indicating no enhanced circulation and therefore
no utilization of the EPR effect. However, what reasons could lead to such a distribution
pattern? Generally, there are 3 varying scenarios that lead to these observations [246]: 1)
insufficient stealthyness of the micelles and therefore rapid opsonization and cell phagocytosis,
2) insufficient stability of the micelles in presence of blood and consequently rapid dissolution
and 3) insufficient stability of the incorporated drug that led to rapid drug extraction from
the carriers toward proteins and continued circulation of “empty” carriers. Stealthyness of
the particles was usually achieved by a complete PEG-coverage of the nanoparticles. Typical
block lengths for the PEG parts had already been investigated and scattered between 2
kDa and 5 kDa PEG and was most effective in weight portions of at least 5% [216]. In
the study PEG-PLGA [5-b-28] with a 5 kDa PEG and a weight portion of around ∼15%
w/w was employed, consequently PEGylation as the basic requirement for stealthyness was
matched. However, surface properties of nanoparticles were not only determined by the
presence of PEG molecules. Drug encapsulation often had a strong influence also on the
surface. As reported by Brigger et al. [247] drug incorporation changed surface charge
and therefore aggregation tendency of the nanoparticles. Compound A had a pka of 3.2
(corresponding acid) and consequently was non-ionic (free base) at pH 7.4. Therefore particle
precipitation due to surface charge changes caused by the encapsulated drug could not be the
reason for this observation. Stability of the investigated PEG-PLGA micelles was previously
analyzed with a FRET probing technique [57]. In this study an intermediate stability of the
micelles in presence of serum proteins was revealed. A residual micellar fraction upon 3 h of
incubation was found to be ∼66%. Consequently one could assume stability in the range
of a few hours for the micellar system in serum. Rapid release properties should have been
also prevented by the selection of a long PLGA block that imparted the resulting micelles
enhanced thermodynamic and kinetic stability [8]. It was known that micelles formed from
polymers with short hydrophobic block lengths disassemble rapidly upon injection as had
been shown for Paclitaxel in PEG-PLA micelles [7].
The second part of this study dealed with the investigation of the mechanisms that lead to
the observed biodistribution of compound A loaded PEG-PLGA micelles. For this purpose
the study was designed with a dual-label to simultaneously track carrier and drug in vivo.
Due to the limited access to the development compound A, IFF was selected as a suitable
model drug which is similar hydrophobic (compound A logP: 4.5, IFF logP: 5.5) compared
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to compound A. Since IFF was labeled with 125I and consequently there was the need of
another label for the polymer that allowed for discrimination between drug and carrier. So
far, mPEG-PLGA beared a methoxy-group at the end of the PEG chain and was therefore
not accessible for a labeling step. Consequently a H2N-PEG-PLGA was de novo synthesized
for finally coupling covalently a chelator with a radioactive metal cation to the polymer chain.
Polymer synthesis by ring opening polymerization was successfully done and H2N-PEG-PLGA
[5.5-b-20.4] was prepared with high purity and low residual monomers (Fig. 5.4). The aimed
and resulting polymer was slightly shorter in terms of hydrophobic block length compared to
the commercially available mPEG-PLGA [5-b-28]. The goal for this experimental design was
that the final 111In-DOTA-NH-PEG-PLGA should not exceed strongly the micellar surface
composed of mPEG-PLGA. In the following bioimaging experiment the formulation was
prepared by mixing mPEG-PLGA with the radioactively labeled H2N-PEG-PLGA. Drug
loading procedure was kept constant for this preparation step. Upon formulation preparation,
the drug loaded micelles were injected into a healthy animal. As indicated by the bioimaging
scintigrams of 111In (carrier), a certain percentage of the injected dose accumulated in the
lungs, liver and spleen directly upon injection. However, due to the diffusity of the scintigrams,
one can conclude on circulating micelles for a few hours. In contrast to this the 125I labeled
drug accumulated rapidly in the liver and spleen. Consequently, the encapsulated drug
did not follow the biodistribution of the carrier. This observation was supported by the
biodistribution data from quantification of radioactivity 24 hours upon injection. Whereas
nearly all 125I was cleared from the animal, there were strong 111In signals detected in liver,
spleen and lungs. Summarizing this, encapsulation of the drug was not maintained upon
injection and similar distribution pattern had been found for micelles and solution which was
supported by the data of the biodistribution experiment with the development compound.
In future studies it has to be clarified if this observation depends on the polymeric carrier
material (e.g. polyester based micelles), on the intrinsic properties of the encapsualted
drug (e.g. hydrophobicity, lipophilicity) or on the type of preparation (e.g. physical drug
incorporation).
5.6 Conclusions
In this study a previously developed drug loading technique was sucessfully applied to the
hydrophobic compound A. Furthermore, based on the loading results a development project
was supported with the micellar formulation (PEG-PLGA/compound A). The pharmaceutical
quality of this formulation was suitable for a biodistribution study. Whereas drug solubilization
in physiological pH (pH 7.4) was possible (solubilization factor: 180) by the micellar delivery
system, unfortunately the desired change of pharmacokinetic properties and increase in tumor
accumulation of the drug was not achieved. This was probably due to the dissociation of
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drug and carrier systems rapidly upon injection.
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Radiolabeling of PEGylated
poly-(4-vinylpyridine) and its
biodistribution
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6.1 Abstract
The purpose of this study was the investigation of the in vivo distribution of PEGylated
poly-(4-vinylpyridine). The in vivo experiments were designed to reveal micellar circulation
and body clearance of the polymer. For this purpose, the PEG-PVPy materials are labeled
with an iodine isotope after pyridine N quaternization with an electron-rich phenol derivative.
The animal experiments revealed a short circulation time (<1 h) of the micelles and a long
liver residence time (half life ∼56 h) of the polymer. Dechloro-4-Iodo-Fenofibrate (IFF) was
encapsulated into non-labeled PEG-PVPy micelles and investigated via bioimaging. From
the scintigrams a fast accumulation of the drug in the liver was obtained. As both drug and
polymeric carrier were bearing identical radioactive isotopes, a discrimination between carrier
and drug effects was not possible.
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6.2 Introduction
PEGylated poly-(4-vinylpyridine) (PEG-PVPy) material is an interesting material for en-
capsulation of hydrophobic drugs. In this connection excellent drug loading results with
dexamethasone were obtained (chapter 2). But the material was not under previous investi-
gation on biodistribution, metabolization and excretion yet. Since in vitro cytotoxicity and
complement activation data (chapter 4) did not reveal severe issues which pose an obstacle
against animal experiments, this in vivo route is followed in the present study.
Radiolabeling is an appropriate mean to investigate the in vivo properties of drugs and
polymeric materials. Generally, radiolabeling of PEG-PVPy can be achieved at the pyridine
part or at the PEG part. Both procedures will alter the micellar properties: the pyridine
labeling changes the micellar core properties (e.g. critical association concentration) whereas
shell labeling could change the surface charge and PEG brush density. In this context,
labeling at the pyridine part is much easier to achieve because the methoxy-endcapping
(H3CO-endcapping) at the commercially available PEG-PVPy does not allow direct coupling
to radioactive isotopes. Consequently for the shell labeling a de novo synthesis must be
applied that maintains an endgroup for coupling to labeling moieties. In this study as a
starting point the pyridine labeling was achieved by quarternization of the pyridine N in the
hydrophobic region of the polymer. This approach delivers a stably coupling to radioactive
isotopes.
6.3 Materials and methods
6.3.1 Materials
Dechloro-4-Iodo-Fenofibrate (IFF) was prepared by de novo synthesis and provided by Breyer
et al. [245]. mPEG-PVPy [5-b-20] was purchased from Polymersource, Inc, Montreal,
Canada. 4-(2-bromoethyl)-phenol, chloramin T (CAT), dithiothreitol (DTT) and PBS buffer
concentrate (10x) were obtained from Sigma Aldrich, Rossdorf, Germany. Dichlormethane,
methanol, ether, dimethylformamide (DMF) were purchased from VWR, Darmstadt, Germany.
Na125I and Na131I were purchased from Perkin Elmer, Waltham, MA, USA. Float-A-Lyzer
dialysis tubes MWCO 3.5 kDa were purchased from Spectrumlabs, Breda, The Netherlands.
Female NMRI mice were obtained from Charles River, Wilmington, MA, USA. Water was of
MilliQ grade.
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6.3.2 Methods
6.3.2.1 PEG-PVPy quaternization and labeling with radioactive iodine isotopes
General approach PEG-PVPy is not subject to direct labeling with iodine isotopes due to
the low electron density of the pyridine hetero-aromates. Consequently, an effective way of
radiolabeling with iodine is the coupling to electron-rich aromates which can be reacted with
iodine isotopes. For this purpose the PEG-PVPy was quaternized at the pyridine N with
4-(2-bromoethyl)-phenol and in a second step labeled with iodine. Fig. 6.1 summarizes this
approach.
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Figure 6.1: Quaternization and labeling of PEG-PVPy.
Quaternization reaction 210 mg PEG-PVPy was dissolved in 13 mL methanol and 4-(2-
bromoehtyl)-phenol was added under constant stirring. This mixture was stirred over 24 h
at room temperature. Then the polymer was precipitated in 35 mL ether, cooled to -20°C
for 35 min and centrifuged at 2900 rpm (10 min at 4°C). The precipitate was dissolved in
methanol and the precipitation step was repeated in triplicate. The resulting quaternized
polymer was dried over night under reduced pressure.
Radiolabeling of quaternized polymer 10 mg of the quaternized polymer were dissolved
in 1 mL methanol. To this solution 50 µL PBS buffer (pH 7.4), 10 µL Na125I or Na131I
solution (∼100 MBq and 50 µL chloramine T solution (CAT) (5 mg/mL w/v in methanol)
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were added. After 30 s the reaction was stopped by a solution of dithiothreitol (DTT) (10 mg/
30 µL), precipitated in ether and washed three times. The resulting polymer was dissolved in
methanol and dialyzed against PBS buffer pH 7.4 containing non-radioactive sodium iodide
(1 g in 450 mL PBS buffer).
6.3.2.2 Bioimaging of labeled PEG-PVPy micelles
All animal experiments in the bioimaging and biodistribution study were conducted following
the German law.
100 µL of each of the formulations were injected into the tail vein of the animals. For
bioimaging study the animals were anesthetized with isoflurane and analyzed on g-imager
SCT (Biospace Lab, Paris, France). In the biodistribution study the animals were sacrificed
and organ radioactivity was measured with a berthold LB951G counter (Berthold Technologies,
Bad Wildbad, Germany).
Drug-free PEG-PVPy micelles 10 mg 125I labeled polymer (20 MBq) was dissolved in
methanol. This solution was dialyzed against PBS buffer overnight to remove the solvent
and free iodine.
IFF-loaded PEG-PVPy micelles Labeled 125IFF (25 MBq) and 10 mg PEG-PVPy were
dissolved in 1 mL THF and diluted with 1 mL water. Finally to prepare the micelles, this
mixture was dialyzed against PBS buffer overnight and concentrated by centrifugation with
Amicon microtubes (MWCO 10 kDa).
6.3.2.3 Biodistribution of labeled PEG-PVPy micelles
Biodistribution was investigated in healthy NMRI mice (Charles River Corp., Wilmington,
MA, USA). The preparation procedure of micelles was carried out as described above with
the exception of using Na131I rather than Na125I.
6.4 Results
6.4.1 Preparation of labeled PEG-PVPy
The polymer was labeled successfully with a resulting activity of ∼9 MBq in 400 µL PBS
buffer. 100 µL of this colloidal disperion was injected into the animal for bioimaging. For
the biodistribution study this dispersion was diluted to 2 mL with non-labeled PEG-PVPy
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micelles in PBS buffer and 100 µL of this mixed micellar solution was injected into each
animal.
6.4.2 Bioimaging of labeled PEG-PVPy micelles
Polymeric micellar formulations were successfully prepared by employing a dialysis method.
The formulation was then intravenously injected into mice and biodistribution was followed
over time. For comparison purposes the IFF solution was injected in the study of Breyer et
al. [245].
6.4.2.1 IFF in unlabeled PEG-PVPy micelles
The encapsulated drug was tracked whereas the carrier ramained unlabeled. The scintigrams
were presented in Fig. 6.2.
Figure 6.2: 125IFF in PEG-PVPy micelles 10 min, 60 min, 6 h and 24 h post injection.
Form the scintograms it is remarkable that directly upon injection a strong radioactive signal
can be found in the liver-spleen region of the animal. Until 1 h post injection the scintigrams
looked quite diffuse, indicating still circulating micelles. This diffusity decreased strongly after
1 h. Over time the liver signal decreased and splitted up into two “green” regions. The lower
“green” center represented the intestinal system of the mouse. The drug was cleared from the
body by using this route. 24 h upon injection a radioactive signal was still detectable.
6.4.2.2 Labeled PEG-PVPy micelles
The labeled polymer was investigated on biodistribution in γ-scintigraphy and quantitative
biodistribution. The results were reported in Fig. 6.3 and Fig. 6.4.
110
6.4. RESULTS
Figure 6.3: 125I-PEG-PVPy micelles 10 min, 60 min, 6 h, 24 h and 7 d post injection.
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Figure 6.4: 131I-PEG-PVPy micelles in a biodistribution experiment (each bar n=3).
The scintigrams showed a strong radioactive signal upon injection in the liver-spleen region.
But in contrast to the sctinigrams at 1 h post injection, the signal was not centered as a circle.
This and the diffusity of the scintigrams indicated still circulating micelles. 1 h post injection
the signal was centered in the liver and remained until 7 d post injection. The biodistribution
data showed a similar pattern: strong accumulation in the liver which increased from injection
to 1 h post injection and remained for more than 6 d. Simultaneously in blood and lungs the
radioactivity decreased rapidly upon injection.
6.4.2.3 Elucidation of PEG-PVPy body clearance
For this purpose the remaining activity in the animals was recorded in dependece of time.
The data were isotope half-life corrected. The results were reported by Fig. 6.5.
111
CHAPTER 6. PEG-PVPY LABELING AND BIODISTRIBUTION
0 20 40 60 80 100 120 140
40
50
60
70
80
90
100
Elimination half life time: 56,29 h
R
e
m
a
in
in
g
 A
c
ti
v
it
y
 [
%
]
D
e
ca
y 
co
rr
e
ct
e
d 
da
ta
Time [h]
Figure 6.5: Body clearance of PEG-PVPy in dependece of time (n=3).
The body clearance half-life was found to be ∼56 h and followed a first-order decay.
6.5 Discussion
The purpose of this study was the preparation and in vivo detection of radiolabeled polymeric
PEG-PVPy carriers with their encapsulated drugs. The central question was the elucidation
of pharmacokinetic properties combined with elimination routes of the polymeric carrier.
Preparation of radiolabeled materials followed by micellization and encapsulation of drugs
generally is quite challenging. Radiolabeling of a polymer for micellization is possible via two
different routes: 1) labeling in the micellar core and 2) labeling of the micellar shell. Option
1) has the advantage that the surface properties of the particles remain unchanged (e.g.
charge) whereas option 2) does not affect the stability of the micellar cores. Core labeling
was received by coupling an electron-rich phenol derivative to the hydrophobic domain of
the PEG-PVPy. This phenol derivative was then accessible for direct labeling with iodine
isotopes. The labeled polyermic carrier showed a strong accumulation in the liver directly
upon injection (Fig. 6.3 and 6.4). The blood compartment showed a strong decrease of
the micellar/polymeric concentration within 60 min upon injection. This indicates that the
circulation of the micelles was less than 1 h. It is remarkable that the residence time in the
liver was very long compared to the circulation time of the micellar system. Isotope half-live
corrected radioactivity measurements of the animals revealed an eliminmation half-life of
∼56 h upon a single injection of the micelles. Excretion of the polymeric species via the
kidneys, as expected for polymeric chains with molar masses below 40 kDa [12, 248], did not
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play a mojor role for micellar systems. Furthermore, micellar/polymeric exposure was found
in organs with high blood flows [4] and strong activity of the reticulo endothelial system (RES),
as expected. For example, spleen and lungs showed strong signals of radioactivity. Although
the micellar stability if biofluids [57] was investigated prior to this in vivo experiment which
was found to be reasonably stable, the circulation of the micelles was strongly limited. From
this experiment the question remains open whether the micelles disassembled prematurely
into single polymeric chains or if the RES cleared the intact particles rapidly upon injection.
Loading the micelles with IFF drug and tracking this drug in vivo was selected to reveal
information about the drug payload (Fig. 6.2). As IFF is a very hydrophobic model compound,
it was previously shown upon injection of an organic drug solution that metabolization and
excretion followed the liver-bile-intestine route [245]. The drug-loaded micelles showed similar
properties as can be seen from the bioimaging sctinigrams. Consequently a separation between
carrier and drug effects was not possible.
6.6 Conclusions
The radiolabeling experiment of PEG-PVPy is very important in several dimensions: 1)
although the materials showed excellent drug-loading results and reasonable in vitro stability,
the in vivo influence on drug pharmacokinetics was insufficient, 2) elimination of polymers
via the kidneys (single chains below 25 kDa) is only a minor route for excretion of micellar
assemblies and 3) information about drug palyoad and polymer can only be received by
different isotope labeling. Taking these conclusions into account, the design of further in vivo
experiments can be optimized.
6.7 Outlook
To overcome the disadvantages of the iodine labels it can be suggested to change the
experimental design: labeling of drug and polymeric carrier had to be different to allow for a
discrimination in vivo. For this purpose a different radiolabel apart from iodine isotopes had
to be included into the polymeric chain. The previously investigated option for PEG-PLGA
(chapter 5) of micellar shell labeling could be a valuable option for the design of potential
111In labeled PEG-PVPy. This option requires a functional group at the PEG end of the
polymeric chain. The idea could be to synthesize a H2N-PEG-PVPy that is not commercially
available yet. Polymerization can be carried out starting from H2N-PEG and 4-vinylpyridine.
The polymerization technqiue of choice is Atom Transfer Radical Polymerization (ATRP).
In 1995 the ATRP technology was independently discovered as a special type of radical
polymerization by the groups of Matyjaszewski [249, 250, 251] and Sawamoto [252, 253,
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254]. The groups leveraged this technology as one option to prepare polymeric materials
with high conversion rates in a reasonable time frame. Uniques features of ATRP are: 1)
preparation of polymeric vinyl backbones with high molar masses (e.g 100 kDa), 2) reaction
in aqueous/organic solvent mixtures, 3) short reaction times (few hours maximum), 4) good
control of polymeric chain length distributions (Mw/Mn < 1.5) compared to other radical
polymerization technqiues and 5) usage of transition metals as catalysts.
However, this technology was described in literature for polymerization with H3CO-PEGs
[255, 256, 257] whereas in this case an amino-PEG should be used. To ensure that the
polymerization is not carried out at the amino group, a protected amino-PEG derivative
should be selected for polymerization.
114
Chapter 7
The fate of carriers and encapsulated
drugs upon injection of self-assembling
polymeric micellar systems
Tobias Miller1,3, Sandra Breyer2, Gwenaelle van Colen1, Simon Geissler1,
Walter Mier2, Uwe Haberkorn2 Senta Uezguen1, MarkusWeigandt1, Achim
Goepferich3
1 Merck KGaA, Exploratory Pharmaceutical Development, Frankfurter Str. 250, 64293
Darmstadt, Germany
2 Department of Nuclear Medicine, University Hospital Heidelberg, Im Neuenheimer Feld 400,
69120 Heidelberg, Germany
3 University of Regensburg, Department of Pharmaceutical Technology, Universitätsstrasse
31, 93040 Regensburg, Germany
To be submitted
115
CHAPTER 7. THE FATE OF CARRIER AND ECAPSULATED DRUGS
7.1 Abstract
The solubilization of hydrophobic drugs, controlling the pharmacokinetics by a carrier system
as well as drug targeting are the driving forces for exploring drug-loaded polymeric micelles.
In this study these issues were investigated for PEGylated poly-(lactic acid) (PEG-PLA)
micelles which incorporated the hydrophobic model drug dechloro-4-iodo-fenofibrate (IFF).
For this purpose amino-PEG-PLA (H2N-PEG-PLA) was synthesized, coupled to 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and labeled with 111-Indium. From
this polymeric species, mixed micelles with methoxy-PEG-PLA (H3CO-PEG-PLA) were
prepared which encapsulated the 125-Iodine or 131-Iodine labeled drug IFF. Bioimaging
and biodistribution experiments in healthy and tumor bearing mice (AR42J model) were
carried out and the uptake of the drug and its carrier was quantified in single organs (Fig.
7.1). As a result successful solubilization of IFF by physical incorporation into the micelles
was possible. Upon injection of this system a rapid dissociation of the polymeric carrier
and the incorporated drug (<10 min post inj.) was found. Furthermore, drug and carrier
exhibited completely different biodistribution patterns; both showed no enhanced tumor
accumulation. As a conclusion, the self-assembling system allowed for successful solubilization
of the hydrophobic drug by physical incorporation into micelles, however, in vivo a rapid
dissociation of drug and carrier was detectable.
Figure 7.1: Summary of the biodistribution study with 111In-HN-PEG-PLA micelles.
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7.2 Introduction
The development of cytostatic agents for the treatment of life-threatening diseases like cancer
excited the scientific community and gave hope for cure to patients. Despite the progress made,
cancer treatment still requires improvements. Major drawbacks of cytostatic therapies were
and still are strong off-target effects caused by adverse drug pharmacokinetics. This leads to
severe side-effects and frequently only limited success in the treatment of the disease [258, 211].
Nanoparticles with their sufficiently small particle size, variable morphology and surface charge
as well as multiple chemical composition are expected to overcome the lack of drug efficacy
since they change the drug pharmacokinetics by a carrier system [259, 260]. A flicker of hope in
this context were the liposomal product Doxil® [20] and the micellar products Genexol-PM®
[7] and Nanoxel-PM® [261]. Doxil® was the first reasonable treatment option for patients
suffering from Kaposi sarcoma that led to complete remission of the tumors combined with low
side effects [262, 263, 264]. In contrast to this, Genexol-PM® and Nanoxel-PM® sufficiently
solubilized highly effective taxol-derivatives which previous formulations were dose limiting
due to strong excipient toxicity [265]. Finally the tolerated doses as well as the treatment
success increased [266]. As can be seen with the products that encapsulate Taxol-derivatives,
many anticancer agents are hydrophobic and, therefore, require solubilization technologies
prior to administration. A very promising approach that combines the challenges, both in
drug targeting and solubilization, are polymeric micelles. These self-assembling systems
generally exhibit a hydrophilic shell and a hydrophobic core [210]. Consequently they are
ideal for solubilizing hydrophobic drugs by encapsulation in their hydrophobic regions whereas
the hydrophilic shell interacts with the biological environment. One intention is to tend
off opsonizing agents by a steric barrier that finally prevents premature blood clearance
of the micelles by the reticulo-endothelial system (RES) [106]. This leads to an increased
blood circulation of the particles and enables the accumulation in tumors by the enhanced
permeability and retention effect (EPR) [131, 140]. The amount of drug solubilization is
not to only increase a substance’s solubility. The idea behind the drug incorporation is
based on the sufficiently stable cargo encapsulation in the micellar core. This assumption,
however, remains questionable because self-assembling micelles are dynamic systems which
encounter multiple stresses upon injection [246]. Therefore, in this study the fate of micellar
carriers and their drug payloads was investigated in biodistribution experiments by means of
radiolabeling. For this purpose the model drug dechloro-4-iodo-fenofibrate was selected which
was derived from the highly hydrophobic drug fenofibrate [245]. The radiolabled model drug
was encapsulated into micelles composed of PEGylated polylactic acid (PEG-PLA). These
micelles were known to form stable associates in water and serum [57] and were accessible for
radiolabeling via synthesis of H2N-PEG-PLA. The terminal amino-group was then modified
with 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) [267] which is able to
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chelate several metallic radioactive isotopes such as indium. Consequently tracking of the
drug delivery system within the same animal was made possible by employing and detecting
an iodine isotope for the drug cargo and a metal isotope for the micellar carrier. These
systems were investigated in tumor-bearing mice on their efficacy of tumor targeting as well
as their in vivo fate. The results are intended to give a deeper understanding on the in vivo
properties of such self-assembling systems.
7.3 Materials and methods
7.3.1 Materials
Amino-polyethylenglycole (H2N-PEG) with a molar mass of 5 kDa was purchased from Rapp
Polymere Inc, Tübingen, Germany. Dilactide, stannous diethylhexanoate (Sn(EtHex)2),
tetrabutylammonium bromide (TBABr) and dried toluene (water content <50 ppm) were
obtained from Sigma-Aldrich, Rossdorf, Germany. H3CO-PEG-PLA [5-b-23] was purchased
from Polymersource Inc., Montreal, Canada. DOTA-2,5-difluorophenyl-ester was synthesized
according to Mier et al. [267]. Acetone, tetrahydrofurane (THF), CDCl3, HCl, acetonitrile,
dimethylsulfoxide (DMSO), polyethylenglycole 200 (PEG-200), ethanol (96% v/v) and
dimethylformamide (DMF) were delivered from VWR, Darmstadt, Germany. Water was of
MilliQ grade. Float-A-Lyzer G2 8-10 kDa dialysis tubes were purchased from Spectrumlabs
Inc., Breda, the Netherlands. Dechloro-4-iodo-fenofibrate (IFF) was prepared as reported
by Breyer et al. [245]. Sodium 125-iodide, sodium 131-iodide and 111-indium chloride were
obtained from Perkin Elmer, USA. NMRI mice and nude mice were delivered by Charles
River Inc, Wilmingham, MA; USA.
7.3.2 Methods
7.3.2.1 Synthesis of H2N-PEG-PDLLA
For radiolabeling purposes a strategy proposed by Lee et al. [268] and Hoang et al. [269] was
followed. Both groups described radiolabeling of PEGylated block copolymers at the terminal
amino functionality of the PEG part. The amino group was used for chemical modification by
coupling of chelators like DOTA via forming a stable amide bond. Therefore H2N-PEG-PLA
with H2N-PEG as macroinitiator was synthesized via ring opening polymerization (ROP).
Generally the method of Tessmar et al. [270] was applied. In brief, H2N-PEG, the dilactide
and the catalyst Sn(EtHex)2 were dissolved in dried toluene under nitrogen atmosphere in
a round bottom flask. Protection of the amino functionality from polymerization reaction
was carried out by addition of 1 M HCl. Then the round bottom flask was equipped with
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a condensor and the reaction mixture was heated to 115°C under constant stirring. After
4 h, the mixture was cooled to room temperature and the organic solvent was removed under
reduced pressure. The crude polymer was dissolved in 2 mL acetone and precipitated upon
addition of 8 mL water. The resulting dispersion was dialyzed twice overnight against 5 L
water to remove unbound PEG and monomers/dimers. The purified premicellar formulation
was lyophilized overnight to receive a dry polymer product.
7.3.2.2 Polymer analytics
Molar masses and mass distributions of the resulting polymers were determined on a Viscotek
GPCmax system equipped with a TDA 302 triple detector system (full system provided by
Malvern Instruments Ltd., Worcestershire, UK). 0.1% TBABr in DMF served as a solvent
mixture on a Tosoh TSK Gel 3000 HHR column (Tosoh Biosciences GmbH, Stuttgart,
Germany). Calibration was carried out by using a set of polystyrene standards. For 1H-NMR
analysis the polymers were dissolved in CDCl3. Spectra were recorded on a Bruker 400 MHz
NMR spectrometer (Bruker BioSpin GmbH, Rheinstetten, Germany).
7.3.2.3 Radioactive labeling of H2N-PEG-PLA
The chelator DOTA was conjugated to the H2N-PEG-PLA by reaction of the primary amino
group with DOTA-2,5-difluorophenyl-ester [245] to form a stable amide bond. In a typical
procedure 10 mg of the block copolymer and 1.3 mg DOTA-2,5-difluorophenyl-ester were
dissolved in a mixture of 500 µL acetonitrile and 0.4 µL triethylamine. The mixture was
stirred at room temperature for 48 h and precipitated by addition of an excess of ethanol
(EtOH) (5 mL). The solid was collected, washed twice with EtOH and water and dried
under vacuum overnight. The polymer conjugate was dissolved in 500 µL acetonitrile and
1.0 mL NH4OAc buffer solution (0.5 M, pH 6) followed by addition of 111InCl3-solution
(∼30 MBq). The mixture was heated to 95°C for 2 h, cooled to room temperature and the
solvent was evaporated. The residue was washed with EtOH and water (3 x 1 mL each)
and dried in vacuum to yield ∼20 MBq of the 111In-labeled polymer. Radiochemical purity
was evaluated by instant thin layer chromatography (ITLC) as follows: A glass fiber strip
was spotted with the sample and developed in NH4OAc buffer (0.5 M, pH 6). The strip
was sectioned and counted for radioactivity at the baseline (retention factor = 0) and at
the solvent front (retention factor = 1). Unbound 111In and unbound 111In-DOTA migrated
with the solvent front whereas 111In-DOTA-NH-PEG-PLA remained at the baseline. The
radiolabeling efficiency was calculated as ratio between detected radioactivity at baseline and
solvent front in percent.
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7.3.2.4 Radiolabeling of H2N-PEG
The amino-PEG species was injected into a healthy NMRI mouse for reference purposes.
H2N-PEG (20 mg) and DOTA-2,5-difluorphenylester (5 mg) were dissolved in a mixture
of 1 mL acetonitrile and 375 µL triethylamine. The solution was stirred for 48 h at room
temperature and evaporated to dryness. The residue was washed with EtOH (3 x 3 mL) and
dried under vacuum. 10 mg of the polymeric conjugate and 111InCl3 were dissolved in 500 µL
acetonitrile and 1 mL NH4OAc buffer solution (0.5 M, pH 6). The mixture was stirred at
95°C for 2 h and cooled to room temperature. The mixture was concentrated and the crude
polymer solution was purified using Amicon® Ultra Centrifugal Filters with 3 kDa cutoff.
After washing with water (3 x 100 µL) the product was dried in vacuum. Radiochemical
purity was analyzed as described above.
7.3.2.5 Formulation preparation for biodistribution and bioimaging
Preparation of 125IFF or 131IFF encapsulated in 111In-HN-PEG-PLA micelles The prepa-
ration of the formulation was performed by employing a modified cosolvent evaporation
method. Briefly, for preparation of 0.4 mL micellar formulation, 1 mg IFF with 8 MBq 125IFF
and a mixture of 20 mg mPEG-PLA and 5 mg 111In-DOTA-NH-PEG-PLA (activity: 8 MBq)
was dissolved in a mixture of 6 mL THF and 1 mL water. Evaporation of THF was performed
under reduced pressure (25 mbar) to load the micelles. Removal of residual solvents was
achieved by a dialysis step against IFF saturated PBS buffer to reduce drug distribution from
the micellar core towards the surrounding dialysis medium. For this purpose Float-A-Lyzer
dialysis tubes with a cutoff between 8-10 kDa were used. This formulation was injected into
the animal. In Fig. 7.2 the concept of the resulting labeled polymeric micelles was portrayed.
Characterization of micelles Particle sizes and size distributions were measured by employ-
ing the dynamic light scattering (DLS) technique. For this purpose the sample was diluted
1:100 and measured with the Zetasizer Nano ZS90, Malvern Instruments, Worcestershire, UK.
Additionally, the zeta potential of the resulting micelles was investigated with this method: a
1:10 dilution of micelles with 0.1% sodium chloride solution was prepared and analyzed.
111In-DOTA-HN-PEG and 111In-DOTA-HN-PEG-PLA solutions The radiolabeled poly-
mers were dissolved in a mixture of 5% DMSO, 45% PEG-200 and 50% PBS buffer. This
solution was then taken for injection.
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Figure 7.2: Micellar composition and morphology. The core components consisted of polylactic
acid which hosted the radioactively labeled drug 131IFF. The particle shell was
covered with PEG chains. The surfaces showed a mixture of 111In-DOTA-HN-
PEG-PLA and H3CO-PEG-PLA.
7.3.2.6 Animal preparation and in vivo studies
The approach of the in vivo studies was summarized in Fig. 7.3. According to the experimental
setup, the polymeric solutions were injected for reference purposes in healthy NMRI mice.
For the micellar formulation loaded with IFF drug a biodistribution study was carried out
with tumor-modified animals. All animal experiments were carried out according to German
law requirements on in vivo experiments.
For bioimaging studies with single animal biodistribution Investigation of biodistribution
for 111In-DOTA-HN-PEG and 111In-DOTA-HN-PEG-PLA solutions as well as 125IFF-loaded
111In-DOTA-HN-PEG-PLA micelles was carried out by bioimaging in one healthy, female
NMRI mouse (6 weeks old, ∼30 g) per specimen. For this purpose, the animal was anaes-
thetized with isoflurane prior to the bioimaging experiment. Then 100 µL of the radioactive
micellar formulation was injected into the tail vein of the mice. Bioimaging was carried
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out on a γ-imager SCT, Biospace Lab, Houston, TX, USA. After finishing the bioimaging
experiments, each animal was sacrificed and radioactivity of 111In and 125I was quantified in
different organs with a berthold LB951G γ-counter (Berthold Technologies, Bad Wildbad,
Germany).
Figure 7.3: Summary of the animal study approach.
For biodistribution studies with drug loaded micelles: tumor inoculation in mice The
AR42J cell line which was derived from a rat exocrine pancreas neuroendocrine tumor
was used. For inoculation of the tumors, a Matrigel matrix/cell suspension was injected
subcutaneously into the flank of the animals (5 x 106 cells per animal). Tumors were grown
up to a size of ∼1.0 cm³. 100 µL of the formulations were injected into the tail vein of the
mice. Groups of 3 animals each were sacrificed 10 min, 30 min, 1 h, 2 h, 24 h upon injection.
The following tissues/organs were extracted and prepared for further analysis: plasma, heart,
lungs, kidneys, liver, spleen, intestines, stomach and where appropriate tumor. The organs
were analyzed for radioactivity of 111In and 131I with a berthold LB951G γ-counter.
7.4 Results
7.4.1 Polymer synthesis, analytics and micelle characterization
Amino functionalized PEG-PLA was successfully synthesized with the following characteristics
obtained from GPC and NMR (Tab. 1).
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Table 7.1: Characterization of H2N-PEG-PLA.
Mn [calc] Mn [1H-NMR] Mn [GPC] Mw [GPC] Mw/Mn
H2N-PEG-PLA
g/mol
28.000 29.300 28.300 32.600 1.15
The chemical shifts for the resulting polymer obtained from 1H-NMR confirmed identity and
structure of the polymer. H2N-PEG-PLA, CDCl3: d 1.55 ppm (1H, -OCHCH3CO-), d 2.7
ppm (2H, H2N-), d 3.6 ppm (4H, -OCH2CH2-), d 5.35 ppm (3H, -OCHCH3CO). Particle sizes,
size distributions as well as zeta potential of the prepared micelles are reported in Table 7.2.
Table 7.2: Characterization of the resulting micelles composed of a mixture of 111In-DOTA-
NH-PEG-PLA and mPEG-PLA (mean ± SD).
Particle size [nm] PdI Zeta-potential [mV]
110 ± 3 0.24 ± 0.02 0 ± 4
7.4.2 Bioimaging
The imaging experiment was carried out prior to the biodistribution study to identify the
scarification time-points. Moreover, for the control experiments with 111In-DOTA-NH-PEG-
PLA and 111In-DOTA-NH-PEG distribution was only followed by bioimaging. 24 h upon
injection the animals were sacrificed and the organs analyzed for radioactivity.
7.4.2.1 Drug-loaded polymeric micelles
Radiochemical purity was obtained from ITLC and found to be 92.4% for the 111In-DOTA-
NH-PEG-PLA (data not shown). This labeled species was taken for further preparation of
micelles followed by in vivo studies. The scintigrams for the drug loaded micelles are shown
in Fig. 7.4. The scintigrams obtained for the carrier immediately upon injection show a
rather diffuse radioactivity pattern indicating the circulation of the carrier system (Fig. 7.4A).
Moreover, the liver-region was clearly detectable in the center of the scintigrams. Over time
the diffuse signal vanished and the radioactivity strongly focused on the liver. 24 h upon
injection radioactivity was still detectable. A different distribution pattern could be found for
the encapsulated drug IFF (Fig. 7.4B): Initially, a strong signal was rather centered in the
liver-region (red spot) but simultaneously showed a diffuse corona around this region. The
scintigrams 1 h to 6 h nicely reveal the rapid liver clearance of the drug from the liver via the
bile into the intestinal system. In contrast to the carrier the drug was cleared rapidly and
nearly no radioactivity could be detected 24 h post injection. Clarification of the question at
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which time point the biodistribution pattern of the drug still followed the carrier system was
revelaed by analyzing the radioactivity in different organs (Fig. 7.4C). The biodistribution
results 24 h after injection revealed a clear accumulation of the polymer in spleen, liver and
lungs whereas the drug only followed the carrier system in liver and lungs.
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Figure 7.4: A. Bioimaging of 125IFF loaded 111In-DOTA-HN-PEG-PLA micelles showing
carrier distribution. B. Bioimaging of 125IFF loaded 111In-DOTA-HN-PEG-PLA
micelles showing drug distribution. C. Preliminary biodistribution of 125IFF
loaded 111In-DOTA-HN-PEG-PLA micelles (n=1). Based on these distribution
results the time points for the final biodistribution experiement was determined.
7.4.2.2 111In-DOTA-NH-PEG-PLA solution
The polymeric solution was dissolved in a formulation containing 5% DMSO, 45% PEG-200
and 50% PBS buffer as a control experiment. Bioimaging in Fig. 7.5A reported the recorded
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scintigrams. Immediately upon injection (0-20 min) the liver-region and kidneys were stained
by radioactivity. Simultaneously a strong signal was detectable in the bladder. Most of
the injected activity was cleared from the organism within 2 h upon injection. Moreover,
a weak signal was still detectable in the liver-region after 24 h. Subsequently the animal
was sacrificed and the organs were analyzed (Fig. 7.5B). Biodistribution of radioactivity
revealed a strong preference of lungs, spleen and liver for the radioactively labeled polymer.
As expected from the scintigrams a signal in the kidneys was detected.
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Figure 7.5: A. Bioimaging of 111In-DOTA-NH-PEG-PLA solution (non-micellar). B. Biodis-
tribution of 111In-DOTA-HN-PEG-PLA polymer 24 h upon injection (n=1). This
experiment was a control for the drug-loaded micelles group.
7.4.2.3 111In-DOTA-NH-PEG solution
As an additional control experiment the radioactively labeled hydrophilic part of the inves-
tigated block copolymer was investigated on biodistribution. The radiochemical purity for
111In-DOTA-NH-PEG detected by ITLC was 80.9% (data not shown). This polymer was
taken for further in vivo studies. The scintigrams in Fig. 57.6 showed the very rapid clearance
of the labeled PEG (5.5 kDa) from the body. Clearly the kidneys were detectable 5 min upon
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injection followed by a strong radioactive signal in the bladder (>20 min). As expected the
biodistribution pattern 2 h upon injected showed a small remaining signal of radioactivity in
the kidneys from which the major blood clearance mechanism appeared (Fig. 7.6B).
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Figure 7.6: A. Bioimaging of 111In-DOTA-NH-PEG solution. B. Biodistribution of 111In-
DOTA-NH-PEG 24 h upon injection (n=1). This experiment was a control for
the biodistribution of drug-loaded micelles.
7.4.3 Biodistribution of dual-labeled polymeric micelles with 131IFF payload
in several animal groups of tumor-bearing mice
Based on the bioimaging data of the drug-loaded formulation the following time points for
the biodistribution study were selected: 10 min, 30 min, 60 min, 2h and 24 h. At each of
these time points 3 animals were sacrificed and analyzed for organ radioactivity. The results
from the analyses are shown in Fig. 7.7.
Generally two methods were selected to present the acquired biodistribution data: %ID/g
and %ID. Both modes of presentation offer different insights into the experiment. The %ID/g
presentation respects the tissue selectivity of a drug/carrier system whereas %ID reported
the quantitative distribution per organ. The data are presented in Fig. 7.7A and 7.7B
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Figure 7.7: A. Biodistribution of polymeric carrier in % ID/g. B. Biodistribution of poly-
meric carrier in % ID C. Biodistribution of IFF drug payload in % ID/g. D.
Biodistribution of IFF drug payload in % ID.
for the biodistribution of the carrier system whereas Fig. 7.7C and 7.7D summarize drug
biodistribution. It was obvious from the biodistribution data of the carrier that the lungs
strongly accumulated the injected micelles (Fig. 7.7A). The signal in the lungs increased
starting from 10 min upon injection (∼26% ID/g) to 1 h (∼80% ID/g) and decreased again
until 24 h (∼35% ID/g). A similar progression of this trend could also be detected in
the liver. In contrast to this, blood concentrations decreased over time compared to the
initial concentration measured at 10 min. However, an increased tumor accumulation of the
nanoparticles could not be detected. Focusing on the absolute biodistribution values of the
carrier (Fig. 7.7B) the data revealed the strongest accumulation of the carrier in the liver
followed by the lungs. 2 h post injection the quantitative radioactivity in lungs (∼12% ID)
was more than half of that in the liver (∼20% ID). It was remarkable that radioactivity in
the kidneys followed the trend of progression in the blood. Moreover, a certain percentage of
ID remained at the site of injection.
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The biodistribution for IFF was quite different to that of the carrier. The strong preference
for the liver compared to the micellar carrier could not be found here (Fig. 7.7C). The organ
preferences for the drug in lungs, liver and kidneys were quite equal over time. Unexpectedly
the blood concentrations of the drug did not show a strong decay upon injection. Until 2
h post injection there was a drug plateau phase in the blood compartment which vanished
after 24 h. Interestingly the tumor preference for the drug was similarly low as for the carrier
(drug: ∼2% ID/g, carrier: ∼1.5%). The absolute biodistribution pattern in Fig. 7.7D for the
drug showed a strong overall accumulation of the drug in the liver which also resulted in a
plateau over the first 2 h post injection. This plateau-phase was also present in blood and
lungs. The absolute blood concentration was higher compared to the carrier (drug: ∼7% ID,
carrier: 2-5% ID). Unexpectedly an increasing progression of drug concentration over time
could be found in the kidneys. Excretion and elimination of the drug could be followed by
increasing concentrations in the intestinal system.
7.5 Discussion
The idea of successful passive drug targeting to disease modified tissue is based on 1) the
long circulation of particles within the blood stream to utilize the EPR effect [131] and
2) the stability of drug encapsulation into the nanoparticulate cores [57]. Long circulation
of polymeric micelles is achieved by covering the particle core with PEG [64] whereas the
stability of encapsulation is generally assumed to be sufficiently high. However, when it was
investigated that premature drug release could occur when the micelles’ integrity was lost, the
results pointed at blood components that could be responsible for this effect. Based on this
hypothesis a couple of studies investigated the stability of micelles in serum [57, 45, 53] or
blood [53]. For the selected polymeric materials in this study, a serum stability study prior to
performing animal experiments was also employed and PEG-PLA micelles were found to be
reasonably stable [57]. Besides a lack in colloidal stability, some groups already doubted that
micelles stability would be the only mechanism which leads to premature drug release. They
argued for diffusion/distribution of the drug from the micelles [214, 58]. Such observations
were made from in vivo experiments by comparing the pharmacokinetic properties of the
nanoparticulate carriers to those of drug solutions. A recent investigation by Letchford and
Burt [87] had shown that rapid distribution processes upon injection of Paclitaxel loaded
PEGylated polycaprolactone (PEG-PCL) micelles occured. In their in vivo experiments
the pharmacokinetic properties of drug encapsulated in PEG-PCL micelles were similar
compared to the standard Taxol®-formulation which is composed of ethanol/Cremohpor
EL® as solubilizers. Given the lower stability of low molar mass surfactants (Cremophor
EL®) these results were rather disappointing. Considering these findings, the goal of the
study was to investigate the fate of the micellar carrier components and the encapsulated
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drug simultaneously. For this purpose, H2N-PEG-PLA was synthesized which was labeled via
coupling 111In-DOTA to the polymer backbone whereas the drug payload IFF was labeled
with a radioactive iodine isotope (131I for biodistribution, 125I for bioimaging). The different
emission energies of the two iodine and indium labels allowed for the discrimination of
carrier and drug distribution in a single in vivo experiment. Bioimaging was carried out
to obtain a qualitative picture of the biodistribution. Furthermore, bioimaging allowed for
checking the experimental setup and concept of dual-labeling: carrier distribution should
be distinguishable from drug payload distribution in a single animal. The scintigrams
confirmed that this was possible: The carrier (Fig. 7.4A) seemed to distribute directly
upon injection into the liver while its rather diffuse distribution indicated empty circulating
micelles. The IFF payload was found in the liver with a strong radioactive signal directly
upon injection (Fig. 7.4B). The scintigrams showed a much lower diffusity compared to the
carrier scintigrams which is a first hint on the separation of drug and carrier distribution
rapidly post injection. Concerning the strong liver accumulation of the carrier it is remarkable
that, besides the lungs and kidneys, the liver is one of the organs with the highest blood
flow [4]. Nanoparticles are known to preferentially accumulate in tissues with high perfusion
[4]. Additional information which can be extracted from the bioimaging scintigrams are
the excretion routes of the injected species. 24 h post injection the radioactivity for both
species, carrier and payload, decreased compared to the initial imaging time points and for
IFF drug nearly no activity was remaining in the animal. Once accumulated in the liver,
the drug payload was excreted via the liver-bile-intestine pathway. This was expected due
to the biodistribution results from IFF solution which were acquired in a previous study
[245]. For the polymeric carrier this information was difficult to obtain from the scintigrams.
For quantitative analyses a preliminary biodistribution experiment was performed at 24 h
upon injection (Fig. 7.4C). The distribution pattern shows that the drug biodistribution
did not follow the carrier system: this could be seen in several organs in which the carrier
persisted (e.g. spleen, lungs, liver) but simultaneously nearly no drug was detectable in
those organs. To confirm the separation of drug and carrier further biodistribution studies
were performed. These studies especially focused on the elucidation of the time points at
which this separation of biodistribution takes place in vivo and if carrier or drug reach tumor
tissue sufficiently. Based on the bioimaging results a descision was made for investigating
primarily earlier time points upon injection (<1 h). Consequently the first time point of
analysis was set to 10 min post injection to portray the possible early differences. Drug-free
111In-DOTA-NH-PEG-PLA solution was rapidly cleared from the blood and finally stained
the kidneys and the liver-heart-lung-region (Fig. 7.5A). Shortly upon injection (20 min) the
excretion of the polymer from the urinary bladder was detectable which increased up to
2 h upon injection. This observation was expected from the literature that single polymeric
chains with molar masses below approximately 40-45 kDa were able to be excreted by free
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renal filtration [12, 248]. Besides renal filtration, the polymer accumulated in liver and
spleen (Fig. 7.5B). This was also not unexpected due to the known rapid blood clearance
of macromolecules by the mononuclear phagocyte system (MPS) and was previously found
for PAMAM dendrimers and HPMA [271]. 111In-DOTA-NH-PEG solutions (Fig. 7.6A) in
contrast are cleared extremely fast from blood and the body. 5 min upon injection the
polymer was detectable in the kidneys and 10 min upon injection radioactivity could be
found in the urinary bladder. 1 h post injection most of the radioactivity seemed to have
been excreted into the urine. Moreover, 2 h post injection there was nearly no radioactivity
remaining in the animal (kidneys ∼3% ID/g, Fig. 7.6B). Summarizing both experiments
from 111In-DOTA-NH-PEG and 111In-DOTA-NH-PEG-PLA it was obvious that the PLA
derivative with a higher molar mass (∼28 kDa) was partly excreted via the kidneys but
increasingly accumulated in the organs with high activity of the RES. 111In-DOTA-NH-PEG
with a molar mass of ∼5.5 kDa was excreted by free renal filtration. The biodistribution of
the PEG derivative differed strongly from that of micelles whereas the PEG-PLA derivative
came closer to it. This was probably a matter of using organic polymer solutions. Rapidly
upon injection the organic solvent is diluted and PEG-PLA micelles form in situ. Pure
PEGs are, however, not amphiphilic and therefore not able to from micelles. Bearing these
biodistribution data of the control groups in mind, the drug loaded micellar system was
investigated on its biodistribution and tumor targeting properties in disease modified mice.
For this purpose the AR42J xenograft model for pancreatic cancer was selected. This model
was previously selected for nanoparticle accumulation studies [272, 273]. Comparing carrier
(Fig. 7.7A) and drug (Fig. 7.7C) biodistribution for organ selectivity it was clear that major
differences could be found in the values for the lungs and the excretion mechanisms of drug
and carrier (kidneys, intestines). The carrier accumulated strongly in the lungs whereas the
drug concentration did not follow the carrier in this organ. Similar observations were found
for the kidneys: carrier excretion via the kidneys decreased over time whereas drug excretion
increased. Due to the hydrophobic nature of the drug and the previous study of intravenous
injection (strong liver accumulation) [245] it was most probable that not the intact drug was
renally excreted but a water soluble metabolite: IFF was derived from fenofibrate which
was known to encounter an ester hydrolysis and was consequently metabolized to fenofibric
acid and is usually coupled in rodents to glucuronic acid [274, 275]. These species were
completely water soluble and consequently renally excreted. However, only a part of the
drug was excreted renally in the studies, most prominent was excretion via the bile into
the intestines. Apart from this, a very unusual distribution pattern was found in the blood:
carrier concentration decreased over time (Fig. 7.7A and B) whereas drug concentration
remained on a plateau for the first 2 h upon injection (Fig. 7.7C and D). An explanation for
this could be the high hydrophobicity of IFF: The derivative fenofibrate already was highly
hydrophobic (logP ∼5.24) [276]. Consequently the modification of the drug molecule by
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substitution of the chlorine atom in fenofibrate in favour of iodine in IFF increased the drugs’
hydrophobicity. Therefore it is not unlikely that distribution into adipose tissue appeared.
Drug in adipose tissue served as a reservoir and could lead to the observed plateau phase.
The general positive correlation between drug hydrophobicity and adipose tissue distribution
was confirmed in silico and in vivo by Poulin et al. [277, 278]. Moreover, very remarkable
issues were the tumor targeting properties of the injected particles. The biodistribution
patterns clearly demonstrated that the micelles were not able to deliver the drug efficiently
into the tumor. The overall exposure for carrier and drug was far below 5% ID/g at each
investigated time point. As was shown by other groups, the blood circulation determined
the tumor accumulation properties by the EPR effect: Heneweer et al. [279] described
effective accumulation above 20 h of circulation whereas Pirollo and Chang [280] suggested
necessary circulation times between 24 h and 48 h. Compared to these numbers in the present
study, the circulation times were much lower (<‌<24 h) and, therefore, an enhanced tumor
accumulation could not be observed. As previously mentioned, encapsulation of the drug was
carried out physically and based on hydrophobic interaction or pi-pi stacking between drug
and polymer. Generally, even when the particles might have reached the tumor target, the
question remained if they would be still drug loaded. As clearly demonstrated by the results,
this physical encapsulation technique was not suitable to deliver a stable incorporation of the
drug in the micellar core. Consequently a more direct interaction will be needed e.g. ionic
interaction or chemical coupling of the drug to single polymer chains. Great success of the
latter method even in humans was found for cisplatin which was attached to PEGylated
poly-(glutamic acid) [281]. Compared to these results the concept of physical incorporation
of drugs into self-assembling systems for targeted delivery seems to be difficult to reduce to
practice.
7.6 Conclusion
The results of this study clearly demonstrate that self-assembling polymeric micelles are a
suitable carrier for the solubilization of the hydrophobic model drug IFF. The encapsulation
process was based on physical interactions between drug and carrier (no chemical coupling).
Although the investigated PEG-PLA micelles exhibited a high stability in serum (in vitro)
which was shown in the previous study, the in vivo experiments led to a completely different
picture: Investigation of the loaded carrier in biodistribution experiments revealed that the
carrier and the encapsulated drug followed different distribution routes rapidly upon injection.
These separation processes of drug and carrier were very fast (<10 min). Moreover, due to
these reasons an effective tumor targeting was not possible. Consequently physical loading of
drugs by non-specific interactions (hydrogen bonding, pi-pi stacking) to the polymeric carrier
seems to be a difficult approach to achieve an effective change on drug pharmacokinetics or
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tumor accumulation. Stronger drug-polymer interactions (e.g. electrostatic encapsulation,
chemical coupling) might be more appropriate to reach this goal.
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Summary and conclusion
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Summary
This thesis focussed on the encapsulation of hydrophobic drugs into polymeric micelles and
was intended to show the strengths and limitations of these self-assembling systems in terms
of solubilization and drug targeting. Characterization of hydrophobic drug solubilization
prior to intravenous injection was one of the key goals of this thesis. For this purpose a
novel drug loading procedure was developed based on mechanistic considerations during
the loading processes (Chapter 2). The cosolvent evaporation combined with appropriate
solvent selection prior to preparation was found to be superior to other well investigated
methods like direct dialysis and O/W emulsion techniques. This loading procedure was
successfully developed for dexamethasone as a model drug but was further applied to all
other investigated drugs in this thesis. Furthermore, storage stability of the micellar systems
was acquired by lyophilization with excipients, showing that β-cyclodextrin derivatives are
versatile lyoprotectors for these purposes.
Besides solubilization, the fate of micelles in biofluids was seen to hamper their application
[8, 29]. For this purpose the existing literature was revisited escpecially on the question of
micellar in vivo stability and accumulation into tumor tissue (Chapter 1). As a result it
was found that colloidal systems undergo several stress factors upon injection that questions
their stability of drug incorporation as well as the colloidal integrity itself. Moreover, tumor
accumulation of colloidal systems with native appearance (before injection) of the particle
shell was found to be very unlikely. It was argued for an active uptake mechanism into tumor
tissue which could be triggered by the protein corona (e.g. albumin via gp-60 receptors in
highly SPARC expressing tissues [150, 151]).
Based on these results it was reasonable to develop adequate in vitro tests prior to in
vivo experiments to assess the micelles’ stability and safety in biological systems. A serum
incubation assay was selected to investigate stability which was based on FRET (Foerster
Resonance Energy Transfer) (Chapter 3) and was previously described by Chen and Savic
[53, 282]. Unfortunately, this assay lacked the possibility of quantifying micellar integrity
and therefore to compare different micellar compositions. Consequently this test was further
developed for this thesis and direct comparison between different micellar species could be
made possible. Micellar safety and potential immunogical responses were assessed with
cytotoxicity studies and complement activation assays (Chapter 4). The results showed
impressively that polymers like mPEG-PDLLA were non-toxic in the selected concentrations
(up to 10 mg/mL) whereas already approved non-ionic surfactants (Cremophor EL®, Tween
80®) showed distinct cytotoxicity on both tested cell types (HepG2 cell line, primary
rat hepatocytes). The test polymer species PEG-PVPy which was not under previous
investigations, showed a slight cytotoxicity in both assays. The complement activation assays
revealed the liposomal product Doxil® as a stronger in vitro complement activator compared
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to the investigated block copolymers. Consequently the safety and toxicity of micelles and
their block copolymers did not exceed exisiting products based on colloidal carrier systems.
The experimental and theoretical results were very relevant prior to the conduction of in
vivo experiments. Animal experiments were intended to show the potential of self-assembling
micelles in drug targeting and altering pharmacokinetics of drugs compared to simple solutions.
The first evidence that this concept of altering the pharmacokinetic profile might not fit to
the polymeric micelles used in this thesis were delivered from compound A encapsulated
in mPEG-PLGA micelles (Chapter 5). Besides successful preparation and solubilization
(solubility increase by factor 180) the in vivo properties of the micellar formulation were
identical to the drug solution of compound B (mesylate salt solution of compound A). An
enhanced circulation and therfore drug targeting into tumors was not observed. The reasons
for this in vivo observation of the compound A loaded micelles were not that clear so far from
this experiment because only the drug was tracked in vivo by using an LC-MS method. No
information was acquired about the polymeric carrier. For this reason a follow-up study was
designed: drug and carrier should be tracked simultaneously. A H2N-PEG-PLGA derivative
was prepared, coupled to DOTA and labeld with 111In. This procedure was quite successful
and allowed for simultaneous detection with 125IFF. Compound A and IFF are similarly
hydrophobic but indeed show structural differences. Regardless of these differences, IFF is a
model compound to probe the fate of micellar drugs upon injection. The bioimaging revealed
remarkable qualitative biodistribution differences between polymeric carrier and encapsulated
drug.
Different approaches were followed with the PEG-PVPy material: excellent drug loads with
hydrophobic compounds were achieved but only little information was available concerning
the in vivo properties of such micelles. To reveal biodistribution and clearance, as a first step
the PEG-PVPy polymer was labeled within the hydrophobic part of the block copolymer
because this species was easily accessable for radiolabeling by quarterization of the pyridine
N (Chapter 6). As a disadvantage of this experimental setup can be seen that both species,
polymer and drug, were labeled with a radioactive iodine isotope and consequently could not
be discriminated. However, this approach showed that PEG-PVPy micelles circulated only
within a short time frame (<1 h) but sustained over weeks in RES organs (e.g. liver: half life
∼56 h). These results indicated the poor biodegradability of PEG-PVPy.
However, the approach for PEG-PLGA was further utilized to reveal the in vivo fate of carrier
and drug (Chapter 7): the block copolymer was de novo synthesized and labeled at the
PEG part by coupling to DOTA and chelating 111In. In these 111In labeled micelles,131I or
125I labeled IFF drug was incorporated. The different emission energies enabled to distinguish
between drug and polymeric carrier. The major outcome of this study was the biodistribution
difference of carrier and payload within the same animal. Rapidly upon injection the drug
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exhibited a different biodistribution pattern compared to its carrier. As previosuly indicated
in the chapters 5 and 6 the polymeric associates disassembled quickly.
Conclusive remarks and future perspective
Self-assembling polymeric micelles consisting of linear block copolymers are ideal systems
for the solubilization of hydrophobic drugs and were pharmaceutically characterized in this
thesis based on the following: 1) high drug loads were achieved e.g. with DXM in PEG-PVPy
(∼19%), 2) storage stability of this drug incorporation could be maintained by removing
any water from the micelles by freeze-drying and 3) the selected block copolymers were
toxicologically unproblematic.
From the in vivo studies it could be concluded that self-assembling systems like these
polymeric micelles consisting of linear block copolymers were not able to carry the drug to its
target site and/or to alter the pharmacokinetic properties compared to free drug. Premature
release from these micelles due to the presence of blood proteins and other components was
observed. These observations were not made with the in vitro test assaying micellar stability
in serum. Consequently this experiment was revealed to be non-predictive for premature in
vivo drug release. Possible reasons for this are the general differences between a static in
vitro assay and a dynamic, complex in vivo system (e.g. blood volume and flow, particle
opsonization followed by premature clearance). The idea of passive drug targeting is based
on the long-circulating properties of particles assuming the stability of drug incorporation.
However, self-assembling polymeric micelles do not seem to justify this expectation due to
their fast release as shown in several animal studies within this thesis. Currently there are
several strategies available to enhance the stability of the particles including their drug-loaded
properties. These strategies focus on 1) increasing drug-polymer interactions (e.g. ionic
interactions, covalent attachment of drug) or 2) increasing the particulate core rigidity (e.g.
crosslinking). Both options are reasonable whereas for the latter one potential toxic chemical
residues should be considered from particle preparation. Consequently the first approach will
achieve more attention which can be seen in ongoing clinical trials with polypeptidic block
copolymers and oppositely charged drugs (e.g. cisplatin, product in clinical trials: NK 6004
[281, 90]).
Generally from this thesis the questions remain open, if the concept of passive targeting based
on the EPR effect can be successfully utilized by “simple” size/surface adjustment of the
nanoparticles. Firstly, superior tumor accumulation could not be shown within the results
from animal experiments although the often proposed size limits for nanoparticles below
200 nm [131] were always met. Secondly, it is generally questionable whether nanoparticles
with their molar masses which are at least by factor 103 times higher compared to serum
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proteins can extravasate effectively from the bloodstream only in artificial tumors (e.g. mice
models). The currently available information concerning an EPR effect in natively growing
tumor in humans is extremely limited. Regardless of these concerns, the achievement of
long-circulating particles could be a valuable option to prolong the blood circulation of rapidly
metabolized drugs or by reducing the free drug fraction of toxic drugs. In this connection,
nanoparticles will pose a treatment advance by the formation of blood drug depots with
sustained release. Future investigations will show if this is the major active principle of the
already approved nanomedicines.
137

Bibliography
[1] Mullard, A. (2011) 2010 FDA drug approvals. Nature Reviews Drug Discovery 10,
82–85.
[2] Dimasi, J., Hansen, R., and Grabowski, H. (2003) The price of innovation: new estimates
of drug development costs. Journal of Health Economics 22, 151–185.
[3] Kola, I., and Landis, J. (2004) Can the pharmaceutical industry reduce attrition rates?
Nature Reviews Drug Discovery 3, 711–715.
[4] Bertrand, N., and Leroux, J. (2011) The journey of a drug-carrier in the body: An
anatomo-physiological perspective. J.Control Release In press.
[5] Lipinski, C. (2002) Poor aqueous solubility - an industry wide problem in drug discovery.
Am.Pharm.Rev. 5, 82–85.
[6] Di, L., Fish, P., and Mano, T. (2011) Bridging solubility between drug discovery and
development. Drug Discov.Today 17, 486–495.
[7] Kim, S., Kim, D., Shim, Y., Bang, J., Oh, H., Wan, K. S., and Seo, M. (2001) In vivo
evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J.Control
Release 72, 191–202.
[8] Jones, M., and Leroux, J. (1999) Polymeric micelles - a new generation of colloidal
drug carriers. Eur.J.Pharm.Biopharm. 48, 101–111.
[9] Trivedi, R., and Kompella, U. (2010) Nanomicellar formulations for sustained drug
delivery: strategies and underlying principles. Nanomedicine (Lond) 5, 485–505.
[10] Hamidi, M., Shahbazi, M., and Rostamizadeh, K. (2012) Copolymers: efficient carriers
for intelligent nanoparticulate drug targeting and gene therapy. Macromol.Biosci. 12,
144–164.
[11] Miyata, K., Christie, R., and Kataoka, K. (2011) Polymeric micelles for nano-scale drug
delivery. Reactive & Functional Polymers 71, 227–234.
[12] Greish, K. (2010) Enhanced permeability and retention (EPR) effect for anticancer
nanomedicine drug targeting. Methods Mol.Biol. 624, 25–37.
139
Bibliography
[13] Kedar, U., Phutane, P., Shidhaye, S., and Kadam, V. (2010) Advances in Polymeric
Micelles for Drug Delivery and Tumor Targeting. Nanomedicine. 6, 714–729.
[14] Wang, J., Sui, M., and Fan, W. (2010) Nanoparticles for tumor targeted therapies and
their pharmacokinetics. Curr.Drug Metab 11, 129–141.
[15] Wang, D., Miller, S., Liu, X., Anderson, B., Wang, X., and Goldring, S. (2007) Novel
dexamethasone-HPMA copolymer conjugate and its potential application in treatment
of rheumatoid arthritis. Arthritis Research & Therapy 9, 1–9.
[16] Matsumura, Y., and Maeda, H. (1986) A New Concept for Macromolecular Therapeutics
in Cancer-Chemotherapy - Mechanism of Tumoritropic Accumulation of Proteins and
the Antitumor Agent Smancs. Cancer Research 46, 6387–6392.
[17] Maeda, H., Sawa, T., and Konno, T. (2001) Mechanism of tumor-targeted delivery of
macromolecular drugs, including the EPR effect in solid tumor and clinical overview of
the prototype polymeric drug SMANCS. Journal of Controlled Release 74, 47–61.
[18] Maeda, H. (2001) The enhanced permeability and retention (EPR) effect in tumor
vasculature: The key role of tumor-selective macromolecular drug targeting. Advances
in Enzyme Regulation, Vol 41 41, 189–207.
[19] Tsukioka, Y., Matsumura, Y., Hamaguchi, T., Koike, H., Moriyasu, F., and Kakizoe, T.
(2002) Pharmaceutical and biomedical differences between micellar doxorubicin (NK911)
and liposomal doxorubicin (Doxil). Japanese Journal of Cancer Research 93, 1145–1153.
[20] Bao, A., Goins, B., Klipper, R., Negrete, G., and Phillips, W. (2004) Direct Tc-99m
labeling of pegylated liposomal doxorubicin (Doxil) for pharmacokinetic and non-
invasive imaging studies. Journal of Pharmacology and Experimental Therapeutics 308,
419–425.
[21] Patel, H., and Moghimi, S. (1998) Serum-mediated recognition of liposomes by phago-
cytic cells of the reticuloendothelial system - The concept of tissue specificity. Adv.Drug
Deliv.Rev. 32, 45–60.
[22] Moghimi, S., Muir, I., Illum, L., Davis, S., and Kolbbachofen, V. (1993) Coating
Particles with A Block-Copolymer (Poloxamine-908) Suppresses Opsonization But
Permits the Activity of Dysopsonins in the Serum. Biochimica et Biophysica Acta 1179,
157–165.
[23] Thiele, L., Diederichs, J., Reszka, R., Merkle, H., and Walter, E. (2003) Competitive
adsorption of serum proteins at microparticles affects phagocytosis by dendritic cells.
Biomaterials 24, 1409–1418.
[24] Elwing, H., Askendal, A., and Lundstrom, I. (1987) Competition between adsorbed
fibrinogen and high-molecular-weight kininogen on solid surfaces incubated in human
140
Bibliography
plasma (the Vroman effect): influence of solid surface wettability. J.Biomed.Mater.Res.
21, 1023–1028.
[25] Szebeni, J., Bedocs, P., Rozsnyay, Z., Weiszhar, Z., Urbanics, R., Rosivall, L., Cohen, R.,
Garbuzenko, O., Bathori, G., Toth, M., Bunger, R., and Barenholz, Y. (2012) Liposome-
induced complement activation and related cardiopulmonary distress in pigs: factors
promoting reactogenicity of Doxil and AmBisome. Nanomedicine 8, 176–184.
[26] Chanan-Khan, A., Szebeni, J., Savay, S., Liebes, L., Rafique, N., Alving, C., and
Muggia, F. (2003) Complement activation following first exposure to pegylated liposomal
doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann.Oncol. 14, 1430–
1437.
[27] Ishida, T., Atobe, K., Wang, X., and Kiwada, H. (2006) Accelerated blood clearance of
PEGylated liposomes upon repeated injections: Effect of doxorubicin-encapsulation
and high-dose first injection. Journal of Controlled Release 115, 251–258.
[28] Torchilin, V. (2001) Structure and design of polymeric surfactant-based drug delivery
systems. Journal of Controlled Release 73, 137–172.
[29] Gaucher, G., Dufresne, M., Sant, V., Kang, N., Maysinger, D., and Leroux, J. (2005)
Block copolymer micelles: preparation, characterization and application in drug delivery.
Journal of Controlled Release 109, 169–188.
[30] Mondon, K., Gurny, R., and Moller, M. (2008) Colloidal Drug Delivery Systems -
Recent Advances With Polymeric Micelles. Chimia 62, 832–840.
[31] Shi, B., Fang, C., You, M., Zhang, Y., Fu, S., and Pei, Y. (2005) Stealth MePEG-PCL
micelles: effects of polymer composition on micelle physicochemical characteristics, in
vitro drug release, in vivo pharmacokinetics in rats and biodistribution in S-180 tumor
bearing mice. Colloid and Polymer Science 283, 954–967.
[32] Cerritelli, S., O’Neil, C., Velluto, D., Fontana, A., Adrian, M., Dubochet, J., and
Hubbell, J. (2009) Aggregation behavior of poly(ethylene glycol-bl-propylene sulfide)
di- and triblock copolymers in aqueous solution. Langmuir 25, 11328–11335.
[33] Yang, L., Zhao, Z., Wei, J., El, G. A., and Li, S. (2007) Micelles formed by self-
assembling of polylactide/poly(ethylene glycol) block copolymers in aqueous solutions.
J.Colloid Interface Sci. 314, 470–477.
[34] Kim, S., Tan, J., Nederberg, F., Fukushima, K., Colson, J., Yang, C., Nelson, A.,
Yang, Y., and Hedrick, J. (2010) Hydrogen bonding-enhanced micelle assemblies for
drug delivery. Biomaterials 31, 8063–8071.
[35] Li, G., and Cho, C. (2008) CMC and dynamic properties of poly(VA-b-St) copolymer
micelles for drug delivery. Korean Journal of Chemical Engineering 25, 1444–1447.
141
Bibliography
[36] Yam, V., Hu, Y., Chan, K., and Chung, C. (2009) Reversible pH- and solvent-responsive
micelle-mediated self-assembly of platinum(II) terpyridyl-based metallo-supramolecular
diblock copolymers. Chemical Communications 6216–6218.
[37] Attia, A., Ong, Z., Hedrick, J., Lee, P., Ee, P., Hammond, P., and Yang, Y. (2011)
Mixed micelles self-assembled from block copolymers for drug delivery. Current Opinion
in Colloid & Interface Science 16, 182–194.
[38] Cao, J., Chen, Y., Chen, N., and Luo, X. (2010) The preparation of phosphorylcholine-
containing poly(L-lactide) nanoparticles with solvent evaporation method. E-Polymers
e-resource.
[39] Zhang, J., Men, K., Gu, Y., Wang, X., Gou, M., Guo, G., Luo, F., and Qian, Z. (2011)
Preparation of Core Cross-Linked PCL-PEG-PCL Micelles for Doxorubicin Delivery In
Vitro. Journal of Nanoscience and Nanotechnology 11, 5054–5061.
[40] Xiong, J., Meng, F., Wang, C., Cheng, R., Liu, Z., and Zhong, Z. (2011) Folate-
conjugated crosslinked biodegradable micelles for receptor-mediated delivery of pacli-
taxel. Journal of Materials Chemistry 21, 5786–5794.
[41] Wilhelm, M., Zhao, C., Wang, Y., Xu, R., Winnik, M., Mura, J., Riess, G., and
Croucher, M. (1991) Poly(Styrene-Ethylene Oxide) Block Copolymer Micelle Formation
in Water - A Fluorescence Probe Study. Macromolecules 24, 1033–1040.
[42] Hans, M., Maxwell, C., Ehrlichman, R., Metzger, K., Liang, Y., Siegel, S., and Low-
man, A. (2007) Evaluation of in vitro release and in vivo efficacy of mPEG-PLA-
haloperidol conjugate micelle-like structures. Journal of Biomedical Materials Research
Part B-Applied Biomaterials 83B, 422–430.
[43] Cerritelli, S., Velluto, D., Hubbell, J. A., and Fontana, A. (2008) Breakdown kinetics of
aggregates from poly(ethylene glycol-bl-propylene sulfide) di- and triblock copolymers
induced by a non-ionic surfactant. J.Polym.Sci.A Polym.Chem. 46, 2477–2487.
[44] Kastantin, M., Missirlis, D., Black, M., Ananthanarayanan, B., Peters, D., and Tirrell, M.
(2010) Thermodynamic and Kinetic Stability of DSPE-PEG(2000) Micelles in the
Presence of Bovine Serum Albumin. Journal of Physical Chemistry B 114, 12632–
12640.
[45] Lu, J., Owen, S., and Shoichet, M. (2011) Stability of Self-Assembled Polymeric Micelles
in Serum. Macromolecules 44, 6002–6008.
[46] Theodoly, O., Jacquin, M., Muller, P., and Chhun, S. (2009) Adsorption kinetics of
amphiphilic diblock copolymers: from kinetically frozen colloids to macrosurfactants.
Langmuir 25, 781–793.
142
Bibliography
[47] Newkome, G. R., Moorefield, C. N., Baker, G. R., Saunders, M. J., and Grossman, S. H.
(1991) Unimolecular Micelles. Angew.Chem.Int.Ed.Engl. 30, 1178–1180.
[48] Liu, M., Kono, K., and Frechet, J. (2000) Water-soluble dendritic unimolecular micelles:
their potential as drug delivery agents. J Control Release 65, 121–131.
[49] Heise, A., Hedrick, J. L., Frank, C. W., and Miller, R. D. (1999) Starlike Block Copoly-
mers with Amphiphilic Arms as Models for Unimolecular Micelles. J.Am.Chem.Soc.
121, 8647–8648.
[50] Kainthan, R., Mugabe, C., Burt, H., and Brooks, D. (2008) Unimolecular micelles based
on hydrophobically derivatized hyperbranched polyglycerols: ligand binding properties.
Biomacromolecules 9, 886–895.
[51] Matsumura, Y., Hamaguchi, T., Ura, T., Muro, K., Yamada, Y., Shimada, Y., Shirao, K.,
Okusaka, T., Ueno, H., Ikeda, M., and Watanabe, N. (2004) Phase I clinical trial and
pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. British
Journal of Cancer 91, 1775–1781.
[52] Hamaguchi, T., Kato, K., Yasui, H., Morizane, C., Ikeda, M., Ueno, H., Muro, K.,
Yamada, Y., Okusaka, T., Shirao, K., Shimada, Y., Nakahama, H., and Matsumura, Y.
(2007) A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating
micellar nanoparticle formulation. British Journal of Cancer 97, 170–176.
[53] Chen, H., Kim, S., He, W., Wang, H., Low, P., Park, K., and Cheng, J. (2008) Fast
release of lipophilic agents from circulating PEG-PDLLA micelles revealed by in vivo
forster resonance energy transfer imaging. Langmuir 24, 5213–5217.
[54] Blunk, T., Hochstrasser, D., Sanchez, J., Muller, B., and Muller, R. (1993) Colloidal
carriers for intravenous drug targeting: plasma protein adsorption patterns on surface-
modified latex particles evaluated by two-dimensional polyacrylamide gel electrophoresis.
Electrophoresis 14, 1382–1387.
[55] Luck, M., Paulke, B., Schroder, W., Blunk, T., and Muller, R. (1998) Analysis of plasma
protein adsorption on polymeric nanoparticles with different surface characteristics.
J.Biomed.Mater.Res. 39, 478–485.
[56] Thode, K., Luck, M., Schroder, W., Semmler, W., Blunk, T., Muller, R., and Kresse, M.
(1997) The influence of the sample preparation on plasma protein adsorption patterns
on polysaccharide-stabilized iron oxide particles and N-terminal microsequencing of
unknown proteins. J.Drug Target 5, 35–43.
[57] Miller, T., Rachel, R., Besheer, A., Uezguen, S., Weigandt, M., and Goepferich, A.
(2012) Comparative Investigations on In Vitro Serum Stability of Polymeric Micelle
Formulations. Pharm.Res. 29, 448–459.
143
Bibliography
[58] Aliabadi, H., Brocks, D., Mahdipoor, P., and Lavasanifar, A. (2007) A novel use of an in
vitro method to predict the in vivo stability of block copolymer based nano-containers.
J.Control Release 122, 63–70.
[59] Jette, K., Law, D., Schmitt, E., and Kwon, G. (2004) Preparation and drug loading of
poly(ethylene glycol)-block-poly(epsilon-caprolactone) micelles through the evaporation
of a cosolvent azeotrope. Pharm.Res. 21, 1184–1191.
[60] Vroman, L. (1962) Effect of Adsorbed Proteins on the Wettability of Hydrophilic and
Hydrophobic Solids. Nature 196, 476–477.
[61] Slack, S., Bohnert, J., and Horbett, T. (1987) The effects of surface chemistry and
coagulation factors on fibrinogen adsorption from plasma. Ann.N.Y.Acad.Sci. 516,
223–243.
[62] Horbett, T. (1984) Mass action effects on competitive adsorption of fibrinogen from
hemoglobin solutions and from plasma. Thromb.Haemost. 51, 174–181.
[63] Brash, J., and ten, H. P. (1984) Effect of plasma dilution on adsorption of fibrinogen to
solid surfaces. Thromb.Haemost. 51, 326–330.
[64] Owens, D., and Peppas, N. (2006) Opsonization, biodistribution, and pharmacokinetics
of polymeric nanoparticles. International Journal of Pharmaceutics 307, 93–102.
[65] Weber, M., Bujotzek, A., Andrae, K., Weinhart, M., and Haag, R. (2011) Computational
entropy estimation of linear polyether-modified surfaces and correlation with protein
resistant properties of such surfaces. Molecular Simulation 37, 899–906.
[66] Lasic, D. D., Woodle, M. C., and Papahadjopoulos, D. (1992) On the Molecular
Mechanism of Steric Stabilization of Liposomes in Biological Fluids. Journal of Liposome
Research 2, 335–353.
[67] Moghimi, S., and Patel, H. (1989) Serum opsonins and phagocytosis of saturated and
unsaturated phospholipid liposomes. Biochim.Biophys.Acta 984, 384–387.
[68] Patel, H., Tuzel, N., and Ryman, B. (1983) Inhibitory Effect of Cholesterol on the
Uptake of Liposomes by Liver and Spleen. Biochimica et Biophysica Acta 761, 142–151.
[69] Moghimi, S., and Patel, H. (1988) Tissue specific opsonins for phagocytic cells and
their different affinity for cholesterol-rich liposomes. FEBS Lett. 233, 143–147.
[70] Moghimi, S., and Patel, H. (1996) Altered tissue-specific opsonic activities and opsono-
recognition of liposomes in tumour-bearing rats. Biochim.Biophys.Acta 1285, 56–64.
[71] Moghimi, S., and Patel, H. (1990) Calcium as a possible modulator of Kupffer cell
phagocytic function by regulating liver-specific opsonic activity. Biochim.Biophys.Acta
1028, 304–308.
144
Bibliography
[72] Ogawara, K., Yoshida, M., Takakura, Y., Hashida, M., Higaki, K., and Kimura, T.
(1999) Interaction of polystyrene microspheres with liver cells: roles of membrane
receptors and serum proteins. Biochimica et Biophysica Acta-General Subjects 1472,
165–172.
[73] Johnstone, S., Masin, D., Mayer, L., and Bally, M. (2001) Surface-associated serum
proteins inhibit the uptake of phosphatidylserine and poly(ethylene glycol) liposomes
by mouse macrophages. Biochimica et Biophysica Acta-Biomembranes 1513, 25–37.
[74] Vert, M., and Domurado, D. (2000) Poly(ethylene glycol): Protein-repulsive or albumin-
compatible? Journal of Biomaterials Science-Polymer Edition 11, 1307–1317.
[75] Tenzer, S. et al. (2011) Nanoparticle Size Is a Critical Physicochemical Determinant of
the Human Blood Plasma Corona: A Comprehensive Quantitative Proteomic Analysis.
Acs Nano 5, 7155–7167.
[76] Emmenegger, C., Brynda, E., Riedel, T., Sedlakova, Z., Houska, M., and Alles, A.
(2009) Interaction of Blood Plasma with Antifouling Surfaces. Langmuir 25, 6328–6333.
[77] Schmaier, A., Silver, L., Adams, A., Fischer, G., Munoz, P., Vroman, L., and Colman, R.
(1984) The effect of high molecular weight kininogen on surface-adsorbed fibrinogen.
Thromb.Res. 33, 51–67.
[78] Unsworth, L., Sheardown, H., and Brash, J. (2005) Polyethylene oxide surfaces of
variable chain density by chemisorption of PEO-thiol on gold: adsorption of proteins
from plasma studied by radiolabelling and immunoblotting. Biomaterials 26, 5927–5933.
[79] Goppert, T., and Muller, R. (2005) Adsorption kinetics of plasma proteins on solid
lipid nanoparticles for drug targeting. Int.J.Pharm. 302, 172–186.
[80] Goppert, T., and Muller, R. (2005) Protein adsorption patterns on poloxamer- and
poloxamine-stabilized solid lipid nanoparticles (SLN). Eur.J.Pharm.Biopharm. 60,
361–372.
[81] Harada, Y., Yamamoto, T., Sakai, M., Saiki, T., Kawano, K., Maitani, Y., and
Yokoyama, M. (2011) Effects of organic solvents on drug incorporation into poly-
meric carriers and morphological analyses of drug-incorporated polymeric micelles.
International Journal of Pharmaceutics 404, 271–280.
[82] Diezi, T., Bae, Y., and Kwon, G. (2010) Enhanced Stability of PEG-block-poly(N-
hexyl stearate L-aspartamide) Micelles in the Presence of Serum Proteins. Molecular
Pharmaceutics 7, 1355–1360.
[83] Woodle, M., Newman, M., and Cohen, J. (1994) Sterically Stabilized Liposomes -
Physical and Biological Properties. Journal of Drug Targeting 2, 397–403.
145
Bibliography
[84] Ritchie, T., and Macdonald, S. (2009) The impact of aromatic ring count on compound
developability - are too many aromatic rings a liability in drug design? Drug Discovery
Today 14, 1011–1020.
[85] Burt, H., Zhang, X., Toleikis, P., Embree, L., and Hunter, W. (1999) Development of
copolymers of poly(D,L-lactide) and methoxypolyethylene glycol as micellar carriers of
paclitaxel. Colloids and Surfaces B-Biointerfaces 16, 161–171.
[86] Letchford, K., Liggins, R., Wasan, K., and Burt, H. (2009) In vitro human plasma
distribution of nanoparticulate paclitaxel is dependent on the physicochemical properties
of poly(ethylene glycol)-block-poly(caprolactone) nanoparticles. European Journal of
Pharmaceutics and Biopharmaceutics 71, 196–206.
[87] Letchford, K., and Burt, H. (2012) Copolymer micelles and nanospheres with different in
vitro stability demonstrate similar Paclitaxel pharmacokinetics. Mol.Pharm. 9, 248–260.
[88] Kumar, G., Walle, U., Bhalla, K., and Walle, T. (1993) Binding of Taxol to Hu-
man Plasma, Albumin and Alpha-1-Acid Glycoprotein. Research Communications in
Chemical Pathology and Pharmacology 80, 337–344.
[89] Liu, J., Zeng, F., and Allen, C. (2005) Influence of serum protein on polycarbonate-
based copolymer micelles as a delivery system for a hydrophobic anti-cancer agent.
J.Control Release 103, 481–497.
[90] Uchino, H., Matsumura, Y., Negishi, T., Koizumi, F., Hayashi, T., Honda, T.,
Nishiyama, N., Kataoka, K., Naito, S., and Kakizoe, T. (2005) Cisplatin-incorporating
polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin
in rats. Br.J.Cancer 93, 678–687.
[91] Rybak-Smith, M., and Sim, R. (2011) Complement activation by carbon nanotubes.
Advanced Drug Delivery Reviews 63, 1031–1041.
[92] Meerasa, A., Huang, J., and Gu, F. (2011) CH(50): A Revisited Hemolytic Comple-
ment Consumption Assay for Evaluation of Nanoparticles and Blood Plasma Protein
Interaction. Current Drug Delivery 8, 290–298.
[93] Karmali, P., and Simberg, D. (2011) Interactions of nanoparticles with plasma proteins:
implication on clearance and toxicity of drug delivery systems. Expert Opinion on Drug
Delivery 8, 343–357.
[94] Zolnik, B., Gonzalez-Fernandez, A., Sadrieh, N., and Dobrovolskaia, M. (2010) Minire-
view: Nanoparticles and the Immune System. Endocrinology 151, 458–465.
[95] Vasir, J., and Labhasetwar, V. (2006) Polymeric nanoparticles for gene delivery. Ex-
pert.Opin.Drug Deliv. 3, 325–344.
146
Bibliography
[96] Szebeni, J. (2005) Complement activation-related pseudoallergy: a new class of drug-
induced acute immune toxicity. Toxicology 216, 106–121.
[97] Szebeni, J. (2001) Complement activation-related pseudoallergy caused by liposomes,
micellar carriers of intravenous drugs, and radiocontrast agents. Crit Rev.Ther.Drug
Carrier Syst. 18, 567–606.
[98] Szebeni, J., Muggia, F., Gabizon, A., and Barenholz, Y. (2011) Activation of comple-
ment by therapeutic liposomes and other lipid excipient-based therapeutic products:
Prediction and prevention. Adv.Drug Deliv.Rev. 63, 1020–1030.
[99] Szebeni, J., Baranyi, L., Savay, S., Milosevits, J., Bodo, M., Bunger, R., and Alving, C.
(2003) The interaction of liposomes with the complement system: in vitro and in vivo
assays. Methods Enzymol. 373, 136–154.
[100] Szebeni, J., Baranyi, L., Savay, S., Milosevits, J., Bunger, R., Laverman, P., Metselaar, J.,
Storm, G., Chanan-Khan, A., Liebes, L., Muggia, F., Cohen, R., Barenholz, Y., and
Alving, C. (2002) Role of complement activation in hypersensitivity reactions to doxil
and HYNICPEG liposomes: Experimental and clinical studies. Journal of Liposome
Research 12, 165–172.
[101] Yang, A., Liu, W., Li, Z., Jiang, L., Xu, H., and Yang, X. (2010) Influence of
Polyethyleneglycol Modification on Phagocytic Uptake of Polymeric Nanoparticles
Mediated by Immunoglobulin G and Complement Activation. Journal of Nanoscience
and Nanotechnology 10, 622–628.
[102] Shan, X., Yuan, Y., Liu, C., Tao, X., Sheng, Y., and Xu, F. (2009) Influence of PEG
chain on the complement activation suppression and longevity in vivo prolongation of
the PCL biomedical nanoparticles. Biomed.Microdevices. 11, 1187–1194.
[103] Yang, A., Liu, W., Li, Z., Jiang, L., Xu, H., and Yang, X. (2010) Influence of
Polyethyleneglycol Modification on Phagocytic Uptake of Polymeric Nanoparticles
Mediated by Immunoglobulin G and Complement Activation. Journal of Nanoscience
and Nanotechnology 10, 622–628.
[104] Chen, A., Kozak, D., Battersby, B., and Trau, M. (2008) Particle-by-particle quantifi-
cation of protein adsorption onto poly(ethylene glycol) grafted surfaces. Biofouling 24,
267–273.
[105] Gaucher, G., Asahina, K., Wang, J., and Leroux, J. (2009) Effect of Poly(N-vinyl-
pyrrolidone)-block-poly(D,L-lactide) as Coating Agent on the Opsonization, Phagocy-
tosis, and Pharmacokinetics of Biodegradable Nanoparticles. Biomacromolecules 10,
408–416.
147
Bibliography
[106] Moghimi, S., and Szebeni, J. (2003) Stealth liposomes and long circulating nanoparticles:
critical issues in pharmacokinetics, opsonization and protein-binding properties. Progress
in Lipid Research 42, 463–478.
[107] Richter, A., and Akerblom, E. (1983) Antibodies against polyethylene glycol produced
in animals by immunization with monomethoxy polyethylene glycol modified proteins.
Int.Arch.Allergy Appl.Immunol. 70, 124–131.
[108] Richter, A., and Akerblom, E. (1984) Polyethylene glycol reactive antibodies in man:
titer distribution in allergic patients treated with monomethoxy polyethylene glycol mod-
ified allergens or placebo, and in healthy blood donors. Int.Arch.Allergy Appl.Immunol.
74, 36–39.
[109] Ganson, N., Kelly, S., Scarlett, E., Sundy, J., and Hershfield, M. (2006) Control of
hyperuricemia in subjects with refractory gout, and induction of antibody against
poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate
oxidase. Arthritis Res.Ther. 8, R12.
[110] Armstrong, J., Hempel, G., Koling, S., Chan, L., Fisher, T., Meiselman, H., and
Garratty, G. (2007) Antibody against poly(ethylene glycol) adversely affects PEG-
asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 110, 103–111.
[111] Ishida, T., Ichihara, M., Wang, X., and Kiwada, H. (2006) Spleen plays an important
role in the induction of accelerated blood clearance of PEGylated liposomes. Journal of
Controlled Release 115, 243–250.
[112] Ishida, T., Ichihara, M., Wang, X., Yamamoto, K., Kimura, J., Majima, E., and
Kiwada, H. (2006) Injection of PEGylated liposomes in rats elicits PEG-specific IgM,
which is responsible for rapid elimination of a second dose of PEGylated liposomes.
Journal of Controlled Release 112, 15–25.
[113] Koide, H., Asai, T., Hatanaka, K., Akai, S., Ishii, T., Kenjo, E., Ishida, T., Kiwada, H.,
Tsukada, H., and Oku, N. (2010) T cell-independent B cell response is responsible for
ABC phenomenon induced by repeated injection of PEGylated liposomes. Int.J Pharm.
392, 218–223.
[114] Romberg, B., Oussoren, C., Snel, C., Carstens, M., Hennink, W., and Storm, G. (2007)
Pharmacokinetics of poly(hydroxyethyl-L-asparagine)-coated liposomes is superior over
that of PEG-coated liposomes at low lipid dose and upon repeated administration.
Biochimica et Biophysica Acta-Biomembranes 1768, 737–743.
[115] Ishihara, T. et al. (2009) Accelerated Blood Clearance Phenomenon Upon Repeated
Injection of PEG-modified PLA-nanoparticles. Pharmaceutical Research 26, 2270–2279.
148
Bibliography
[116] Tagami, T., Uehara, Y., Moriyoshi, N., Ishida, T., and Kiwada, H. (2011) Anti-PEG
IgM production by siRNA encapsulated in a PEGylated lipid nanocarrier is dependent
on the sequence of the siRNA. J Control Release 151, 149–154.
[117] Koide, H., Asai, T., Hatanaka, K., Urakami, T., Ishii, T., Kenjo, E., Nishihara, M.,
Yokoyama, M., Ishida, T., Kiwada, H., and Oku, N. (2008) Particle size-dependent
triggering of accelerated blood clearance phenomenon. Int.J Pharm. 362, 197–200.
[118] Liu, Y., Reidler, H., Pan, J., Milunic, D., Qin, D., Chen, D., Vallejo, Y., and Yin, R.
(2011) A double antigen bridging immunogenicity ELISA for the detection of antibodies
to polyethylene glycol polymers. J Pharmacol.Toxicol.Methods 64, 238–245.
[119] Talekar, M., Kendall, J., Denny, W., and Garg, S. (2011) Targeting of nanoparticles in
cancer: drug delivery and diagnostics. Anti-Cancer Drugs 22, 949–962.
[120] Barreto, J., O’Malley, W., Kubeil, M., Graham, B., Stephan, H., and Spiccia, L. (2011)
Nanomaterials: Applications in Cancer Imaging and Therapy. Adv.Mater. 23, H18–H40.
[121] Maeda, H., Bharate, G., and Daruwalla, J. (2009) Polymeric drugs for efficient tumor-
targeted drug delivery based on EPR-effect. European Journal of Pharmaceutics and
Biopharmaceutics 71, 409–419.
[122] Maeda, H. (2010) Tumor-selective delivery of macromolecular drugs via the EPR effect:
background and future prospects. Bioconjug.Chem. 21, 797–802.
[123] Maeda, H., Greish, K., and Fang, J. (2006) The EPR effect and polymeric drugs: A
paradigm shift for cancer chemotherapy in the 21st century. Polymer Therapeutics Ii:
Polymers As Drugs, Conjugates and Gene Delivery Systems 193, 103–121.
[124] Maeda, H., Fang, J., Inutsuka, T., and Kitamoto, Y. (2003) Vascular permeability
enhancement in solid tumor: various factors, mechanisms involved and its implications.
Int.Immunopharmacol. 3, 319–328.
[125] Maeda, H., Bharate, G., and Daruwalla, J. (2009) Polymeric drugs for efficient tumor-
targeted drug delivery based on EPR-effect. Eur.J Pharm.Biopharm. 71, 409–419.
[126] Iyer, A., Khaled, G., Fang, J., and Maeda, H. (2006) Exploiting the enhanced perme-
ability and retention effect for tumor targeting. Drug Discov.Today 11, 812–818.
[127] Dellian, M., Yuan, F., Trubetskoy, V., Torchilin, V., and Jain, R. (2000) Vascular
permeability in a human tumour xenograft: molecular charge dependence. Br.J.Cancer
82, 1513–1518.
[128] Kobayashi, A., Oda, T., and Maeda, H. (1988) Protein Binding of Macromolecular
Anticancer Agent SMANCS: Characterization of Poly(styrene-co-maleic acid) Deriva-
tives as an Albumin Binding Ligand. Journal of Bioactive and Compatible Polymers 3,
319–333.
149
Bibliography
[129] Maeda, H. (2001) SMANCS and polymer-conjugated macromolecular drugs: advantages
in cancer chemotherapy. Advanced Drug Delivery Reviews 46, 169–185.
[130] Pimm, M., and Hudecz, F. (1996) Biodistribution in tumour-bearing mice of polycationic,
amphoteric and polyanionic branched polypeptides with a poly(L-lysine) backbone
labelled with I-125 and In-111: Tumour accumulation less than that of labelled serum
proteins. Journal of Cancer Research and Clinical Oncology 122, 45–54.
[131] Torchilin, V. (2007) Micellar nanocarriers: pharmaceutical perspectives. Pharm.Res.
24, 1–16.
[132] Dreher, M., Liu, W., Michelich, C., Dewhirst, M., Yuan, F., and Chilkoti, A. (2006)
Tumor vascular permeability, accumulation, and penetration of macromolecular drug
carriers. Journal of the National Cancer Institute 98, 335–344.
[133] Kwon, G., Suwa, S., Yokoyama, M., Okano, T., Sakurai, Y., and Kataoka, K. (1994)
Enhanced Tumor Accumulation and Prolonged Circulation Times of Micelle-Forming
Poly(Ethylene Oxide-Aspartate) Block Copolymer-Adriamycin Conjugates. Journal of
Controlled Release 29, 17–23.
[134] Iyer, A., Greish, K., Seki, T., Okazaki, S., Fang, J., Takeshita, K., and Maeda, H. (2007)
Polymeric micelles of zinc protoporphyrin for tumor targeted delivery based on EPR
effect and singlet oxygen generation. J Drug Target 15, 496–506.
[135] Ahmed, F., Pakunlu, R., Srinivas, G., Brannan, A., Bates, F., Klein, M., Minko, T., and
Discher, D. (2006) Shrinkage of a rapidly growing tumor by drug-loaded polymersomes:
pH-triggered release through copolymer degradation. Mol.Pharm. 3, 340–350.
[136] Savla, R., Taratula, O., Garbuzenko, O., and Minko, T. (2011) Tumor targeted quantum
dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer. Journal
of Controlled Release 153, 16–22.
[137] Ishida, O., Maruyama, K., Sasaki, K., and Iwatsuru, M. (1999) Size-dependent extrava-
sation and interstitial localization of polyethyleneglycol liposomes in solid tumor-bearing
mice. Int.J.Pharm. 190, 49–56.
[138] Hobbs, S., Monsky, W., Yuan, F., Roberts, W., Griffith, L., Torchilin, V., and Jain, R.
(1998) Regulation of transport pathways in tumor vessels: role of tumor type and
microenvironment. Proc.Natl.Acad.Sci.U.S.A 95, 4607–4612.
[139] Zhao, M., Yang, M., Ma, H., Li, X., Tan, X., Li, S., Yang, Z., and Hoffman, R. (2006)
Targeted therapy with a Salmonella typhimurium leucine-arginine auxotroph cures
orthotopic human breast tumors in nude mice. Cancer Res. 66, 7647–7652.
[140] Yuan, F., Dellian, M., Fukumura, D., Leunig, M., Berk, D., Torchilin, V., and Jain, R.
150
Bibliography
(1995) Vascular permeability in a human tumor xenograft: molecular size dependence
and cutoff size. Cancer Res. 55, 3752–3756.
[141] Xiao, K., Luo, J., Li, Y., Xiao, W., Lee, J., Gonik, A., and Lam, K. (2010) The
Passive Targeting of Polymeric Micelles in Various Types and Sizes of Tumor Models.
Nanoscience and Nanotechnology Letters 2, 79–85.
[142] Feng, D., Nagy, J., Dvorak, A., and Dvorak, H. (2000) Different pathways of macro-
molecule extravasation from hyperpermeable tumor vessels. Microvasc.Res. 59, 24–37.
[143] Stehle, G., Sinn, H., Wunder, A., Schrenk, H., Stewart, J., Hartung, G., Maier-Borst, W.,
and Heene, D. (1997) Plasma protein (albumin) catabolism by the tumor itself–
implications for tumor metabolism and the genesis of cachexia. Crit Rev.Oncol.Hematol.
26, 77–100.
[144] Wunder, A., Stehle, G., Sinn, H., Schrenk, H., Hoffbiederbeck, D., Bader, F.,
Friedrich, E., Peschke, P., Maierborst, W., and Heene, D. (1997) Enhanced albumin
uptake by rat tumors. Int.J.Oncol. 11, 497–507.
[145] Wilkinson.P„ Jeremy, R., Brooks, F., and Hollander.JL, (1965) Mechanism of Hypoal-
buminemia in Rheumatoid Arthritis. Annals of Internal Medicine 63, 109–114.
[146] Wang, D., and Goldring, S. (2011) The bone, the joints and the Balm of Gilead.
Mol.Pharm. 8, 991–993.
[147] Zhou, Q., Wood, R., Schwarz, E., Wang, Y., and Xing, L. (2010) Near-infrared lymphatic
imaging demonstrates the dynamics of lymph flow and lymphangiogenesis during the
acute versus chronic phases of arthritis in mice. Arthritis Rheum. 62, 1881–1889.
[148] Maruotti, N., Cantatore, F., Crivellato, E., Vacca, A., and Ribatti, D. (2006) Angio-
genesis in rheumatoid arthritis. Histol.Histopathol. 21, 557–566.
[149] Quan, L., Purdue, P., Liu, X., Boska, M., Lele, S., Thiele, G., Mikuls, T., Dou, H.,
Goldring, S., and Wang, D. (2010) Development of a macromolecular prodrug for
the treatment of inflammatory arthritis: mechanisms involved in arthrotropism and
sustained therapeutic efficacy. Arthritis Res.Ther. 12, R170–.
[150] Desai, N., Trieu, V., Yao, Z., Louie, L., Ci, S., Yang, A., Tao, C., De, T., Beals, B.,
Dykes, D., Noker, P., Yao, R., Labao, E., Hawkins, M., and Soon-Shiong, P. (2006)
Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial
cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with
cremophor-based paclitaxel. Clin.Cancer Res. 12, 1317–1324.
[151] Desai, N., Trieu, V., Damascelli, B., and Soon-Shiong, P. (2009) SPARC Expression
Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck
Cancer Patients. Transl.Oncol. 2, 59–64.
151
Bibliography
[152] Jendraschak, E., and Sage, E. (1996) Regulation of angiogenesis by SPARC and
angiostatin: implications for tumor cell biology. Semin.Cancer Biol. 7, 139–146.
[153] Sage, H., Johnson, C., and Bornstein, P. (1984) Characterization of a novel serum
albumin-binding glycoprotein secreted by endothelial cells in culture. J.Biol.Chem. 259,
3993–4007.
[154] Greish, K., Nagamitsu, A., Fang, J., and Maeda, H. (2005) Copoly(styrene-maleic acid)-
pirarubicin micelles: high tumor-targeting efficiency with little toxicity. Bioconjug.Chem.
16, 230–236.
[155] Monopoli, M., Walczyk, D., Campbell, A., Elia, G., Lynch, I., Bombelli, F., and
Dawson, K. (2011) Physical-chemical aspects of protein corona: relevance to in vitro
and in vivo biological impacts of nanoparticles. J Am.Chem.Soc. 133, 2525–2534.
[156] Walczyk, D., Bombelli, F., Monopoli, M., Lynch, I., and Dawson, K. (2010) What the
cell "sees" in bionanoscience. J Am.Chem.Soc. 132, 5761–5768.
[157] Ehrenberg, M., Friedman, A., Finkelstein, J., Oberdorster, G., and McGrath, J. (2009)
The influence of protein adsorption on nanoparticle association with cultured endothelial
cells. Biomaterials 30, 603–610.
[158] Ogawara, K., Furumoto, K., Nagayama, S., Minato, K., Higaki, K., Kai, T., and
Kimura, T. (2004) Pre-coating with serum albumin reduces receptor-mediated hepatic
disposition of polystyrene nanosphere: implications for rational design of nanoparticles.
Journal of Controlled Release 100, 451–455.
[159] Furumoto, K., Yokoe, J., Ogawara, K., Amano, S., Takaguchi, M., Higaki, K., Kai, T.,
and Kimura, T. (2007) Effect of coupling of albumin onto surface of PEG liposome on
its in vivo disposition. Int.J Pharm. 329, 110–116.
[160] Crielaard, B., Yousefi, A., Schillemans, J., Vermehren, C., Buyens, K., Braeckmans, K.,
Lammers, T., and Storm, G. (2011) An in vitro assay based on surface plasmon
resonance to predict the in vivo circulation kinetics of liposomes. J.Control Release 156,
307–314.
[161] Kratz, F. (2008) Albumin as a drug carrier: Design of prodrugs, drug conjugates and
nanoparticles. Journal of Controlled Release 132, 171–183.
[162] Pierri, E., and Avgoustakis, K. (2005) Poly(lactide)-poly(ethylene glycol) micelles as a
carrier for griseofulvin. J.Biomed.Mater.Res.A 75, 639–647.
[163] Carstens, M., De Jong, P., van Nostrum, C., Kemmink, J., Verrijk, R., De Leede, L.,
Crornmelin, D., and Hennink, W. (2008) The effect of core composition in biodegradable
oligomeric micelles as taxane formulations. European Journal of Pharmaceutics and
Biopharmaceutics 68, 596–606.
152
Bibliography
[164] Velluto, D., Demurtas, D., and Hubbell, J. (2008) PEG-b-PPS diblock copolymer
aggregates for hydrophobic drug solubilization and release: cyclosporin A as an example.
Mol.Pharm. 5, 632–642.
[165] Chen, H., Kim, S., Li, L., Wang, S., Park, K., and Cheng, J. (2008) Release of
hydrophobic molecules from polymer micelles into cell membranes revealed by Forster
resonance energy transfer imaging. Proc.Natl.Acad.Sci.U.S.A 105, 6596–6601.
[166] Moghimi, S., Hunter, A., Dadswell, C., Savay, S., Alving, C., and Szebeni, J. (2004)
Causative factors behind poloxamer 188 (Pluronic F68, Flocor)-induced complement
activation in human sera. A protective role against poloxamer-mediated complement
activation by elevated serum lipoprotein levels. Biochim.Biophys.Acta 1689, 103–113.
[167] Hamad, I., Al-Hanbali, O., Hunter, A., Rutt, K., Andresen, T., and Moghimi, S. (2010)
Distinct Polymer Architecture Mediates Switching of Complement Activation Pathways
at the Nanosphere-Serum Interface: Implications for Stealth Nanoparticle Engineering.
Acs Nano 4, 6629–6638.
[168] Hamad, I., Hunter, A., Szebeni, J., and Moghimi, S. (2008) Poly(ethylene glycol)s
generate complement activation products in human serum through increased alternative
pathway turnover and a MASP-2-dependent process. Mol.Immunol. 46, 225–232.
[169] Lipinski, C., Lombardo, F., Dominy, B., and Feeney, P. (1997) Experimental and
computational approaches to estimate solubility and permeability in drug discovery
and development settings. Advanced Drug Delivery Reviews 23, 3–25.
[170] Lipinski, C. (2000) Drug-like properties and the causes of poor solubility and poor
permeability. Journal of Pharmacological and Toxicological Methods 44, 235–249.
[171] Di, L., Kerns, E., and Carter, G. (2009) Drug-Like Property Concepts in Pharmaceutical
Design. Current Pharmaceutical Design 15, 2184–2194.
[172] Marupudi, N., Han, J., Li, K., Renard, V., Tyler, B., and Brem, H. (2007) Paclitaxel:
a review of adverse toxicities and novel delivery strategies. Expert Opinion on Drug
Safety 6, 609–621.
[173] Tyrrell, Z., Shen, Y., and Radosz, M. (2010) Fabrication of micellar nanoparticles
for drug delivery through the self-assembly of block copolymers. Progress in Polymer
Science 35, 1128–1143.
[174] Kim, S., Shi, Y., Kim, J., Park, K., and Cheng, J. (2010) Overcoming the barriers in
micellar drug delivery: loading efficiency, in vivo stability, and micelle-cell interaction.
Expert.Opin.Drug Deliv. 7, 49–62.
[175] Sant, V., Smith, D., and Leroux, J. (2005) Enhancement of oral bioavailability of poorly
153
Bibliography
water-soluble drugs by poly(ethylene glycol)-block-poly(alkyl acrylate-co-methacrylic
acid) self-assemblies. J.Control Release 104, 289–300.
[176] Avgoustakis, K., Beletsi, A., Panagi, Z., Klepetsanis, P., Karydas, A., and Ithakissios, D.
(2002) PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in
vitro drug release and in vivo drug residence in blood properties. J.Control Release 79,
123–135.
[177] Song, C., Labhasetwar, V., Murphy, H., Qu, X., Humphrey, W., Shebuski, R., and
Levy, R. (1997) Formulation and characterization of biodegradable nanoparticles for
intravascular local drug delivery. Journal of Controlled Release 43, 197–212.
[178] Jeon, H., Jeong, J., Jang, M., Park, Y., and Nah, J. (2000) Effect of solvent on the prepa-
ration of surfactant-free poly(DL-lactide-co-glycolide) nanoparticles and norfloxacin
release characteristics. International Journal of Pharmaceutics 207, 99–108.
[179] Aliabadi, H., Elhasi, S., Mahmud, A., Gulamhusein, R., Mahdipoor, P., and Lavasan-
ifar, A. (2007) Encapsulation of hydrophobic drugs in polymeric micelles through
co-solvent evaporation: the effect of solvent composition on micellar properties and
drug loading. Int.J.Pharm. 329, 158–165.
[180] Fournier, E., Dufresne, M., Smith, D., Ranger, M., and Leroux, J. (2004) A novel
one-step drug-loading procedure for water-soluble amphiphilic nanocarriers. Pharm.Res.
21, 962–968.
[181] Jansook, P., and Loftsson, T. (2008) gamma CD/HP gamma CD: Synergistic solubi-
lization. International Journal of Pharmaceutics 363, 217–219.
[182] Moretton, M., Chiappetta, D., and Sosnik, A. (2012) Cryoprotection-lyophilization
and physical stabilization of rifampicin-loaded flower-like polymeric micelles. J.R
Soc.Interface 9, 487–502.
[183] Richter, A., Olbrich, C., Krause, M., Hoffmann, J., and Kissel, T. (2010) Polymeric
micelles for parenteral delivery of Sagopilone: physicochemical characterization, novel
formulation approaches and their toxicity assessment in vitro as well as in vivo.
Eur.J.Pharm.Biopharm. 75, 80–89.
[184] Abdelwahed, W., Degobert, G., Stainmesse, S., and Fessi, H. (2006) Freeze-drying of
nanoparticles: formulation, process and storage considerations. Adv.Drug Deliv.Rev. 58,
1688–1713.
[185] Sander, B., Golas, M., and Stark, H. (2003) Corrim-based alignment for improved speed
in single-particle image processing. Journal of Structural Biology 143, 219–228.
[186] EMA, European Medicines Agency: ICH Topic Q3C (R4) Impurities: Guideline for
Residual Solvents CPMP/ICH/283/95. 2009.
154
Bibliography
[187] Wang, W. (2000) Lyophilization and development of solid protein pharmaceuticals.
Int.J.Pharm. 203, 1–60.
[188] Li, X., Yang, H., Xu, L., Fu, X., Guo, H., and Zhang, X. (2010) Janus Micelle Formation
Induced by Protonation/Deprotonation of Poly(2-vinylpyridine)-block-Poly(ethylene
oxide) Diblock Copolymers. Macromolecular Chemistry and Physics 211, 297–302.
[189] Leson, A., Hauschild, S., Rank, A., Neub, A., Schubert, R., Forster, S., and Mayer, C.
(2007) Molecular exchange through membranes of poly(2-vinylpyridine-block-ethylene
oxide) vesicles. Small 3, 1074–1083.
[190] Selb, J., and Gallot, Y. (1975) Micelle Formation in Polystyrene-Poly(Vinyl-N-
Alkylpyridinium Bromide) Block Copolymer Solutions in Methanol-Water Mixtures.
Journal of Polymer Science Part C-Polymer Letters 13, 615–619.
[191] Cinelli, S., Freda, M., Onori, G., Paciaroni, A., and Santucci, A. (2005) Hydration-
dependent internal dynamics of macromolecules: a neutron scattering study. Journal of
Molecular Liquids 117, 99–105.
[192] Zhao, J., Allen, C., and Eisenberg, A. (1997) Partitioning of pyrene between ”crew
cut” block copolymer micelles and H2O/DMF solvent mixtures. Macromolecules 30,
7143–7150.
[193] Vangeyte, P., Gautier, S., and Jerome, R. (2004) About the methods of preparation of
poly(ethylene oxide)-b-poly(epsilon-caprolactone) nanoparticles in water analysis by
dynamic light scattering. Colloids and Surfaces A-Physicochemical and Engineering
Aspects 242, 203–211.
[194] Lee, M., Kim, M., Kim, S., and Lee, J. (2009) Cryoprotectants for freeze drying of drug
nano-suspensions: effect of freezing rate. J.Pharm.Sci. 98, 4808–4817.
[195] Miyajima, K. (1997) Role of saccharides for the freeze-thawing and freeze drying of
liposome. Advanced Drug Delivery Reviews 24, 151–159.
[196] Tanaka, K., Takeda, T., Fujii, K., and Miyajima, K. (1992) Cryoprotective Mechanism
of Saccharides on Freeze-Drying of Liposome. Chemical & Pharmaceutical Bulletin 40,
1–5.
[197] Abdelwahed, W., Degobert, G., and Fessi, H. (2006) Investigation of nanocap-
sules stabilization by amorphous excipients during freeze-drying and storage.
Eur.J.Pharm.Biopharm. 63, 87–94.
[198] Allison, S., Molina, M., and Anchordoquy, T. (2000) Stabilization of lipid/DNA com-
plexes during the freezing step of the lyophilization process: the particle isolation
hypothesis. Biochim.Biophys.Acta 1468, 127–138.
155
Bibliography
[199] Guo, M., and Jiang, M. (2007) Macromolecular self-assembly based on inclusion
complexation of cyclodextrins. Progress in Chemistry 19, 557–566.
[200] Dreiss, C., Nwabunwanne, E., Liu, R., and Brooks, N. (2009) Assembling and de-
assembling micelles: competitive interactions of cyclodextrins and drugs with Pluronics.
Soft Matter 5, 1888–1896.
[201] Qin, J., Meng, X., Li, B., Ha, W., Yu, X., and Zhang, S. (2010) Self-assembly of
beta-cyclodextrin and pluronic into hollow nanospheres in aqueous solution. Journal of
Colloid and Interface Science 350, 447–452.
[202] Becheri, A., Lo Nostro, P., Ninham, B. W., and Baglioni, P. (2003) The Curious World
of Polypseudorotaxanes:a Cyclodextrins As Probes of Water Structure. J.Phys.Chem.B
107, 3979–3987.
[203] He, L., Huang, J., Chen, Y., Xu, X., and Liu, L. (2005) Inclusion Interaction of
Highly Densely PEO Grafted Polymer Brush and a-Cyclodextrin. Macromolecules 38,
3845–3851.
[204] Plumridge, T., and Waigh, R. (2002) Water structure theory and some implications for
drug design. Journal of Pharmacy and Pharmacology 54, 1155–1179.
[205] Lerbret, A., Bordat, P., Affouard, F., Descamps, M., and Migliardo, F. (2005) How
Homogeneous Are the Trehalose, Maltose, and Sucrose Water Solutions? An Insight
from Molecular Dynamics Simulations. J.Phys.Chem.B 109, 11046–11057.
[206] Sano, H., Ichi, T., Kumashiro, Y., Kontani, K., Kuze, T., Mizutani, G., Ooya, T., and
Yui, N. (2003) Raman scattering study of water clusters around polyrotaxane and
pseudopolyrotaxane supramolecular assemblies. Spectrochimica Acta Part A: Molecular
and Biomolecular Spectroscopy 59, 285–289.
[207] Liu, K. L., Goh, S. H., and Li, J. (2008) Threading a-Cyclodextrin through Poly[(R,S)-
3-hydroxybutyrate] in Poly[(R,S)-3-hydroxybutyrate]-Poly(ethylene glycol)-Poly[(R,S)-
3-hydroxybutyrate] Triblock Copolymers: Formation of Block-Selected Polypseudoro-
taxanes. Macromolecules 41, 6027–6034.
[208] Adams, M., Lavasanifar, A., and Kwon, G. (2003) Amphiphilic block copolymers for
drug delivery. J.Pharm.Sci. 92, 1343–1355.
[209] Kataoka, K., Harada, A., and Nagasaki, Y. (2001) Block copolymer micelles for drug
delivery: design, characterization and biological significance. Adv.Drug Deliv.Rev. 47,
113–131.
[210] Aliabadi, H., Shahin, M., Brocks, D., and Lavasanifar, A. (2008) Disposition of
drugs in block copolymer micelle delivery systems: from discovery to recovery.
Clin.Pharmacokinet. 47, 619–634.
156
Bibliography
[211] Wiradharma, N., Zhang, Y., Venkataraman, S., Hedrick, J., and Yang, Y. (2009) Self-
assembled polymer nanostructures for delivery of anticancer therapeutics. Nano Today
4, 302–317.
[212] Hamaguchi, T. (2009) [Cancer chemotherapy utilizing nanotechnology]. Gan To Kagaku
Ryoho 36, 372–376.
[213] Chung, T.-W., Liu, D.-Z., Hsieh, J.-H., Fan, X.-C., Yang, J.-D., and Chen, J.-H.
(2006) Characterizing Poly(-caprolactone)-b-Chitooligosaccharide-b-Poly(ethylene gly-
col) (PCP) Copolymer Micelles for Doxorubicin (DOX) Delivery: Effects of Crosslinked
of Amine Groups. Journal of Nanoscience and Nanotechnology 6, 2902–2911.
[214] Gaucher, G., Marchessault, R., and Leroux, J. (2010) Polyester-based micelles and
nanoparticles for the parenteral delivery of taxanes. J.Control Release 143, 2–12.
[215] Kamat, P., and Fox, M. (1984) Photophysics and Photochemistry of Xanthene Dyes in
Polymer-Solutions and Films. Journal of Physical Chemistry 88, 2297–2302.
[216] Gref, R., Luck, M., Quellec, P., Marchand, M., Dellacherie, E., Harnisch, S., Blunk, T.,
and Muller, R. (2000) ’Stealth’ corona-core nanoparticles surface modified by polyethy-
lene glycol (PEG): influences of the corona (PEG chain length and surface density) and
of the core composition on phagocytic uptake and plasma protein adsorption. Colloids
Surf.B Biointerfaces 18, 301–313.
[217] Savic, R., Luo, L., Eisenberg, A., and Maysinger, D. (2003) Micellar nanocontainers
distribute to defined cytoplasmic organelles. Science 300, 615–618.
[218] Kalyanasundaram, K., and Thomas, J. (1977) Environmental Effects on Vibronic
Band Intensities in Pyrene Monomer Fluorescence and Their Application in Studies of
Micellar Systems. Journal of the American Chemical Society 99, 2039–2044.
[219] Berney, C., and Danuser, G. (2003) FRET or no FRET: a quantitative comparison.
Biophys.J. 84, 3992–4010.
[220] Fraunhofer, W., and Winter, G. (2004) The use of asymmetrical flow field-flow fraction-
ation in pharmaceutics and biopharmaceutics. Eur.J.Pharm.Biopharm. 58, 369–383.
[221] Zimm, B. (1948) The Scattering of Light and the Radial Distribution Function of High
Polymer Solutions. Journal of Chemical Physics 16, 1093–1099.
[222] Zheng, Z., and Obbard, J. (2002) Evaluation of an elevated non-ionic surfactant critical
micelle concentration in a soil/aqueous system. Water Res. 36, 2667–2672.
[223] Allen, C., Maysinger, D., and Eisenberg, A. (1999) Nano-engineering block copolymer
aggregates for drug delivery. Colloids and Surfaces B-Biointerfaces 16, 3–27.
157
Bibliography
[224] Sagalowicz, L., Leser, M., Watzke, H., and Michel, M. (2006) Monoglyceride self-
assembly structures as delivery vehicles. Trends in Food Science & Technology 17,
204–214.
[225] Wang, L., Zeng, R., Li, C., and Qiao, R. (2009) Self-assembled polypeptide-block-
poly(vinylpyrrolidone) as prospective drug-delivery systems. Colloids Surf.B Biointer-
faces. 74, 284–292.
[226] EMA, European Medicines Agency: Reflection paper on the pharmaceutical devel-
opment of intravenous medicinal products containing active substances solubilised in
micellar systems (non-polymeric surfactants). EMA/CHMP/QWP/574767/2010, 2010.
[227] Ahyayauch, H., Bennouna, M., Alonso, A., and Goni, F. (2010) Detergent Effects on
Membranes at Subsolubilizing Concentrations: Transmembrane Lipid Motion, Bilayer
Permeabilization, and Vesicle Lysis/Reassembly Are Independent Phenomena. Langmuir
26, 7307–7313.
[228] Lasseter, K., Gambale, J., Jin, B., Bergman, A., Constanzer, M., Dru, J., Han, T.,
Majumdar, A., Evans, J., and Murphy, M. (2007) Tolerability of fosaprepitant and
bioequivalency to aprepitant in healthy subjects. J.Clin.Pharmacol. 47, 834–840.
[229] Riley, T., Govender, T., Stolnik, S., Xiong, C., Garnett, M., Illum, L., and Davis, S.
(1999) Colloidal stability and drug incorporation aspects of micellar-like PLA-PEG
nanoparticles. Colloids and Surfaces B-Biointerfaces 16, 147–159.
[230] Jacquin, M., Muller, P., Cottet, H., and Theodoly, O. (2010) Self-Assembly of Charged
Amphiphilic Diblock Copolymers with Insoluble Blocks of Decreasing Hydrophobicity:
From Kinetically Frozen Colloids to Macrosurfactants. Langmuir 26, 18681–18693.
[231] Toncheva, V., Schacht, E., Ng, S., Barr, J., and Heller, J. (2003) Use of Block Copolymers
of Poly(Ortho Esters) and Poly (Ethylene Glycol) Micellar Carriers as Potential Tumour
Targeting Systems. Journal of Drug Targeting 11, 345–353.
[232] Lin, Z., and Will, Y. (2012) Evaluation of drugs with specific organ toxicities in
organ-specific cell lines. Toxicol.Sci. 126, 114–127.
[233] Lu, S., Jessen, B., Strock, C., and Will, Y. (2012) The contribution of physicochemical
properties to multiple in vitro cytotoxicity endpoints. Toxicol.In Vitro 26, 613–620.
[234] Scheers, E., Ekwall, B., and Dierickx, P. (2001) In vitro long-term cytotoxicity testing
of 27 MEIC chemicals on Hep G2 cells and comparison with acute human toxicity data.
Toxicology in Vitro 15, 153–161.
[235] WANG, K., SHINDOH, H., INOUE, T., and HORII, I. (2002) Advantages of in vitro
Cytotoxicity Testing by using Primary Rat Hepatocytes in Comparison with established
Cell Lines. The Journal of Toxicological Sciences 27, 229–237.
158
Bibliography
[236] Szebeni, J., Muggia, F., Gabizon, A., and Barenholz, Y. (2011) Activation of comple-
ment by therapeutic liposomes and other lipid excipient-based therapeutic products:
Prediction and prevention. Adv.Drug Deliv.Rev. 63, 1020–1030.
[237] Hong, J., Park, J., Huh, K., Chung, H., Kwon, I., and Jeong, S. (2004) PEGylated
polyethylenimine for in vivo local gene delivery based on lipiodolized emulsion system.
J.Control Release 99, 167–176.
[238] Scripture, C., Szebeni, J., Loos, W., Figg, W., and Sparreboom, A. (2005) Com-
parative in vitro properties and clinical pharmacokinetics of Paclitaxel following the
administration of taxol(r) and paxene(r). Cancer Biol.Ther. 4, 555–560.
[239] Gao, X., Yao, L., Song, Q., Zhu, L., Xia, Z., Xia, H., Jiang, X., Chen, J., and Chen, H.
(2011) The association of autophagy with polyethylenimine-induced cytotoxicity in
nephritic and hepatic cell lines. Biomaterials 32, 8613–8625.
[240] Engels, F., Mathot, R., and Verweij, J. (2007) Alternative drug formulations of docetaxel:
a review. Anticancer Drugs 18, 95–103.
[241] Gelderblom, H., Verweij, J., Nooter, K., and Sparreboom, A. (2001) Cremophor EL:
the drawbacks and advantages of vehicle selection for drug formulation. Eur.J Cancer
37, 1590–1598.
[242] Zhou, D., Zhang, M., Ye, X., Gu, C., Piser, T. M., Lanoue, B. A., Schock, S. A.,
Cheng, Y.-F., and Grimm, S. W. (2011) In vitro metabolism of a7 neuronal nico-
tinic receptor agonist AZD0328 and enzyme identification for its N-oxide metabolite.
Xenobiotica 41, 232–242.
[243] Kim, S., Williams, D., Schuetz, E., Guzelian, P., and Novak, R. (1988) Pyridine
induction of cytochrome P-450 in the rat: role of P-450j (alcohol-inducible form) in
pyridine N-oxidation. J Pharmacol.Exp.Ther. 246, 1175–1182.
[244] Anuszewska, E., and Koziorowska, J. (1995) Role of pyridine N-oxide in the cytotoxicity
and genotoxicity of chloropyridines. Toxicol.In Vitro 9, 91–94.
[245] Breyer, S., Semmler, A., Miller, T., Hill, A., Geissler, S., Haberkorn, U., and Mier, W.
(2012) Radioiodinated dechloro-4-iodofenofibrate: a hydrophobic model drug for molec-
ular imaging studies. Int.J.Pharm. In press.
[246] Miller, T., Hill, A., Uezguen, S., Weigandt, M., and Goepferich, A. (2012) Analysis of
immediate stress mechanisms upon injection of polymeric micelles and related colloidal
drug carriers: implications on drug targeting. Biomacromolecules In press.
[247] Brigger, I., Morizet, J., Laudani, L., Aubert, G., Appel, M., Velasco, V., Terrier-
Lacombe, M., Desmaele, D., d’Angelo, J., Couvreur, P., and Vassal, G. (2004) Negative
159
Bibliography
preclinical results with stealth nanospheres-encapsulated Doxorubicin in an orthotopic
murine brain tumor model. J.Control Release 100, 29–40.
[248] Seymour, L., Duncan, R., Strohalm, J., and Kopecek, J. (1987) Effect of Molecular-
Weight (Mbarw) of N-(2-Hydroxypropyl)Methacrylamide Copolymers on Body Distri-
bution and Rate of Excretion After Subcutaneous, Intraperitoneal, and Intravenous
Administration to Rats. Journal of Biomedical Materials Research 21, 1341–1358.
[249] Wang, J. S., and Matyjaszewski, K. (1995) Controlled/"living" radical polymerization.
atom transfer radical polymerization in the presence of transition-metal complexes.
Journal of the American Chemical Society 117, 5614–5615.
[250] Wang, J. S., and Matyjaszewski, K. (1995) "Living"/Controlled Radical Polymerization.
Transition-Metal-Catalyzed Atom Transfer Radical Polymerization in the Presence of a
Conventional Radical Initiator. Macromolecules 28, 7572–7573.
[251] Wang, J. S., and Matyjaszewski, K. (1995) Controlled/"Living" Radical Polymerization.
Halogen Atom Transfer Radical Polymerization Promoted by a Cu(I)/Cu(II) Redox
Process. Macromolecules 28, 7901–7910.
[252] Fukui, H., Sawamoto, M., and Higashimura, T. (1995) Multifunctional Coupling Agents
for Living Cationic Polymerization .5. Synthesis of Amphiphilic Tetraarmed Star
Poly(Vinyl Ethers) by Coupling Reactions with Tetrafunctional Silyl Enol Ether.
Macromolecules 28, 3756–3765.
[253] Katayama, H., Kamigaito, M., Sawamoto, M., and Higashimura, T. (1995) In-Situ C-13
and H-1-Nmr Analysis of the Growing Species in Living Cationic Polymerization of
Isobutyl Vinyl Ether by the Hcl/Sncl4 Initiating System in the Presence of A Nbu(4)Ncl
Salt. Macromolecules 28, 3747–3755.
[254] Kato, M., Kamigaito, M., Sawamoto, M., and Higashimura, T. (1995)
Polymerization of Methyl-Methacrylate with the Carbon-Tetrachloride
Dichlorotris(Triphenylphosphine)Ruthenium(Ii) Methylaluminum Bis(2,6-Di-Tert-
Butylphenoxide) Initiating System - Possibility of Living Radical Polymerization.
Macromolecules 28, 1721–1723.
[255] Ishizu, K., Satoh, J., and Sogabe, A. (2004) Architecture and solution properties of
AB-type brush-block-brush amphiphilic copolymers via ATRP techniques. J Colloid
Interface Sci. 274, 472–479.
[256] Tan, B., Hussain, H., Liu, Y., He, C., and Davis, T. (2010) Synthesis and self-
assembly of brush-type poly[poly(ethylene glycol)methyl ether methacrylate]-block-
poly(pentafluorostyrene) amphiphilic diblock copolymers in aqueous solution. Langmuir
26, 2361–2368.
160
Bibliography
[257] Hussain, H., Mya, K., and He, C. (2008) Self-assembly of brush-like poly[poly(ethylene
glycol) methyl ether methacrylate] synthesized via aqueous atom transfer radical
polymerization. Langmuir 24, 13279–13286.
[258] Brannon-Peppas, L., and Blanchette, J. (2004) Nanoparticle and targeted systems for
cancer therapy. Adv.Drug Deliv.Rev. 56, 1649–1659.
[259] Vasir, J., and Labhasetwar, V. (2005) Targeted drug delivery in cancer therapy. Tech-
nol.Cancer Res.Treat. 4, 363–374.
[260] De Jong, W., and Borm, P. (2008) Drug delivery and nanoparticles:applications and
hazards. Int.J.Nanomedicine 3, 133–149.
[261] Lee, S. W., Yun, M. H., Jeong, S. W., In, C. H., Kim, J. Y., Seo, M. H., Pai, C. M.,
and Kim, S. O. (2011) Development of docetaxel-loaded intravenous formulation,
Nanoxel-PM using polymer-based delivery system. Journal of Controlled Release 155,
262–271.
[262] Bogner, J., Kronawitter, U., Rolinski, B., Truebenbach, K., and Goebel, F. (1994)
Liposomal doxorubicin in the treatment of advanced AIDS-related Kaposi sarcoma. J
Acquir.Immune.Defic.Syndr. 7, 463–468.
[263] Goebel, F., Goldstein, D., Goos, M., Jablonowski, H., and Stewart, J. (1996) Efficacy
and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi’s sarcoma. The
International SL-DOX Study Group. Br.J Cancer 73, 989–994.
[264] James, N., Coker, R., Tomlinson, D., Harris, J., Gompels, M., Pinching, A., and
Stewart, J. (1994) Liposomal doxorubicin (Doxil): an effective new treatment for
Kaposi’s sarcoma in AIDS. Clin.Oncol.(R Coll.Radiol.) 6, 294–296.
[265] Utreja, P., Jain, S., Yadav, S., Khandhuja, K., and Tiwary, A. (2011) Efficacy and
toxicological studies of cremophor el free alternative Paclitaxel formulation. Curr.Drug
Saf 6, 329–338.
[266] Lim, W., Tan, E., Toh, C., Hee, S., Leong, S., Ang, P., Wong, N., and Chowbay, B.
(2010) Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation
(Genexol-PM) in patients with solid tumors. Ann.Oncol. 21, 382–388.
[267] Mier, W., Hoffend, J., Kramer, S., Schuhmacher, J., Hull, W., Eisenhut, M., and
Haberkorn, U. (2005) Conjugation of DOTA using isolated phenolic active esters: the
labeling and biodistribution of albumin as blood pool marker. Bioconjug.Chem. 16,
237–240.
[268] Lee, H., Hoang, B., Fonge, H., Reilly, R., and Allen, C. (2010) In vivo distribution of
polymeric nanoparticles at the whole-body, tumor, and cellular levels. Pharm.Res. 27,
2343–2355.
161
Bibliography
[269] Hoang, B., Lee, H., Reilly, R., and Allen, C. (2009) Noninvasive monitoring of the
fate of 111In-labeled block copolymer micelles by high resolution and high sensitivity
microSPECT/CT imaging. Mol.Pharm. 6, 581–592.
[270] Tessmar, J., Mikos, A., and Gopferich, A. (2002) Amine-reactive biodegradable diblock
copolymers. Biomacromolecules 3, 194–200.
[271] Sadekar, S., Ray, A., Janat-Amsbury, M., Peterson, C., and Ghandehari, H. (2011) Com-
parative Biodistribution of PAMAM Dendrimers and HPMA Copolymers in Ovarian-
Tumor-Bearing Mice. Biomacromolecules 12, 88–96.
[272] Helbok, A., Rangger, C., von, G. E., Saba-Lepek, M., Radolf, T., Thurner, G., An-
dreae, F., Prassl, R., and Decristoforo, C. (2012) Targeting properties of peptide-
modified radiolabeled liposomal nanoparticles. Nanomedicine 8, 112–118.
[273] Surujpaul, P., Gutierrez-Wing, C., Ocampo-Garcia, B., Ramirez, F. M., rteaga de, M. C.,
Pedraza-Lopez, M., Camacho-Lopez, M., and Ferro-Flores, G. (2008) Gold nanoparticles
conjugated to [Tyr3]octreotide peptide. Biophys.Chem. 138, 83–90.
[274] Weil, A., Caldwell, J., and Strolin-Benedetti, M. (1988) The metabolism and disposition
of fenofibrate in rat, guinea pig, and dog. Drug Metabolism and Disposition 16, 302–309.
[275] Liu, A., Patterson, A., Yang, Z., Zhang, X., Liu, W., Qiu, F., Sun, H., Krausz, K.,
Idle, J., Gonzalez, F., and Dai, R. (2009) Fenofibrate metabolism in the cynomolgus
monkey using ultraperformance liquid chromatography-quadrupole time-of-flight mass
spectrometry-based metabolomics. Drug Metab Dispos. 37, 1157–1163.
[276] Najib, J. (2002) Fenofibrate in the treatment of dyslipidemia: A review of the data as
they relate to the new suprabioavailable tablet formulation. Clinical Therapeutics 24,
2022–2050.
[277] Poulin, P., and Theil, F. (2000) A priori prediction of tissue:plasma partition coefficients
of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug
discovery. J.Pharm.Sci. 89, 16–35.
[278] Poulin, P., Schoenlein, K., and Theil, F. (2001) Prediction of adipose tissue: plasma
partition coefficients for structurally unrelated drugs. J.Pharm.Sci. 90, 436–447.
[279] Heneweer, C., Holland, J., Divilov, V., Carlin, S., and Lewis, J. (2011) Magnitude
of enhanced permeability and retention effect in tumors with different phenotypes:
89Zr-albumin as a model system. J.Nucl.Med. 52, 625–633.
[280] Pirollo, K., and Chang, E. (2008) Does a targeting ligand influence nanoparticle tumor
localization or uptake? Trends Biotechnol. 26, 552–558.
[281] Plummer, R., Wilson, R., Calvert, H., Boddy, A., Griffin, M., Sludden, J., Tilby, M.,
Eatock, M., Pearson, D., Ottley, C., Matsumura, Y., Kataoka, K., and Nishiya, T.
162
Bibliography
(2011) A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004)
in patients with solid tumours. Br.J.Cancer 104, 593–598.
[282] Savic, R., Azzam, T., Eisenberg, A., and Maysinger, D. (2006) Assessment of the in-
tegrity of poly(caprolactone)-b-poly(ethylene oxide) micelles under biological conditions:
a fluorogenic-based approach. Langmuir 22, 3570–3578.
163

List of abbreviations
ACN . . . . . . . . . . . . . . . . . . Acetonitrile
AF4 . . . . . . . . . . . . . . . . . . Asymmetrical Flow Field Flow Fractionation
ATP . . . . . . . . . . . . . . . . . . Adenosine triphosphate
ATRP . . . . . . . . . . . . . . . . Atom Transfer Radical Polymerization
CAC . . . . . . . . . . . . . . . . . . Critical Association Concentration
CARPA . . . . . . . . . . . . . . C-Activation Related Pseudoallergy
CAT . . . . . . . . . . . . . . . . . . Chloramine T
cryo-EM . . . . . . . . . . . . . . Cryo Transmission Electron Microscopy
DCM . . . . . . . . . . . . . . . . . Dichlormethane
DiI . . . . . . . . . . . . . . . . . . . 1,1´-Dioctadecyl-3,3,3´,3´-tetramethylindocarbocyanine perchlorate
DiO . . . . . . . . . . . . . . . . . . 3,3´-Dioctadecyloxacarbocyanine perchlorate
DLS . . . . . . . . . . . . . . . . . . Dynamic Light Scattering
DMAc . . . . . . . . . . . . . . . . Dimethylacetate
DMF . . . . . . . . . . . . . . . . . Dimethylformamide
DMSO . . . . . . . . . . . . . . . . Dimethylsulfoxide
DOTA . . . . . . . . . . . . . . . . 1,4,7,10-tetraazacylcododecane-1,4,7,10-tetraacetic acid
DTT . . . . . . . . . . . . . . . . . Dithiothreitol
DXM . . . . . . . . . . . . . . . . . Dexamethasone
ELISA . . . . . . . . . . . . . . . . Enzyme Linked Immuno Sorbent Assay
EPR . . . . . . . . . . . . . . . . . . Enhanced Permeability and Retention
FDA . . . . . . . . . . . . . . . . . . Food and Drug Administration
FRET . . . . . . . . . . . . . . . . Foerster Resonance Energy Transfer
GPC . . . . . . . . . . . . . . . . . . Gel Permeation Chromatography
HPβCD . . . . . . . . . . . . . . Hydroxy Propyl β-Cyclodextrin
IFF . . . . . . . . . . . . . . . . . . . Dechloro-4-iodo-fenofibrate
LOQ . . . . . . . . . . . . . . . . . . Limit Of Quantification
MALS . . . . . . . . . . . . . . . . Multiple Angle Light Scattering
MBq . . . . . . . . . . . . . . . . . . Mega Bequerel
MPS . . . . . . . . . . . . . . . . . . Mononuclear Phagocyte System
165
Bibliography
MWCO . . . . . . . . . . . . . . . Molecular Weigh Cut-Off
NMR . . . . . . . . . . . . . . . . . Nuclear Magnetic Resonance
O/W . . . . . . . . . . . . . . . . . Oil in water
PBS . . . . . . . . . . . . . . . . . . Phosphate Buffered Saline
mPEG-PCL . . . . . . . . . . methoxy PEGylated poly-(-caprolactone)
PDI . . . . . . . . . . . . . . . . . . Poly Dispersity Index
mPEG-PDLLA . . . . . . . methoxy PEGylated poly-(D,L-lactic acid)
mPEG-PLA . . . . . . . . . . methoxy PEGylated poly-(lactic acid)
mPEG-PLGA . . . . . . . . . methoxy PEGylated poly-(lactic acid-co-glycolic acid)
mPEG-PLLA . . . . . . . . . methoxy PEGylated poly-(L-lactic acid)
PTA . . . . . . . . . . . . . . . . . . Phosphor Tungistic Acid
mPEG-PVPy . . . . . . . . . methoxy PEGylated poly-4-(vinylpyridine)
RES . . . . . . . . . . . . . . . . . . Reticulo Endothelial System
RMF . . . . . . . . . . . . . . . . . Residual Micellar Fraction
RMS . . . . . . . . . . . . . . . . . Root Mean Square
ROP . . . . . . . . . . . . . . . . . . Ring Opening Polymerization
SANS . . . . . . . . . . . . . . . . . Small Angle Neutron Scattering
SBEβCD . . . . . . . . . . . . . Sulfobutyl Ether β-Cyclodextrin
TEM . . . . . . . . . . . . . . . . . Transmission Electron Microscopy
TFA . . . . . . . . . . . . . . . . . . Trifluoracetic acid
THF . . . . . . . . . . . . . . . . . . Tetrahydrofurane
166
List of Figures
1.1 Summary of stress factor analysis. . . . . . . . . . . . . . . . . . . . . . . . . 6
1.2 Scenario analysis of protein-carrier interactions. . . . . . . . . . . . . . . . . . 11
1.3 Immunological responses that could lead to premature particle clearance. . . . 17
2.1 Summary of cosolvent evaporation and lyophilization. . . . . . . . . . . . . . 30
2.2 Solubility screen of DXM in organic solvents. . . . . . . . . . . . . . . . . . . 36
2.3 Tg’ determination of lyoprotectors. . . . . . . . . . . . . . . . . . . . . . . . . 38
2.4 Polymeric micelles upon lyophilization: size and size distributions. . . . . . . 39
2.5 Lyoprotector optimum for lyophilized for DXM-loaded PEG-PVPy micelles. . 40
2.6 Cryo-EM analysis of PEG-PVPy micelles. . . . . . . . . . . . . . . . . . . . . 41
2.7 Cryo-EM micrograph analysis regarding particle sizes and size distributions. . 42
2.8 Schematic drawing of the O/W emulsion process. . . . . . . . . . . . . . . . . 45
2.9 Schematic drawing of the direct dialysis process. . . . . . . . . . . . . . . . . 46
2.10 Schematic drawing of the cosolvent evaporation process. . . . . . . . . . . . . 47
2.11 Schematic drawing of the β-cyclodextrin inclusion complexes with PEGylated
surfaces (pseudopolyrotaxane formation). . . . . . . . . . . . . . . . . . . . . 49
3.1 CAC values for block copolymers. . . . . . . . . . . . . . . . . . . . . . . . . . 59
3.2 TEM micrographs of block copolymer micelles. . . . . . . . . . . . . . . . . . 62
3.3 FRET fluorescence spectra of Tween 80® micelles. . . . . . . . . . . . . . . . 63
3.4 Residual micellar fractions of Tween 80® micelles. . . . . . . . . . . . . . . . 63
3.5 Residual micellar fractions of block copolymer micelles upon serum incubation. 64
3.6 AF4 fractograms of PEG-PVPy micelles upon serum incubation. . . . . . . . 66
4.1 Preparation steps for PEG-PEI derivatives. . . . . . . . . . . . . . . . . . . . 75
4.3 EC50 cruve for Cremophor EL® micelles on HepG2 cells. . . . . . . . . . . . 79
4.4 Results of the complement activation assays. . . . . . . . . . . . . . . . . . . . 83
4.2 1H-NMR spectrum of PEG-PEI. . . . . . . . . . . . . . . . . . . . . . . . . . 86
5.1 Solubility screen of compound A in organic solvents. . . . . . . . . . . . . . . 93
5.2 Biodistribution of compound A loaded PEG-PLGA micelles compared to
compound B solution. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 96
167
List of Figures
5.3 Recorded drug plasma concentrations over time upon injection of micellar drug
or drug solution. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97
5.4 1H-NMR spectrum of H2N-PEG-PLGA. . . . . . . . . . . . . . . . . . . . . . 98
5.5 Scintigrams of dual-labeled IFF-loaded PEG-PLGA micelles. Indium traces. . 99
5.6 Scintigrams of dual-labeled IFF-loaded PEG-PLGA micelles. Iodine traces. . 100
5.7 Biodidstribution of dual-labeled IFF-loaded PEG-PLGA micelles. . . . . . . . 101
6.1 Quaternization and labeling of PEG-PVPy. . . . . . . . . . . . . . . . . . . . 108
6.2 Scintigrams of IFF-labeled PEG-PVPy micelles. . . . . . . . . . . . . . . . . . 110
6.3 Sctintigrams of PEG-PVPy labeled micelles. . . . . . . . . . . . . . . . . . . . 111
6.4 Biodistribution of labeled PEG-PVPy micelles. . . . . . . . . . . . . . . . . . 111
6.5 Body clearance of PEG-PVPy in mice. . . . . . . . . . . . . . . . . . . . . . . 112
7.1 Summary of the biodistribution study with 111In-HN-PEG-PLA micelles. . . . 116
7.2 Concept of micellar dual-label with IFF encapsualted in PEG-PLA micelles. . 121
7.3 Summary of the animal study approach. . . . . . . . . . . . . . . . . . . . . . 122
7.4 Scintigrams and biodistribution of IFF-loaded dual labeled PEG-PLA micelles.124
7.5 Scintigrams and biodistribution of labeled PEG-PLA as solution. . . . . . . . 125
7.6 Scintigrams and biodistribution of labeled PEG as solution. . . . . . . . . . . 126
7.7 Biodistribution study of dual-labeled IFF-loaded PEG-PLA micelles. . . . . . 127
168
List of Tables
2.1 Loading results of DXM in PEG-PVPy micelles. . . . . . . . . . . . . . . . . 37
2.2 Particle size distribution parameters obtained from cryo-EM micrograph analysis. 43
3.1 Physical state of block copolymers. . . . . . . . . . . . . . . . . . . . . . . . . 60
3.2 Particle sizes of micelles in negative staining TEM vs DLS. . . . . . . . . . . 61
3.3 Residual micellar fraction of block copolymer micelles upon serum incubation. 64
3.4 AF4 results of PEG-PVPy micelles upon serum incubation. . . . . . . . . . . 65
4.1 Testing materials/particles in the cytotoxicity and complement assays. . . . . 76
4.2 PEG-PEI characteristics obtained from 1H-NMR spectroscopy. . . . . . . . . 79
4.3 Particle sizes and size distributions of micelles/particles in cytotoxicity and
immunogenicity assays. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80
4.4 EC50 values for micelles on rat hepatocytes and HepG2 cells. . . . . . . . . . 81
4.5 Evaluation of the complement activation results. . . . . . . . . . . . . . . . . 84
5.2 Physicochemical characterization of the injected formulations. . . . . . . . . . 94
5.1 Loading results of compound A in varying block copolymer micelles. . . . . . 95
5.3 Pharmacokinetic parameters of compound A and compound B in different
tissues/organs. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97
5.4 Molar mass characterizations of H2N-PEG-PLGA. . . . . . . . . . . . . . . . 98
7.1 Characterization of H2N-PEG-PLA. . . . . . . . . . . . . . . . . . . . . . . . 123
7.2 Characterization of labeled PEG-PLA micelles. . . . . . . . . . . . . . . . . . 123
169

Appendix
171
Appendix
Curriculum vitae
Personal information
Name: Tobias Miller
Date of birth: 1/14/1984
Place of birth: Potsdam, Germany
Nationality: German
Professional experience
4/2009 - 6/2012 PhD student at Merck Serono, Darmstadt, Germany, in
collaboration with Prof. A. Goepferich, University of
Regensburg, Germany
11/2008 - 3/2009 Scientific coworker at University of Brunswick, Germany
5/2008 - 10/2008 Pharmacy internship in Kaenguruh-Apotheke, Potsdam,
Germany (public pharmacy)
11/2007 - 4/2008 Pharmacy internship at Haupt Pharma Wuelfing GmbH,
Gronau (Leine), Germany (CMO)
7/2004 - 8/2004 Internship in dispensary of Ernst-von-Bergmann Klinikum,
Potsdam, Germany
03/2004 Internship Linden Apotheke, Werder, Germany (public
pharmacy)
Education
10/2003 - 10/2007 Studies of Pharmaceutical Sciences at the Free University of
Berlin, Germany
06/2003 General qualification for university entrance (“Allgemeine
Hochschulreife”)
172
List of publications
Peer-reviewed scientific articles
Tobias Miller, Reinhard Rachel, Ahmed Besheer, Senta Uezguen, Markus Weigandt, Achim
Göpferich: Comparative investigations on in vitro serum stability of polymeric micelles
formulations. Pharm Research 29 (2): 448-459, 2012. (Chapter 3)
Tobias Miller, Alexandra Hill, Senta Uezguen, Markus Weigandt, Achim Göpferich: Analysis
of stress mechanisms occurring immediately upon injection of polymeric micelles and their
potential implications on passive drug targeting. Published in: Biomacromolecules. In press.
(Section 1.2)
Tobias Miller, Gwenaelle van Colen, Mariola Monika Golas, Bjoern Sander, Senta Uezguen,
Markus Weigandt, Achim Goepferich: Drug loading of polymeric micelles. Submitted to:
Pharm Research. (Chapter 2)
Tobias Miller, Sandra Breyer, Gwenaelle van Colen, Walter Mier, Uwe Haberkorn, Senta
Uezguen, Markus Weigandt, Achim Goepferich: Dual-label of carrier micelle and pay-
load revealed biodistribution differences rapidly occuring upon injection. To be submitted.
(Chapter 7)
Sandra Breyer, Angelika Semmler, Tobias Miller, Alexandra Hill, Simon Geissler, Uwe
Haberkorn, Walter Mier: Radioiodinated dechloro-4-iodofenofibrate: a hydrophobic model
drug for molecular imaging studies. Published in: Int J Pharm.
Conference abstracts
Tobias Miller, Ahmed Besheer, Markus Weigandt, Achim Goepferich: Preparation and
in vitro serum stability testing of polymeric PEG-PLA micelles by Foerster Resonance
Energy Transfer (FRET). 7th World Meeting on Pharmaceutics, Biopharmaceutics and
Pharmaceutical Technology, Valletta, Malta (2010).
Angelika Semmler, Simon Geissler, Tobias Miller, Uwe Haberkorn, Walter Mier: Syn-
these des hydrophoben Modellwirkstoffes Deschlor-4-iodfenofibrat. 18. Jahrestagung der
Arbeitsgemeinschaft Radiochemie/Radiopharmazie, Bad Boll, Germany (2010).
Tobias Miller, Ahmed Besheer, Senta Uezguen, Markus Weigandt, Achim Goepferich:
In vitro serum stability of polymeric micelles. 38th Annual Meeting & Exposition of the
Controlled Release Society. National Harbor, MD, USA (2011).
Tobias Miller, Angelika Semmler, Sandra Breyer, Walter Mier, Senta Uezguen, Markus
Weigandt, Achim Goepferich: Challenges in nanoparticulate drug delivery: What fate
173
Appendix
do polymeric micelles encounter upon injection? 8th World Meeting on Pharmaceutics,
Biopharmaceutics and Pharmaceutical Technology, Istanbul, Turkey (2012).
Poster and oral presentations
Tobias Miller, Ahmed Besheer, Markus Weigandt, Achim Goepferich: Preparation and in
vitro serum stability testing of polymeric PEG-PLA micelles by Förster resonance energy
transfer (FRET). 7th Worldmeeting on Pharmaceutics and Biopharmaceutics, Valletta, Malta
(2010). Poster presentation.
Tobias Miller, Ahmed Besheer, Senta Uezguen, Markus Weigandt, Achim Goepferich: In
vitro serum stability of polymeric micelles. 38th Annual Meeting of the Controlled Release
Society, National Harbor, MD, USA (2011). Poster presentation.
Tobias Miller, Angelika Semmler, Sandra Breyer, Walter Mier, Senta Uezguen, Markus
Weigandt, Achim Goepferich: What fate do polymeric micelles encounter upon injection?
8th World Meeting on Pharmaceutics and Biopharmaceutics, Istanbul, Turkey (2012). Oral
presentation.
Patents
Applications
Tobias Miller, Senta Uezguen, Markus Weigandt, Achim Goepferich: Verfahren zur Herstel-
lung wirkstoffbeladener Nanopartikel. Deutsches Patent- und Markenamt (German Patent and
Trademark Office), Munich, Germany (2012). Preliminary application #: DE102012004099
174
Acknowledgements
An dieser Stelle möchte ich die Möglichkeit nutzen, all den Menschen zu danken, die mich
sowie diese Arbeit in den letzten Jahren begleitet haben.
Allen voran geht dieser Dank an Achim Göpferich, der diese Arbeit hervorragend betreut
hat und trotz der permanenten geografischen Entfernung zwischen uns stets als überaus
kompetenter Gesprächspartner erreichbar war. Ich danke ihm insbesondere für das Interesse
an der Arbeit, die konstruktive Kritik an den Experimenten sowie Manuskripten und darüber
hinaus für seine Ideen, die zum Gelingen dieser Arbeit wesentlich beigetragen haben.
Besonderer Dank gebührt weiterhin Senta Üzgün und Markus Weigandt (Merck Serono,
Darmstadt) die diese Arbeit organisatorisch und inhaltlich betreut haben. Ohne die wis-
senschaftlichen Diskussionen, das kritische Hinterfragen der experimentellen Ergebnisse sowie
die Sichtbarkeit innerhalb der Firma wären einige Möglichkeiten verschlossen geblieben.
Die enge Zusammenarbeit mit Alexandra Hill sowie Simon Geissler (Merck Serono, Darmstadt)
war ebenfalls Triebkraft für das vorliegende Manuskript. Ich danke Alexandra für ihre stetige
konstruktive Kritik, die aufmunternden Worte sowie besonders für ihre persönliche Begleitung
während der Hochs und Tiefs in den vergangenen Jahren. Simon danke ich für seine persönliche,
labororganisatorische sowie fachliche Unterstützung in dieser Zeit. Beide sind hervorragende
Wissenschaftler und es war ein großer Lichtblick, mit ihnen zusammen zu arbeiten.
Dem Radiologie-Team an der Universität Heidelberg gebührt sehr großer Dank, insbesondere
Sandra Breyer, Angelika Semmler, Karin Leotta und Walter Mier, das an der Durchführung
der Tierversuche mit radioaktiv markierten Polymeren/Wirkstoffen beteiligt war.
Weiterhin danke ich Finn Bauer und dem gesamten Team von EMD Millipore in Woburn (MA,
USA) für die freundliche Aufnahme am Standort und die Möglichkeit, dort intensiv Serum-
experimente durchzuführen. Die 2 Monate in einem US-Labor waren sehr erfahrungsreich,
fachlich sowie persönlich und haben mich und die Arbeit erheblich positiv beeinflusst.
Besonderer Dank geht ebenfalls an Ahmed Besheer, LMU München, der die Idee für diese
Doktorarbeit entwickelte, mich in den ersten 6 Monaten der Arbeit fachlich begleitete und
für mich persönlich über die gesamte Arbeit ein wissenschaftliches Vorbild war.
Dem Team der in vitro Toxikologie am Standort Merck Serono, Darmstadt, möchte ich für
ihre Unterstützung bei den Zytotoxizitätsexperimenten danken. Hier haben mich bei den
Zellkulturexperimenten Johanna Sebbel und Stefan O. Müller unterstützt.
Reinhard Rachel an der Universität Regensburg danke ich für die Aufnahme der negativ-
kontrastierten TEM Bilder.
Bjoern Sander und Monika Golas (Universität Aarhus) danke ich für die Aufnahme der
cryo-EM Bilder.
175
Appendix
Frank Zenke, Christiane Amendt sowie Gerhard Schuster (Merck Serono, Darmstadt) danke
ich für die Durchführung der Tierversuche mit compound A-beladenen Mizellen.
Weiterhin möchte den Mitdoktoranden sowie allen Kollegen in ED (Merck Serono, Darmstadt)
danken, insbesondere:
- Gwenaelle van Colen für ihre Leidensfähigkeit, Mitarbeit, Ideen und Interesse an meiner
Arbeit.
- Katharina Anhalt, Stefan Schiller, Bernd Sterner für die fachlichen Diskussionen und die
gemeinsame Zeit während der Doktorarbeit.
- Andrea Hanefeld, Patrizia Boniforte sowie Nadja Foster für Labororganisation.
- Dirk Schiroky für gelegentliche MS-Experimente.
Darüber hinaus möchte ich dem Team von WL-ACP-7 (Merck KGaA, Darmstadt) danken,
insbesondere Christoph Hoffmann und Sven Brüninghoff für die Möglichkeit der Durchführung
von Fluoreszenzexperimenten.
Am Lehrstuhl für Pharmazeutische Technologie, Regensburg, danke ich Miriam Breunig und
Sonja Bauhuber. Miriam für die Zell- und FACS-Experimente und Sonja für Aufnahme von
NMR Spektren.
Abschließend, aber nicht minder bedeutend, danke ich meinen Eltern, die mich immer auf
jedem meiner Wege und in jeder Entscheidung unterstützt haben. Ohne sie wäre ich wohl
niemals so weit gekommen. Leider wird auch in Zukunft die räumliche Entfernung zwischen
uns nicht kleiner.
176
